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ABSTRACT 
 
The development of drugs for central nervous system (CNS) disorders has 
encountered high failure rates. In part, this has been due to the sole focus on 
blood-brain barrier (BBB) permeability of drugs, without taking into account all 
other processes that determine drug concentrations at the brain target site. This 
review deals with an overview of the processes that determine the drug 
distribution into and within the CNS, followed by a description of in vivo 
techniques that can be used to provide information on CNS drug distribution. A 
plea follows for the need for more mechanistic understanding of the 
mechanisms involved in brain target site distribution, and the condition-
dependent contributions of these mechanisms to ultimate drug effect. As future 
direction, such can be achieved by performing integrative cross-compare 
designed studies, in which mechanisms are systematically influenced (e.g. 
inhibition of an efflux transporter, or induction of pathological state). With the 
use of advanced mathematical modeling procedures we may dissect 
contributions of individual mechanisms in animals as links to the human 
situation. 
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INTRODUCTION 
 
Central nervous system (CNS) disorders like Alzheimer’s disease, Parkinson’s 
disease, multiple sclerosis, epilepsy, schizophrenia, migraine, insomnia, 
depression, and attention-deficit hyperactivity disorder are currently estimated 
to affect hundreds of millions of people worldwide (World Health Organization, 
2007). While established treatments are currently available for most of these 
disorders, significant unmet medical needs still remain, as currently available 
drugs are treating symptoms rather than curing the disease (Business Insights, 
2010). Therefore, novel treatments or drugs with a different mechanism of 
action are needed. 
In these days, the CNS sector is struggling as the average cost of getting a 
drug onto the market is ever increasing and now approaching US$1 billion, 
whereas there is an expected decline in income due to pricing pressure from 
generics (Business Insights, 2010). Moreover, many potentially therapeutic 
compounds fail during development because early drug discovery programs are 
often using the wrong parameters for estimating CNS exposure (Hammarlund-
Udenaes et al., 2008). 
It is often said that many CNS drug candidates fail because they do not reach 
the CNS target due to lack of blood-brain barrier (BBB) permeability. Indeed, 
the BBB effectively isolates the brain from the blood by the presence of tight 
junction proteins, connecting the endothelial cells of the brain vessels. In 
addition, specific metabolizing enzymes and efflux pumps, such as P-
glycoprotein (P-gp), are located within the endothelial cells, which may actively 
remove drugs from the brain. It is therefore true that the BBB can play a major 
role in limiting the delivery of systemically administered drugs to the CNS. 
However, this is not the sole reason for the high failure rate in CNS drug 
development. For a proper CNS effect, the unbound drug should have the ability 
to access the relevant target site within the CNS. Apart from BBB permeability, 
this also depends upon other factors, such as plasma pharmacokinetics (PK) and 
within-brain distribution. These factors are controlled by many mechanisms. 
Each mechanism has its particular influence by its specific rate and extent, and 
thereby plays a more or less important role in having the drug in the right place, 
at the right time, and at the right concentration. Moreover, influences of 
variables like genetics, gender, age, environmental and pathological conditions 
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have generally been neglected. It is therefore not surprising that most CNS drug 
candidates finally fail during development. 
As the driving force of CNS drug action is the concentration-time profile at 
the brain target site, it is important for pharmaceutical companies to have 
effective, cost-efficient tools to measure and predict human brain target site 
exposure before proceeding to more expensive clinical trials. 
For many (potential) CNS drugs, brain target site concentrations are closely 
linked, or may even be equal, to unbound drug concentrations in the brain 
extracellular fluid (brainECF) (De Lange et al., 2000; Hammarlund-Udenaes, 
2009). However, the possibility of direct measurement of brainECF 
concentrations is highly limited in the clinical phase of drug development. 
Therefore, unbound drug concentrations in human cerebrospinal fluid (CSF) are 
used as a surrogate for human brainECF concentrations. However, the usefulness 
of CSF concentrations as a predictor of brain target site concentrations can be 
questioned, as a generally applicable relationship between CSF concentrations 
and brainECF concentrations does not exist due to qualitative and quantitative 
differences in processes that govern the PK at these sites (De Lange and 
Danhof, 2002; Lin, 2008; Shen et al., 2004). 
 
 
FACTORS THAT GOVERN THE 
PHARMACOKINETICS IN THE BRAIN 
 
Drug distribution into the brain is governed by many processes, including 
plasma PK, plasma protein binding, passive and active transport across the BBB 
or blood-CSF barrier (BCSFB), and once within the brain, bulk flow, diffusion, 
and passive and active extra-intracellular exchange. 
 
Plasma pharmacokinetics and protein binding 
 
Once drugs are in the systemic circulation, they can bind to different proteins 
that are present in plasma. Of the many plasma proteins that can interact with 
drugs, the most important ones are human serum albumin, α1-acid glycoprotein, 
and lipoproteins (Peletier et al., 2009). Acidic and neutral drugs are usually 
bound more extensively to albumin, whereas basic drugs are usually bound 
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more extensively to α1-acid glycoprotein and lipoproteins (Peletier et al., 2009). 
As protein-bound drugs cannot cross the BBB or BCSFB, unbound plasma 
concentrations, rather than total plasma concentrations, are considered to be the 
main determinant for the rate and extent of drug entry into the brain (Mayer et 
al., 1959). However, it must be noted that information about the level of protein 
binding by itself is not sufficient for predicting drug distribution into the brain 
(Pardridge, 1995). As the association and dissociation of drugs to plasma 
proteins is a dynamic process, it indicates that extensively protein-bound drugs 
can still enter the brain in sufficient amounts, provided that the rate of 
dissociation and permeability of the BBB and BCSFB is high enough (Mandula 
et al., 2006; Morgan and Huang, 1993; Tanaka and Mizojiri, 1999). This 
implicates that information on the kinetics of plasma protein binding is also 
essential for accurate prediction of the rate and extent of drug entry into the 
brain. 
 
Transport across the blood-brain barriers 
 
The barriers between blood and brain are the BBB and the BCSFB. These 
barriers have many similarities but also important differences, as will be 
discussed below. 
 
The blood-brain barrier - The BBB is formed by the brain capillary endothelial 
cells, which are interconnected by tight junction proteins that restrict 
paracellular diffusion of small hydrophilic molecules from blood to the brain. In 
addition to these tight junctions, numerous active transport systems are present 
at the BBB that protect the brain from neurotoxic substances, but also help to 
maintain the homeostasis of the brain by influx of essential substrates such as 
electrolytes, nucleosides, amino acids, and glucose. These processes are 
regulated by interactions with adjacent pericytes, astrocytes, and neuronal cells 
(Abbott et al., 2006; Bernacki et al., 2008; Davson and Oldendorf, 1967). 
However, in certain specialized regions in the brain, comprising the choroid 
plexuses and the circumventricular organs, the capillary endothelial cells are 
fenestrated and therefore highly permeable (Abbott, 2004). Thus, compounds 
can cross the capillary walls more or less freely in these specialized regions, but 
may be restricted in entering the rest of the brain by the BCSFB. 
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The blood-cerebrospinal fluid barrier - The BCSFB is located at the choroid 
plexuses in the lateral, third and fourth ventricles of the brain, which are 
responsible for the production of CSF. The barrier function of the BCSFB is 
provided by the tight junctions between the epithelial cells of the choroid plexus 
at the apical site, which contacts the CSF. Like the BBB, several different active 
transport systems are located at the BCSFB to limit the entrance into the brain 
of compounds that can easily permeate the choroid plexus’ capillaries (Davson 
and Oldendorf, 1967; Wolburg and Paulus, 2010).  
 
BBB versus BCSFB - It has been assumed that the surface area of the BBB in 
humans, which is estimated to be ~20 m2 (Pardridge, 2002), is at least a 
hundred-fold larger than that of the BCSFB, which is reported to be only 0.2 m2 
(Dohrmann, 1970). This implicates that the BCSFB only plays a minor role in 
the control of the brain environment (Hammarlund-Udenaes et al., 2008; Lee 
and Bendayan, 2004; Lee et al., 2001; Roberts et al., 2008). However, this 
calculation ignores the large surface area provided by the apical microvilli on 
the epithelial cells. When taking these into account, the total surface area of all 
choroid plexuses in the rat is estimated to be ~75 cm2 (Keep and Jones, 1990a). 
This is only two-fold smaller than the surface area of the BBB, which is 
estimated to be ~150 cm2 (Gjedde, 1981; Keep and Jones, 1990b). This 
implicates that the BCSFB plays a more important role in drug transport 
between blood and brain than originally assumed. However, because the BBB 
and BCSFB are anatomically and physiologically different, their relative 
contributions in the exchange of compounds between blood and brain does not 
necessarily correspond to the ratio of their respective surfaces. BCSFB transport 
will (initially) influence the periventricular spaces and tissues, while BBB 
transport will more affect the total brain. 
Active transport across the BBB and BCSFB can be either by carrier-
mediated (facilitated) transport, or ATP-dependent transport. Facilitated 
transport across the BBB and BCSFB is carried out by members of the solute 
carrier (SLC) family, which include organic cation transporters (OCT), 
carnitine/organic cation transporters (OCTN), organic anion transporters 
(OAT), organic anion-transporting polypeptide (OATP), and glucose transporter 
(GLUT). The different ATP-dependent transport systems at the BBB and 
BCSFB are all members of the ATP-binding cassette (ABC) transporter 
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superfamily and include P-gp, breast cancer resistance protein (BCRP), and the 
multidrug resistance-associated protein (MRP) family (Graff and Pollack, 
2004). The direction of flux and subcellular localization of the different 
transporter systems at the human BBB and BCSFB are depicted in figure 1. Due 
to inconsistencies in the literature, the direction of flux and subcellular 
localization of the different transporters are classified as either ‘known’, 
‘likely’, or ‘unknown’. However, it can be concluded that there are some 
differences between the BBB and BCSFB. 
 
 
Figure 1. Cartoon of the different active transport systems that are located on the human BBB 
and BCSFB 
 
It has been well established that P-gp functions as an efflux transporter at the 
BBB (Schinkel, 1999). However, there has been some evidence that P-gp 
functions as an influx transporter at the BCSFB (Kassem et al., 2007; Rao et al., 
1999). However, previous work by Gazzin and colleagues has indicated that P-
gp levels at the BBB are over 200-fold higher than at the BCSFB (Gazzin et al. 
2008). In contrast, MRP1 has a much higher expression at the choroid plexuses 
compared to the brain microvessels. This indicates that there are major 
differences in the mechanisms by which the BBB and BCSFB protect the brain, 
which could result in significant differences between concentrations at the brain 
target site and in CSF (Gazzin et al., 2008).  
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Altogether, this indicates that the impact of active transport on the 
predictability of brain target site concentrations from CSF concentrations needs 
to be considered and further investigated. 
 
Enzymatic activity 
 
Several drug metabolizing enzymes, like cytochromes P-450, monoamine 
oxidases, and UDP-glucuronosyltransferases, have been found at different 
extracellular and intracellular sites in the brain (Ghersi-Egea et al., 1993; 
Ghersi-Egea et al., 1994). The activities of some drug-metabolizing enzymes 
appeared to be several times higher in the small brain microvessels and choroid 
plexus epithelial cells compared to the cortical parenchymal cells. Thus, the 
BBB and BCSFB also form an enzymatic barrier to limit the exposure of the 
brain to drugs (Ghersi-Egea et al., 1993; Ghersi-Egea et al., 1994). 
The metabolism that takes place within the brain could result in the 
conversion of molecules and/or prodrugs to pharmacologically active 
metabolites. This needs to be taken into account as well during drug 
development. 
 
BrainECF bulk flow and CSF turnover 
 
In rats, approximately 80% of the CSF is generated by the choroid plexuses of 
the lateral, third and fourth ventricles, whereas the remaining 20% comes 
directly from the brainECF (Cserr, 1965). In humans, the contribution of brainECF 
is estimated to be about 50% (Kimelberg, 2004). After formation, CSF flows 
from the lateral ventricle through the third and into the fourth ventricle via the 
aqueduct of Sylvius. CSF then leaves the brain to enter the basal cisterns and 
subarachnoid spaces, where it is absorbed in the venous system (figure 2) 
(Miyan et al., 2003; Proescholdt et al., 2000; Segal, 1993).  
In humans, CSF is produced at a rate of about 0.4 ml/min (Nilsson et al., 
1992). With a total CSF volume of approximately 140 ml (Kohn et al., 1991), 
this indicates that the total volume of CSF is replaced every 6 hours. In rats, the 
relative rate of CSF turnover is much higher. With a rate of production of 2.2 
μl/min (Cserr, 1965), and a total CSF volume of 250 μl (Bass and Lundborg, 
____ 
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Figure 2. Schematic representation of the CSF flow path 
 
1973), this indicates that the total volume of CSF in the rat is replaced every 2 
hours. 
It is often stated that drugs equilibrate readily between brainECF and CSF as 
the ependymal epithelium that separates brainECF from CSF does not present a 
significant barrier to drug movement (Lee et al., 2001). However, compounds 
do not only diffuse from brainECF into CSF. It has been shown that there is also 
bulk flow of brainECF (Abbott, 2004; Cserr et al., 1981). Due to the bulk flow of 
brainECF to CSF, the transport of drugs from brainECF into CSF is more efficient 
than the diffusion of drugs from CSF into the brainECF. As a result, the continual 
drainage of CSF can act as a ‘sink’ for brain tissue, indicating an active 
elimination from the brain. 
In humans, the rate of brainECF production is estimated to be 0.15-0.2 ml/min 
(Begley, 2000; Kimelberg 2004) which is calculated from the estimation that 
50% of the CSF production comes from brainECF. With a total brainECF volume 
of approximately 240 ml (Begley, 2000), this indicates the total brainECF volume 
is replaced every 20-27 hours. At a rate of 0.2-0.5 μl/min in rat brain (Abbott, 
2004; Cserr et al., 1981), the rate of brainECF production is about 10-20% of that 
of CSF, which corresponds well to the 20% of CSF production from brainECF 
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(Cserr, 1965). With a total brainECF volume of 290 μl (Cserr et al., 1981), this 
indicates that the total brainECF volume in rats is replaced every 10-24 hours. 
It has been suggested that the source of the brainECF is from a combination of 
ions and water that come from the bloodstream and from CSF that flows back 
into the brain along perivascular channels from the ventral surface in the 
subarachnoid space (Abbott, 2004). This indicates that there is a fraction of CSF 
that takes a longer route from its site of origin in the choroid plexuses back into 
the systemic circulation. This also indicates that drug concentrations in brainECF 
and CSF are only in part directly related. 
 
Extra-intracellular exchange 
 
Once a drug is in the brainECF or CSF, it can bind to brain tissue or distribute 
into brain cells, depending on its physicochemical properties. Hydrophilic drugs 
are more likely to remain dissolved in the brainECF and CSF, whereas lipophilic 
drugs are more likely to bind to brain tissue, or distribute into brain cells (De 
Lange and Danhof, 2002). However, active transport between brainECF and the 
cell is possible as well (Lee et al., 2001). The effect of brainECF-parenchymal 
exchange has been clearly demonstrated by the study on valproate by Scism et 
al. (2000). Co-administration of probenecid increased the intracellular 
concentrations without affecting brainECF concentrations, indicating the presence 
of a probenecid-sensitive efflux transporter at the brain parenchymal cells. 
While most CNS drug targets are facing the brainECF, intracellular targets 
also exist (Lee et al., 2001). This has to be considered when aiming to 
determine brain target site concentrations. For targets like membrane receptors, 
extracellular enzymes, and transporters, brainECF concentrations may provide the 
most useful information (De Lange and Danhof, 2002). 
 
 
TECHNIQUES 
 
In the preclinical setting there are several in vitro, ex vivo and in vivo techniques 
that provide information on brain target site exposure. Such information can be 
either direct or indirect, on bound or unbound concentrations, with or without 
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temporal resolution, and with or without spatial resolution (De Lange et al., 
1997; Hammarlund-Udenaes et al., 2009). 
A typical parameter that is often used to describe the level of brain exposure 
is the brain-to-plasma partition coefficient (Kp), which is defined as the ratio of 
the total drug concentration in the brain versus the total drug concentration in 
plasma. To compensate for differences in plasma protein binding, as that may 
restrict brain entry, the total brain-to-unbound plasma partition coefficient (Kp,u) 
can be calculated. However, as it is pharmacologically more relevant to use 
unbound brain target site concentrations rather than total brain concentrations, 
the unbound brain-to-unbound plasma partition coefficient (Kp,uu) is considered 
to be a better parameter for brain target site exposure (Gupta et al., 2006). 
All the processes discussed in the previous section affect the rate and/or 
extent of drug distribution to the brain, being two distinct parameters 
(Hammarlund-Udenaes et al., 2008). The rate of transport into the brain is 
dependent on the speed at which a drug molecule can pass the BBB and 
BCSFB. This is often expressed as permeability (distance/time) or clearance 
(volume/time). The rate of transport across the BBB and BCSFB is often 
limited to the permeability rate of the BBB and BCSFB, which is dependent on 
their condition-dependent characteristics and the physicochemical properties of 
the drugs. As classical paradigm, BBB and BCSFB transport is governed by 
lipophilicity. Indeed, if passive transport (diffusion) is the only transport 
mechanism involved, small lipophilic drugs cross the BBB and BCSFB more 
readily than large hydrophilic drugs (De Lange and Danhof, 2002; Levin, 1980). 
For highly permeable compounds, however, the rate of transport across the 
BBB and BCSFB is limited by the cerebral blood flow (Dagenais et al., 2000). 
Furthermore, active transport processes into or out of the brain may increase or 
reduce the permeability rate. 
The extent of drug distribution to the brain can be calculated as the ratio of 
unbound drug concentrations in the brain compared to unbound drug 
concentrations in plasma at steady state, or by the ratio of unbound AUC in 
brain relative to unbound AUC in plasma. For compounds that freely diffuse 
into and out of the brain, thus irrespective of what time that may take, this ratio 
should be equal to 1. If the ratio is < 1, this indicates that elimination processes 
(bulk flow, metabolism, active transport out of the brain) play an additional 
role. For a ratio > 1, active transport into the brain occurs, but may also be the 
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consequence of tissue binding. Alternatively, if ionization plays a role, ratios < 
or > 1 may as well result from pH differences between one site and another. 
Generally, the extent of drug distribution into the brain is considered of most 
importance in relation to brain target site exposure. This means that drug 
discovery and development studies have focused on measuring drug 
concentrations in brain and plasma under (assumed) steady-state conditions. 
However, for drugs with a desired rapid onset of action (e.g. analgesics or 
anesthetics), the rate of entry into the brain is also relevant. Finally, it may be 
questioned whether fluctuations in brain concentrations, due to fluctuations in 
plasma concentrations following multiple dosing regimens, may have an impact 
on the pharmacodynamics (PD) of the drug. 
This all implies the need for mechanistic investigations on the contribution 
of the different processes that govern the brain target site exposure. The 
techniques that are used to provide information on CNS drug distribution, in the 
perspective of extrapolation to the clinical setting and prediction of the effect, 
are discussed below. 
 
Brain perfusion technique 
 
Mayer and colleagues were one of the first to study the rate and extent of drug 
penetration into the brain (Mayer et al., 1959). During the experiments, plasma 
concentrations were maintained at steady state by a bolus dose, followed by a 
constant rate infusion. By measuring brain homogenate concentrations at certain 
time points, distribution ratios could be calculated. Based on the time needed to 
reach a distribution ratio of 1, compounds were classified as having a fast (<5 
min), intermediate (1.5-2 h), and very slow (>3 h) rate of entry. 
Over time, this technique has been adapted so the initial rate of drug 
transport into the brain could be studied in more detail. Among the adapted 
techniques are the indicator diffusion technique (Crone, 1965), the brain uptake 
index technique (Oldendorf, 1970), the intravenous injection technique (Ohno et 
al., 1978), and the in situ brain perfusion technique (Takasato et al., 1984). In 
short, radiotracer quantities of a test substance and a diffusible reference such as 
3H2O and/or a non-diffusible reference such as [14C]inulin are injected 
intracarotidly or intravenously and the animal is decapitated 5-30 s later. Total 
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brain concentrations of the test substance and reference are then compared to 
concentrations in the injected solution or plasma. 
These techniques are very suitable to study the rate and extent of exposure of 
the brain to the radioactivity, reflecting the compound of interest. However, the 
radioactivity potentially also includes metabolites. The major disadvantage of 
the different brain perfusion techniques is that they all use brain homogenate, so 
they cannot distinguish between intracellular space (ICS), brainECF or CSF, and 
bound or unbound concentrations (Liu et al., 2009). Modifications to the in situ 
brain perfusion technique have allowed distinguishing between accumulation in 
brain endothelial cells and uptake into brain parenchyma (Preston et al., 1995), 
as well as uptake into the choroid plexus (Deane et al., 2004). However, none of 
the brain perfusion techniques can distinguish between the different routes of 
entry to the brain, which could be by crossing the BBB or BCSFB. 
Furthermore, it is expensive and time-consuming to synthesize radioactively 
labeled drugs, making this technique less suited for early drug discovery (Liu 
and Jia, 2007). Alternatively, non-labeled compounds can be used as well. 
However, this requires the development of adequate analytical methods, which 
is evenly time consuming. 
 
Brain homogenate free fraction method 
 
Different methods have been developed to be able to distinguish between 
unbound and bound concentrations. Lin and colleagues used an equilibrium 
dialysis setup to determine the unbound fractions in plasma and brain 
homogenate (Lin et al., 1982). Using the equilibrium dialysis setup, calculation 
of unbound brain concentrations from total brain concentrations improves the 
prediction of receptor occupancy compared to the use of just total brain 
concentrations (Watson et al., 2009). Kalvass and Maurer (2002) adapted the 
equilibrium dialysis technique to a 96-wells plate that allowed for more high 
throughput screening. When the fraction unbound in plasma and brain is known, 
the Kp,uu can be calculated from the Kp. Also, the unbound volume of 
distribution in the brain, which relates the total brain concentration to the 
unbound brainECF concentration, can be determined (Fridén et al., 2007).  
Even though the brain homogenate free fraction method allows for higher 
throughput screening during early drug discovery compared to the brain 
Chapter 1 
24 
 
perfusion technique, the disadvantages remain of using brain homogenate. 
Because the brain tissue is homogenized, cell structures are destroyed and 
binding sites that are normally not accessible to a drug in vivo may be unmasked 
(Fridén et al., 2007; Liu et al., 2009). This could result in an erroneous 
estimation of the unbound fraction in brain tissue. As an alternative, the brain 
slice technique was developed. 
 
Brain slice technique 
 
The brain slice technique was developed by Newman et al. (1991). However, it 
was Kakee et al. (1996) that first applied the brain slice technique to determine 
unbound drug concentrations in brain tissue. In short, a section of a drug-naïve 
brain is cut into 300 μm slices, which are then incubated at 37°C in buffer 
containing the drug. After a certain time, assuming a steady state between buffer 
and brain slice ECF, the slices are homogenized and drug concentrations in the 
homogenate and buffer analyzed. In contrast to the brain homogenization 
method, the cellular structure of the brain tissue remains intact with the brain 
slice technique, thus it allows to distinguish between intracellular and 
extracellular as well as bound and unbound concentrations (Fridén et al., 
2009a). 
Kakee et al. (1996) applied the brain slice technique to determine the 
unbound volume of distribution, which they used for the calculation of the brain 
efflux clearance rather than brain target site exposure. Fridén and colleagues 
compared the brain slice technique to the brain homogenate free fraction 
method in their ability to predict unbound volumes of distribution, as 
determined by the intracerebral microdialysis technique (see below). They 
concluded that the brain slice technique was better than the brain homogenate 
free fraction method for predicting unbound volumes of distribution (Fridén et 
al., 2007). 
All in all, the brain slice technique appears to be better than the brain 
homogenate free fraction method for the prediction of unbound brain target site 
concentrations. However, as the brain slice technique is more labor intensive 
and lower throughput compared to the brain homogenate free fraction method, 
the latter is still preferred during early CNS drug discovery (Read and Braggio, 
2010). Even though recent developments have improved the throughput of the 
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brain slice technique (Fridén et al., 2009a), it remains to be seen if the brain 
slice technique will replace the brain homogenate free fraction method during 
early CNS drug discovery. 
 
CSF sampling 
 
Back in 1959, Mayer and colleagues already recognized that the unbound 
plasma concentrations, rather than total plasma concentrations, are the main 
determinant for the rate and extent of drug entry into the brain, as protein-bound 
drugs cannot cross the BBB or BCSFB (Mayer et al., 1959). However, due to 
the lack of suitable methods, it took nearly 25 years to acknowledge that the 
free drug hypothesis is also applicable for pharmacological activity at the brain 
target site. Danhof and Levy (1984) were one of the first to suggest the use of 
unbound CSF concentrations rather than total brain concentrations for relating 
pharmacological activity. They showed that, for phenobarbital, not plasma, nor 
total brain, but CSF concentrations were constant at the onset of anesthesia (the 
minimal effective concentration). 
The most common method for collecting a CSF sample from humans is by a 
lumbar puncture (Hill et al., 1999). However, for continuous CSF sampling, a 
cannula could also be implanted in the lumbar region (Bruce and Oldfield, 
1988). In animals, CSF can be obtained relatively easy by a single puncture or 
the implantation of a cannula in the lateral ventricle or cisterna magna (Bouman 
and van Wimersma Greidanus, 1979; Cserr, 1965; Cserr, 1971; Nielsen et al., 
1980; van Bree et al., 1989). Also, a few examples in literature exist on a 
lumbar puncture taken from in rats (De La Calle and Paíno, 2002; Wang et al., 
2005). As a concentration gradient could exist along the CSF flow path due to 
its high flow, the location of CSF sampling is very important for interpretation 
of data and extrapolation to the clinical setting (Summerfield and Jeffrey, 2006). 
Mayer and colleagues combined the brain perfusion technique with CSF 
sampling from the cisterna magna in rabbits to compare the rate and extent of 
drug penetration between CSF and specific areas of the brain (Mayer et al., 
1959). They concluded that these parameters are determined by the lipophilicity 
of the compound. However, small differences in the rate of entry between CSF 
and the brain were observed for antipyrine and barbital, whereas their extent of 
brain entry was similar. Also, differences in both the rate and extent of 
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penetration of salicylic acid between CSF and brain were observed (Mayer et 
al., 1959). As salicylic acid is known to be transported by an organic anion 
transport system (Lorenzo and Spector, 1973), the difference in the rate and 
extent of penetration may in part result from differences in the activity of such 
transport systems at the BBB and BCSFB. However, the difference in the rate 
and extent of penetration may also in part result from differences in physiology 
between the BBB and BCSFB. 
Kalvass and Maurer (2002), Maurer et al. (2005), Liu et al. (2006), and 
Fridén et al. (2009b), all used single time point CSF samples from the cisterna 
magna of rats or mice in combination with the brain perfusion technique to 
compare steady state CSF concentrations to steady state unbound brain 
concentrations of over one hundred structurally diverse compounds. They all 
concluded that steady state CSF concentrations were comparable to steady state 
unbound brain concentrations within a 3-fold error range for compounds that 
freely diffuse across the BBB and BCSFB. Liu et al. (2009) also applied CSF 
sampling from the cisterna magna of rats in combination with the intracerebral 
microdialysis technique and showed that steady state CSF concentrations 
predicted steady state unbound brain concentrations very well within the 3-fold 
error range for the selected compounds, which also include some P-gp 
substrates. Possibly, CSF and brainECF concentrations have had the time to reach 
equilibrium at steady state. However, for compounds with differences between 
CSF and brainECF concentrations beyond the 3-fold error range, qualitative and 
quantitative differences in transporter activity between BBB and BCSFB may 
play a role. 
The use of CSF as a surrogate for unbound brain target site concentrations 
has been discussed previously by De Lange and Danhof (2002), Shen et al. 
(2004), and Lin (2008). In short, they concluded that the use of CSF offers one 
significant advantage over other methods, in that this fluid is accessible both in 
animals as well as in humans, and provides information on the unbound 
concentration. However, CSF sampling generally lacks the possibility to obtain 
concentration-time profiles, at least in humans, whereas in animals, taking a 
CSF sample significantly affects the CSF volume, of which the impact is not yet 
known (De Lange et al., 1997).  
 
 
Preclinical prediction of human brain target site concentrations 
27 
 
Intracerebral microdialysis 
 
The intracerebral microdialysis technique is an in vivo technique that permits 
monitoring of local concentrations of drugs and metabolites by implantation of 
a microdialysis probe in a specific site in the brain (De Lange et al., 1994; 
Morrison et al., 1991; Nicolaysen et al., 1988; Sabol and Freed, 1988; Ståhle et 
al., 1991; Terasaki et al., 1991; Wang et al., 1995; Wong et al., 1992). The 
probe contains a semipermeable membrane that is continuously perfused with a 
physiological solution that matches the ionic composition of the (extracellular) 
fluid surrounding the probe. Small enough molecules that are able to pass the 
membrane will diffuse into or out of the perfusate, down their concentration 
gradients. The solution that exits the probe, the dialysate, is then collected for 
analysis. However, because of the continuous flow of the perfusing solution, the 
concentration in the dialysate will be different from that in the surrounding 
fluid. The term ‘concentration recovery’ is used to describe this relationship and 
should always be determined for quantification of microdialysis data (De Lange 
et al., 2000). 
The microdialysis technique has a number of advantages: (1) Sampling can 
be performed continuously without fluid loss. (2) High resolution concentration-
time profiles can be obtained from distinct brain regions in freely moving 
individual animals. (3) This reduces the number of animals needed for PK 
investigations. (4) The samples obtained are protein free. (5) Ex vivo analysis of 
the dialysate samples permits measurement of drug concentrations by any 
suitable analytical technique. However, the microdialysis also has its 
disadvantages: (1) The microdialysis technique is labor intensive, expensive, 
and low throughput. (2) Due to the invasive nature of implantation of the 
microdialysis probe, this technique only has a limited applicability in the human 
situation. (3) Due to the diluting effect of the dialysis, sensitive analytical 
methods are required to detect low concentrations. (4) The microdialysis 
technique is not always suitable for lipophilic compounds as they tend to adsorb 
to the microdialysis equipment (De Lange et al., 1997; De Lange et al., 2000; 
Sun and Stenken, 2003). However, the composition of the microdialysis 
perfusion fluid may be altered to improve the recovery, for example by addition 
of albumin or cyclodextrins to the perfusion fluid (Sun and Stenken, 2003). 
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Despite the very important advantage of being able to measure unbound 
brain concentrations as a function of time, the microdialysis technique is not 
often applied during early drug discovery because of the low throughput. 
However, it may provide information on the rate and extent of BBB and BCSFB 
transport, and modulations thereof. Furthermore, the microdialysis technique 
can be used to further distinguish the possible contribution of many dynamically 
regulated passive and active transport mechanisms. 
One particular case is the investigation of the relationship between CSF and 
brainECF concentrations, for the interpretation of human CSF data (De Lange 
and Danhof, 2002; Lin, 2008; Shen et al., 2004). Several studies have been 
performed in which two microdialysis probes were implanted in a single 
animal; one in a selected brain region for measuring drug concentrations in the 
brainECF, and one in the lateral ventricle or cisterna magna for measuring drug 
concentrations in the CSF (Malhotra et al., 1994; Matos et al., 1992; Wong et 
al., 1992). 
Wong et al. (1992) found ventricular CSF concentrations being twice as high 
compared to rabbit brainECF concentrations for zidovudine. Matos et al. (1992) 
measured morphine in CSF from the rat lateral ventricle, third ventricle, cisterna 
magna and spinal cord in the rat, and found morphine evenly distributed in all 
selected brain regions and CSF, except for cisternal CSF. Interestingly, cisternal 
CSF concentrations were about 5-fold higher than ventricular and lumbar CSF 
concentrations. This is counterintuitive, considering the CSF flow path. 
However, the concentration recovery was not addressed adequately. Finally, 
Malhotra et al, (1994) found that rat ventricular CSF concentrations were ~3-
fold higher compared to brainECF concentrations at steady state for EAB 515. 
 
PET and SPECT  
 
Positron emission tomography (PET) and single-photon emission computed 
tomography (SPECT) are very powerful techniques to study brain kinetics at 
multiple sites (Dresel et al., 1998; Erlandsson et al., 2005; Mamo et al., 2004; 
Remington et al., 2006; van Waarde, 2000). In short, small amounts of 
radiolabeled compounds are injected into the bloodstream, after which the total 
brain uptake can be estimated by calculating the ratio of the total brain 
radioactivity divided by the injected radioactivity. 
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The main difference between PET and SPECT is the type of radiation that is 
used. PET, as the name suggests, uses a positron emitter (usually 11C or 18F) for 
imaging, whereas SPECT uses a gamma emitter (often 123I) (Erlandsson et al., 
2005; Haubner, 2010; Kouris, 1984). PET provides higher resolution images 
than SPECT. The major advantages of PET and SPECT are that these 
techniques are noninvasive and applicable to both animals and humans (van 
Waarde, 2000). As disadvantages, however, (1) PET and SPECT require 
radioactively labeled compounds, which is expensive and time-consuming in 
producing (Liu and Jia, 2007). Moreover, especially for PET radionuclides, the 
duration of a scan is limited by the decay of the radioactive label. For 11C, 
which has a half-life of only 20 min, this means that synthesis of the 
radiolabeled compound should be performed on-site, right before the 
experiment. (2) While 18F (half-life of 110 min) and 123I (half-life of 13.2 h) can 
provide more flexibility in time, the labeling with these nuclei may change the 
compounds’ properties. (3) Also, for animals, anesthesia is required, which may 
affect the physiological status of the animal, and may further limit the 
comparison to humans (Claassen, 1994). (4) Another disadvantage is that PET 
and SPECT signals do not distinguish between compounds and their 
metabolites, (5) nor between bound and unbound concentrations, as they can 
only localize the level of radioactivity (Neuwelt et al., 2008). 
 
 
CONSIDERATIONS IN ANIMAL-TO-HUMAN 
EXTRAPOLATION / PREDICTION 
 
All vertebrates share the same mechanisms of blood-brain transport (Cserr and 
Bundgaard, 1984). However, the rate and extent of these mechanisms depend on 
conditions such as species, gender, tissue, genetic background, diet, disease, 
drug use, etc. As a result, observations in a particular setting are not necessarily 
predictive of what would be observed in another setting. In the following 
section, we will discuss the possible use of the different techniques in the 
clinical setting or for the prediction of human brain target site concentrations, as 
well as how different conditions may affect brain processes and therewith drug 
distribution into the brain. 
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Application of the different techniques in the extrapolation to the clinical 
setting 
 
The brain perfusion technique, the brain homogenate free fraction method and 
the brain slice technique can all be applied to determine the rate and extent of 
brain target site exposure. This is often done during early CNS drug discovery, 
as these techniques have relatively high throughput and allow for good drug 
candidate selection (Read and Braggio 2010). However, these techniques have 
very limited applicability in the extrapolation to the clinical setting. The 
techniques that can be applied both in animals as well as in humans are the CSF 
sampling technique, the intracerebral microdialysis technique, PET, and 
SPECT. Of these techniques, PET and SPECT are the most promising, as they 
are very powerful techniques to study brain kinetics at multiple sites (Dresel et 
al., 1998; Erlandsson et al., 2005; Mamo et al., 2004; Remington et al., 2006; 
van Waarde, 2000). However, the time needed for the development of 
appropriate tracers and high costs of PET and SPECT scanning currently limit 
the use of these techniques during drug development. 
So far, the CSF sampling technique is the technique that is most often used 
during drug development, as CSF sampling is relatively simple, straightforward, 
and cheap, compared to intracerebral microdialysis, PET, and SPECT (Lin, 
2008). Moreover, this can be applied both to humans and animals. However, the 
use of CSF concentrations as a surrogate marker for brain target site 
concentrations is not that simple and straightforward, as a generally applicable 
relationship between CSF concentrations and brain target site concentrations 
does not exist (De Lange and Danhof, 2002; Lin, 2008; Shen et al., 2004). 
Therefore, it is questionable whether brain target site concentrations can be 
predicted on the basis of CSF concentrations. 
A number of studies have indicated that for most compounds there is not 
much difference between apparent steady-state concentrations in CSF and 
brainECF in the rat (concentration ratios are < 3) (Fridén et al., 2009b; Kalvass 
and Maurer, 2002; Liu et al., 2006; Maurer et al., 2005). However, the 
following questions still remain: 
• Are such ratios predictive for the human situation? 
• How does disease state influence such ratios? 
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• And, most importantly: if human CSF concentrations would have been 
predictive than why hasn’t it proven itself as such? 
The only technique that allows the measurement of unbound drug 
concentrations at the brain target site as well as in CSF in vivo is the 
intracerebral microdialysis technique. In the preclinical setting, the intracerebral 
microdialysis technique could very well be used to investigate the relationship 
between CSF concentrations and brain target site concentrations (Malhotra et 
al., 1994; Matos et al., 1992; Wong et al., 1992). All in all, each of the different 
techniques has its advantages and disadvantages for extrapolating to the clinical 
setting. 
 
Condition-dependent factors 
 
In the drug development setting we would like to use animal data as best as 
possible for prediction of the human situation. This means that we have to 
consider sources of variation from controlled preclinical situations to clinical 
practice. One of the major issues in extrapolating from animal data to the human 
situation is that the vast majority of studies are being done in healthy animals, 
whereas there is increasing evidence that dysfunctional BBB mechanisms are at 
the core of CNS diseases (Jeffrey and Summerfield, 2010). However, for certain 
CNS disorders, there are simply no appropriate animal models available. In that 
case, animal experiments can improve our understanding of the biological 
system, which is essential to be able to understand the processes that underlie 
the disease. Then, for accurate prediction of CNS drug concentrations and effect 
in humans on the basis of animal data, one should take into account the possible 
influences of CNS diseases and genetic differences between species on the 
processes that govern CNS exposure (Syvänen et al., 2009). 
Inflammatory and oxidative stress, which are cofactors in nearly every CNS 
disease, can acutely disrupt the BBB and BCSFB at the level of the tight 
junctions (Miller, 2010). It has also been shown that a bacterial or viral 
infection of the CNS can cause a disruption in the integrity of the BBB and 
BCSFB (Paul et al., 1998). So far, only limited information is available on the 
impact of CNS diseases on the expression levels of the different active transport 
systems that are located on the BBB and BCSFB. Of the different transport 
systems, most information is available on the regulation of expression levels of 
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P-gp. However, there is some evidence that also BCRP, MRP1, MRP2, and 
MRP4 expression is altered after exposure to certain xenobiotics, which include 
therapeutic agents and environmental toxicants (Miller, 2010). Some of these 
xenobiotics have also been found to increase expression of drug metabolizing 
enzymes in brain capillary endothelial cells. Increased expression levels of the 
different transport systems and drug metabolizing enzymes can make it very 
difficult to get sufficient amounts of drugs to their brain target site. Despite the 
success of specific transport inhibitors in improving drug delivery to the brain in 
animal studies, the results have not been translated to the clinic (Miller, 2010). 
It has been suggested that blocking of P-gp could improve drug delivery across 
the BBB. However, effective doses of P-gp inhibitors, such as cyclosporine and 
verapamil, are often toxic (Neuwelt, 2004). 
The effect of inflammation on the activity and expression levels of transport 
systems is rather complex, as the direction and degree of change in expression 
levels is found to be dependent on the inflammatory signal and time after 
exposure. For instance, it has been found that P-gp activity is decreased after 
short-term exposure to proinflammatory signals, whereas there is no change in 
P-gp expression (Roberts and Goralski, 2008). Following a more prolonged 
exposure, the activity and expression of P-gp are both increased (Roberts and 
Goralski, 2008). However, rather than being an effect of CNS diseases, the 
change in transporter expression can also be the cause of CNS diseases. There 
have been some reports that a decrease in P-gp expression causes an increase in 
amyloid β protein levels in the brain, which is involved in the pathogenesis of 
Alzheimer’s disease (Cirrito et al., 2005; Vogelgesang et al., 2002; 
Vogelgesang et al., 2004). Reduced expression or activity of P-gp has also been 
associated with Creutzfeld-Jakob disease (Vogelgesang et al., 2005), 
Parkinson’s disease (Vautier et al., 2009), HIV infection (Langford et al., 
2004), and normal aging (Bauer et al., 2009). Furthermore, increased expression 
or activity of P-gp, but also BCRP, MRP1, and MRP2 is associated with 
epileptic seizures (Löscher and Potschka, 2005a). 
Of all the different transporter systems, P-gp is considered to be the most 
clinically relevant, as it has a broad substrate specificity and plays an important 
role in drug disposition and response. Besides being expressed at the BBB and 
BCSFB, P-gp can also be found in the liver, kidneys, and intestine (Thiebaut et 
al., 1987). As a result, a variable expression or activity of P-gp will alter the 
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extent of absorption, tissue distribution, and excretion of compounds that are 
substrates for P-gp (Marzolini et al., 2004). The variable expression or activity 
could be caused by single-nucleotide polymorphisms (SNPs) that have been 
reported for the gene encoding P-gp (Marzolini et al., 2004). While the effect of 
most SNPs on the expression or activity of P-gp still remains unclear, it has 
been reported that the absorption by the gut is altered by a specific 
polymorphism in exon 26 (C3435T), which results in a lower expression level 
of P-gp (Hoffmayer et al., 2000). The same SNP has also been reported to be 
involved in drug-resistant epilepsy, where epileptic patients that have the 
specific SNP are more likely to respond to antiepileptic drugs (Siddiqui et al., 
2003). This is probably the result of a decreased expression and activity of P-gp 
at the BBB. 
Even though most of the different transport systems at the BBB and BCSFB 
are expressed both in humans as well as in rats, their expression levels and 
activities might differ greatly between species (table 1) (Begley, 2004; 
Choudhuri et al., 2003; Graff and Pollack, 2004; Hagenbuch and Meier, 2004; 
Hoshi et al., 2013; Kusuhara and Sugiyama, 2004; Kusuhara and Sugiyama, 
2005; Löscher and Potschka, 2005b; Perrière et al., 2007; Syvänen et al., 2009; 
Uchida et al., 2011; Vannucci, 1994). This is probably the result of the genetic 
differences between humans and rats. The most profound differences can be 
seen for P-gp and the OATP family. 
In humans, P-gp is encoded by the MDR1 gene, whereas in rodents it is 
encoded by two genes; mdr1a and mdr1b. Both mdr1a and mdr1b are present in 
rodent brain, but only mdr1a is located at the BBB, while mdr1b is present in 
brain parenchyma (Demeule et al., 2002). The substrate specificity of mdr1a 
and mdra1b P-gp is largely overlapping, although there are some differences 
(Schinkel, 1999). As the tissue distribution of mdr1a and mdr1b P-gp is 
different, but partly overlapping, this suggests that the mdr1a and mdr1b P-gp in 
rodents functions the same as the MDR1 P-gp in humans (Schinkel, 1999). For 
the OATP family, the differences between species are more profound 
(Hagenbuch and Meier, 2004). However, because the OATP family has a broad 
and partially overlapping substrate specificity, it is likely that the functions of 
the different subtypes are comparable between rodents and humans (Hagenbuch 
and Meier, 2004). 
  
Chapter 1 
34 
 
Table 1. Overview of the different active transport systems that are located at the human and rat 
BBB and BCSFB 
Transporter 
protein Human BBB Rat BBB Human BCSFB Rat BCSFB 
P-gp + 1 + 5,a + 2 + 2,a 
BCRP + 1 + 5 - - 
MRP1 + 2 + 6 + 2 + 11 
MRP2 + 2 + 7 - + 11 
MRP3 + 2 + 6 - + 11 
MRP4 + 1 + 5 + 8 + 11 
MRP5 + 2 + 6 + 8 + 11 
MRP6 + 2 - - + 11 
OCT1 + 2 - + 2 + 11 
OCT2 + 2 + 8 + 2 + 11 
OCT3 + 2 + 8 + 2 + 8 
OCTN1 + 2 + 8 + 8 + 11 
OCTN2 + 2 + 8 + 8 + 11 
OATP A + 3 - - - 
OATP B + 3 + 8,b + 8 + 11,b 
OATP E + 3 + 8,c + 8 + 11,c 
OATP F + 3 + 8,d - + 11,d 
Oatp1 - + 3 - + 2 
Oatp2 - + 3 - + 2 
Oatp3 - + 3 - + 2 
OAT1 + 2 + 2 + 10 + 8 
OAT2 - - - + 8 
OAT3 + 4 + 5 + 10 + 8 
GLUT-1 + 1 + 5 + 2 + 9 
 
Notes to table 1: 1 Uchida et al., 2011; 2 Graff and Pollack, 2004; 3 Hagenbuch and Meier, 2004; 
4 Löscher and Potschka, 2005b; 5 Hoshi et al., 2013; 6 Perrière et al., 2007; 7 Begley, 2004;          
8 Kusuhara and Sugiyama, 2004; 9 Vannucci, 1994; 10 Kusuhara and Sugiyama, 2005;                 
11 Choudhuri et al., 2003.  
a Human P-gp encoded by MDR1, rat P-gp encoded by mdr1a/mdr1b; b The rat ortholog of OATP 
B is Oatp9; c The rat ortholog of OATP E is Oatp12; d The rat ortholog of OATP F is Oatp14. 
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Another important difference between species is the relative rate of CSF 
production, which is estimated to be about 0.88 %/min in rats, compared to 0.29 
%/min in humans (table 2). Thus, there is a higher CSF turnover in rats 
compared to humans. This could be important for hydrophilic compounds, as 
they can be taken along with the CSF and the relatively high flow of CSF could 
thereby prevent the diffusion to the brain target site. As for lipophilic 
compounds, even though the protein concentration in human CSF is reported to 
be about 400 times less than in human blood, the CSF protein concentration in 
the rat is 5-10 times higher compared to humans (Maurer, 2010). It has also 
been reported that CSF protein concentrations increase along the flow path. 
Therefore, a concentration gradient could exist along the CSF flow path for both 
hydrophilic as well as lipophilic compounds. This indicates that the location of 
CSF sampling is very important (Summerfield and Jeffrey, 2006). 
These are all examples illustrative of the fact that we need a more thorough 
understanding of the processes that occur in the brain. To do so, we must gather 
and combine mechanistic information on the contribution of processes on the 
causal chain from drug administration, to drug brain target site PK, to ultimate 
CNS drug effects, including the variability in these contributions that will exist 
between conditions. Such will pave the way for adequate prediction of human 
drug effects. Consequently, a lot of data needs to be integrated, which is beyond 
individual intellectual capabilities. Therefore, we need to make use of 
mathematical modeling. 
 
Table 2. Differences between rat and human physiological parameters 
Parameter Human value Rat value 
BrainECF volume 240 ml 1 290 μl 6 
BrainECF production 
rate 
0.15-0.2 ml/min (0.0625-0.083 
%/min) 1,2 
0.2-0.5 μl/min (0.069-0.17 
%/min) 6,7 
CSF volume 140 ml 3 250 μl 8 
CSF production rate 0.4 ml/min (0.29 %/min) 4 2.2 μl/min (0.88 %/min) 9 
Cerebral blood flow 
700 ml/min (14% of cardiac 
output) 5 
1.1 ml/min (2.5% of cardiac 
output) 10 
 
1 Begley, 2000; 2 Kimelberg, 2004; 3 Kohn et al., 1991; 4 Nilsson et al., 1992; 5 Ito et al., 2006;     
6 Cserr et al., 1981; 7 Abbott, 2004; 8 Bass and Lundborg, 1973; 9 Cserr, 1965; 10 Harashima et 
al., 1985. 
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Mathematical modeling 
 
We can learn more on the inter-relationship between plasma PK, BBB transport 
and intra-brain distribution, by performing integrative cross-compare designed 
studies in animals in which variables are systematically varied (e.g. inhibition of 
an efflux transporter, or induction of pathological state). This allows us to 
dissect contributions of individual mechanisms of blood-brain transport in 
animals, which provides links to the human situation. Humans have the same 
mechanisms as animals, but these may have a different rate and extent and 
therefore have different contributions to the dose-effect relationships (Cserr and 
Bundgaard, 1984). As many variables are in play, we need to organize and 
integrate all these, and further condense and store such knowledge in 
mathematical models. 
 
Compartmental modeling - In order to be able to predict human brain target site 
concentrations and ultimate drug effect on the basis of preclinical data, different 
mathematical modeling techniques can be applied (Danhof et al., 2008). The 
most commonly applied mathematical modeling technique is the relatively 
simple compartmental model analysis, viewing the body as a series of virtual 
and interconnected compartments (Fleishaker and Smith, 1987). Using mass 
balance differential equations, concentration-time profiles in different 
compartments can be described. These equations can also be used to calculate 
PK parameters like volume of distribution, systemic clearance, and elimination 
half-life. 
 
Allometric scaling - Extrapolation of animal PK parameters to the human 
situation is necessary for designing first in human trials, which can sometimes 
be done reasonably well by allometric scaling (Bonati et al., 1984; Lavé et al., 
1999; Mahmood and Balian, 1999; Obach et al., 1997; Yassen et al., 2007; 
Zuideveld et al., 2007). Allometric scaling uses bodyweight or body surface 
area as the main determinant of PK parameters, assuming that there are 
anatomical, physiological and biochemical similarities among different species 
(Boxenbaum, 1982; Dedrick, 1973; Mordenti, 1986). However, for predicting 
human PK parameters that are involved in more complex systems on the basis 
of animal data, a physiologically-based (PB) PK model is more appropriate. 
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PBPK modeling - PBPK models integrate drug-dependent, physiological, and 
biological parameters as they vary in between species, subjects, or with age and 
disease state (Colburn, 1988a; Espié et al., 2009; Ings, 1990). In a PBPK model 
the tissues of interest are viewed as body compartments and are arranged in 
anatomical order, based on blood circulation, to form an integrated 
physiological model (Colburn, 1988a; Espié et al., 2009; Ings, 1990; Rowland 
et al., 2004). Once a suitable model has been developed, the concentration-time 
profiles of the drug in each of the body compartments can be calculated based 
on a mass balance. The distribution of the drug can then be linked to the 
physicochemical properties of the drug and the type of tissue involved. 
Distribution of the drug into tissues can further be classified as either perfusion 
rate limited or permeability rate limited (Colburn, 1988a; Ings, 1990; Jones et 
al., 2009). 
A typical PBPK model consists of non-eliminating (adipose, bone, brain, 
gut, heart, lung, muscle, skin, spleen) and eliminating tissues (kidney and liver) 
(figure 3A) (Jones et al., 2006; Jones et al., 2009; Rowland et al., 2004). 
However, to be able to properly predict brain target site concentrations, the 
brain compartment in the PBPK model should describe the complexity of the 
CNS (De Lange and Danhof, 2002; Ooie et al., 1997; Shen et al., 2004). Figure 
3B shows the complexity of the CNS in the brain compartment of a PBPK 
model. 
Even though the PBPK approach may be more suitable for complex systems, 
it also results in complex mathematical models that are expensive and time 
consuming. Therefore, PBPK models are often only used in the later stages of 
drug development (Espié et al., 2009; Ings, 1990; Jones et al., 2006; Jones et 
al., 2009; Rowland et al., 2004). 
 
Modeling of drug effect - Ultimately, the goal of mathematical modeling is to 
be able to predict drug efficacy and safety in humans on the basis of animal data 
(Danhof et al., 2008). To link drug concentration-time data to the physiologic 
response, PK-PD modeling is often applied. The primary objective of PK-PD 
modeling is prediction of the time course of the drug effect in vivo in health and 
disease (Breimer and Danhof, 1997). Depending on the concentration-effect 
relationship, as well as the type of response (inhibition or stimulation), different 
PK-PD models can be used (Csajka and Verotta, 2006; Swinghammer and 
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Kroboth, 1988). When the effect is directly related to plasma concentrations, a 
PK compartmental model with the addition of an effect compartment could be 
sufficient (Sheiner et al., 1979). However, as CNS drug effects often have their 
origin in the brain, an alternate model that relates the effect to drug 
concentrations in a peripheral compartment is more appropriate (Colburn, 1981; 
Colburn, 1988b). 
 
Prediction of human drug effect - Extrapolation of animal PK-PD data to 
predict the time course of the drug effect in humans can sometimes be done by 
simple allometric scaling of the PK parameters and the PK-PD relationship 
(Mager et al., 2009). However, for accurate prediction of human drug effect on 
the basis of animal data, one should also understand the biological processes 
that underlie the effect. These processes include target site distribution, target 
binding, target activation, transduction, homeostatic feedback, and disease 
processes (Danhof et al., 2005; Danhof et al., 2007). Information on these 
processes is included in mechanism-based (MB) PK-PD modeling. A major 
advantage of MBPK-PD modeling is the distinction between drug-specific 
parameters and biological system-specific parameters. Drug-specific parameters 
are dependent on the physicochemical properties of the drug and include target 
affinity and target activation, whereas biological system-specific parameters 
describe the functioning of the biological system (Danhof et al., 2008). This 
indicates that MBPK-PD modeling can be applied for the extrapolation of 
animal data to the human situation, but also from one drug to another. 
 
 
DISCUSSION AND CONCLUSIONS 
 
The development of drugs for central nervous system (CNS) disorders has 
encountered high failure rates. In part this has been due to the sole focus on 
BBB permeability of drugs, without taking into account all other processes that 
determine drug concentrations at the target site. Moreover, conditional 
dependence of these processes has typically been neglected. 
The impact of these processes can be studied in the preclinical setting with 
several in vitro, ex vivo, and in vivo techniques. However, considering the 
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animal-to-human extrapolation, the CSF sampling technique and intracerebral 
microdialysis technique are currently the best available techniques. 
In practical terms, of special interest is CSF sampling as it can be performed 
in animals as well as in humans and provides information on unbound drug 
concentrations. A number of studies have shown that steady state CSF 
concentrations can be used very well for the prediction of steady state brain 
concentrations within a 3-fold error range for compounds that freely diffuse 
across the BBB and BCSFB, whereas the difference between CSF exposure and 
brain exposure may be beyond 3-fold for compounds that are substrates for the 
different active transport systems at the BBB and BCSFB (Fridén et al., 2009b; 
Kalvass and Maurer, 2002; Liu et al., 2006; Maurer et al., 2005). On that basis 
it may be questioned: 
• How useful are steady state concentration ratios? What is the degree of 
fluctuation in plasma concentrations and how does this correspond to 
the degree of variation in concentrations at the brain target site? And, in 
what extent are the CNS effects sensitive for such fluctuations? 
• How useful are single time point CSF or total brain samples? One 
should consider that the use of a single time point sample as a marker 
for CSF or total brain exposure tells us nothing about the rate of blood-
brain transport, which is relevant for drugs with a desired rapid onset of 
action. 
• What is the impact of the 3-fold error that is allowed for the estimation 
of CSF-brainECF concentration ratios? The 3-fold error is considered to 
be of little pharmacologic or pharmacokinetic consequence for the 
prediction of unbound brain concentrations on the basis of CSF 
concentrations (Maurer et al., 2005). However, the 3-fold error is also 
allowed for the prediction of human CSF exposure on the basis of rat 
CSF exposure (Fridén et al., 2009b). This results in a 9-fold error that is 
allowed for the prediction of human unbound brain exposure on the 
basis of human CSF exposure. This may have significant consequences 
if a drug has a steep concentration-effect relationship or a narrow 
therapeutic window. 
This implicates that in order to be able to accurately predict CNS drug effect in 
humans, it is essential that we increase our understanding of the complexity of 
the CNS and CNS disorders. Given that CSF concentrations are often 
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considered to be the best available surrogate for brain target site concentrations 
in humans (Fridén et al., 2009b; Kalvass and Maurer, 2002; Liu et al., 2006; 
Liu et al., 2009; Maurer et al., 2005), future research should focus on studying 
the relationship between CSF concentrations and brain target site 
concentrations. 
The only technique that allows the measurement of unbound drug 
concentrations at the brain target site, provided that the CNS drug target faces 
the brainECF, as well as in CSF in vivo is the intracerebral microdialysis 
technique. In the preclinical setting, the intracerebral microdialysis technique 
could very well be used to investigate the relationship between CSF 
concentrations and extracellular brain target site concentrations (Malhotra et al., 
1994; Matos et al., 1992; Wong et al., 1992). When the CNS drug target is 
located intracellularly, there is not a single technique that allows to study the 
relationship between CSF concentrations and intracellular concentrations. This 
indicates that a combination of different techniques should be applied. 
However, to be able to predict CNS drug effect in humans, it is also essential to 
study the underlying processes that govern the concentration-effect relationship. 
In combination with CSF sampling, brain tissue sampling and serial blood 
sampling, the intracerebral microdialysis technique provides very useful data to 
determine the kinetics of transport equilibration across the BBB and BCSFB 
under a variety of conditions, in the species of choice, such as mice, rats, 
rabbits, piglets and monkeys, as well as in humans (intensive care patients). 
Therefore it is of importance to investigate the inter-relationship between 
plasma PK, BBB transport and intra-brain distribution in integrative cross-
compare designed studies. By systematically influencing one (or a subset) of 
variables, one can decipher the impact of changes at the level of this variable on 
the blood-brain transport. 
Such information on the rate and extent of BBB and BCSFB transport, and 
modulations thereof, will be useful to further distinguish the possible 
contribution of many dynamically regulated passive and active transport 
mechanisms. The knowledge thus provided on BBB and BCSFB transport 
mechanisms and regulation is critical for the understanding of brain 
homeostasis, and how disturbances thereof may lead to CNS diseases. Also, it 
will be critical in ultimately being able to predict the PK-PD relationship of 
CNS active compounds. 
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Apart from striving towards reduction of the use of animals and the fact that 
animal models of CNS diseases will never exactly reflect the disease conditions 
in human, we will move forward considerably by systematic research on CNS 
drugs in the preclinical setting, including animal models of CNS diseases that 
reflect important parts of disease mechanisms. As many variables are in play, 
we need to organize and integrate all these, and further condense and store such 
knowledge in mathematical frameworks. 
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Drug distribution into the brain is governed by many processes, including 
plasma pharmacokinetics (PK), plasma protein binding, passive and active 
transport across the blood-brain (BBB) or blood-cerebrospinal fluid barrier 
(BCSFB). In addition, once within the brain, it includes bulk flow, diffusion, 
and extra-intracellular exchange. This multifactorial nature of brain distribution 
complicates the prediction of central nervous system (CNS) drug effects in man. 
To predict (desired or undesired) CNS drug effects in humans, a mechanistic 
understanding is needed of the individual contributions of the abovementioned 
processes involved in brain target site distribution. With the unbound drug 
concentrations at the brain target site being responsible for the CNS effect it is 
important to determine or predict in particular the unbound drug concentration-
time profiles at their site of action. For many CNS active compounds, brain 
target site concentrations are closely linked to, or even indistinguishable from, 
the unbound drug concentrations in the brain extracellular fluid (brainECF) (De 
Lange et al., 2000; Hammarlund-Udenaes, 2009; Jeffrey and Summerfield, 
2010; Watson et al., 2009). This indicates that direct measurement of brainECF 
concentrations in human would be very valuable. The only technique currently 
available to measure brainECF concentration-time profiles is the intracerebral 
microdialysis technique. Unfortunately, this technique is invasive, though 
minimally, and therefore highly limited for general application in humans. The 
search is therefore for approaches to predict human brainECF PK via other 
approaches. 
 
In Chapter 1 several techniques that can be applied during the preclinical phase 
of drug development to determine or predict human brain target site 
concentrations are reviewed. In practical terms, CSF sampling is of special 
interest as it can be performed in animals as well as in humans and provides 
information on unbound drug concentrations (Danhof and Levy, 1984). 
Furthermore, CSF concentrations are often considered to be the best available 
surrogate for brain target site concentrations in humans as it is assumed that 
CSF concentrations readily equilibrate with brainECF concentrations due to the 
lack of a physical barrier between these sites (Lee et al., 2001). However, 
qualitative and quantitative differences in processes that govern the PK of drugs 
in the brain exist between different conditions (species, gender, diet, disease 
etc.). This makes that a generally applicable relationship between CSF 
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concentrations and brainECF concentrations does not exist (De Lange and 
Danhof, 2002; Lin, 2008; Shen et al., 2004). This underscores the need for more 
quantitative understanding of the processes involved in brain target site 
distribution, and their individual and condition-dependent contributions to the 
brain PK and therewith to the ultimate CNS drug effect.  
With the use of several different preclinical techniques mechanistic 
information on the rate and extent of unbound drug distribution into and within 
the brain can be gathered. However, most of the preclinical techniques appear to 
have very limited applicability in the extrapolation to the human situation due to 
fact that (total) brain tissue concentrations are measured that, for obvious 
reasons, can never be directly compared to human measurements. In both 
humans and animals, non-invasive techniques like positron emission 
tomography (PET) and single-photon emission computed tomography (SPECT) 
can be applied for measurement of total brain activity of the ligand, which may 
provide information on the total drug concentration to calculate PK or brain 
target occupancy. Also CSF can be sampled from both humans and animals. 
Thus far, CSF sampling in animal and human is most often used during drug 
development. As the compound is typically present in its unbound form in the 
CSF and CSF may be obtained at multiple time points, this fluid is of special 
value. Therefore, its usefulness as a surrogate marker for brain target site 
concentrations is of interest. 
In a preclinical setting CSF sampling has been combined with other 
techniques to study the relationship between CSF concentrations and unbound 
brain target site concentrations. These studies have typically used single time-
point CSF and brain tissue samples, in healthy animals and under the 
presumption of steady state conditions (Fridén et al., 2009; Kalvass and Maurer, 
2002; Liu et al., 2006; Liu et al., 2009; Maurer et al., 2005).  
The only technique that allows the measurement of unbound drug 
concentrations at the brain target site as well as in CSF as a function of time is 
the intracerebral microdialysis technique. As this technique is (minimally) 
invasive it cannot readily be used in the clinical setting. However, it is 
anticipated that studies in experimental animals will provide data that can be 
used to build a mathematical brain distribution model that can be translated to 
the human situation if based on physiological systems parameters (Kielbasa and 
Stratford Jr, 2012). 
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Chapter 3 describes the application of multiple intracerebral microdialysis 
probes to single animals for direct comparison between unbound concentrations 
of acetaminophen, a paradigm compound for passive transport, in brainECF, CSF 
from lateral ventricle (CSFLV) and CSF from cisterna magna (CSFCM). In 
combination with advanced mathematical modeling, taking into account the 
physiology of the rat brain, a systems-based pharmacokinetic (SBPK) model 
was developed to describe our experimental data. Furthermore, by scaling the 
physiological parameters to the human values, the SBPK model was then used 
to predict human brainECF concentrations by comparison with human CSF 
concentrations available from literature. As acetaminophen is a small, 
moderately lipophilic molecule, and distribution is governed by passive 
transport only, it was expected to be readily and evenly distributed over the 
brain, in both rats and humans. 
For compounds subjected to active transport at the BBB and/or BCSFB, 
such as by the efflux transporter P-glycoprotein (P-gp), differences between 
brainECF and CSF are anticipated to be more profound. With P-gp functioning as 
an efflux transporter at both the luminal and abluminal membranes of capillary 
endothelial cells of the BBB, as well as at the adjacent pericytes and astrocytes, 
it is suggested that P-gp may regulate drug transport processes within the brain 
at both the cellular and subcellular level. Although the localization and 
functionality of P-gp at the BCSFB is still subject of debate, this could result in 
significant differences between concentrations at the brain target site and in 
CSF for compounds that are substrates for P-gp mediated transport.  
 
Chapter 4 describes the application of the multiple microdialysis probes 
approach for continuous measurement and direct comparison of brainECF and 
CSF kinetics of quinidine, a well-known P-gp substrate. The impact of P-gp 
functionality on non-steady state relationships between CSF and brainECF 
quinidine concentrations was investigated by co-administration of the P-gp 
blocker tariquidar. The previously developed SBPK model for acetaminophen 
was expanded to allow the characterization of the specific impact of P-gp 
functionality on the within brain distribution using quinidine as paradigm 
compound. This resulted in a number of key findings. 
Besides P-gp, there is a wide range of other active transport systems located 
at the BBB and BCSFB, including organic cation transporters (OCT), organic 
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anion transporters (OAT), organic anion-transporting polypeptide (OATP), 
breast cancer resistance protein (BCRP), and the multidrug resistance-
associated protein (MRP) family (Graff and Pollack, 2004).  
Methotrexate is currently given in the clinic for CNS prophylaxis in case of 
malignant diseases with a high risk of prevalence of tumor metastases in the 
CNS. With the CNS being the target site for CNS prophylaxis, it is the aim to 
have the appropriate unbound methotrexate concentration at the brain target 
site. To characterize brain distribution of methotrexate, CSF concentrations are 
used, since brainECF concentrations are not readily measurable in humans. 
However, methotrexate is known to be a substrate for a wide variety of 
transporters, including the reduced folate carrier 1 (RFC1), BCRP, MRP2, 3 and 
4, OAT1 and 3, and OATP A and B. This could have major implications for the 
predictability of brainECF methotrexate concentrations on the basis of CSF 
concentrations. Consequently, to be able to determine whether methotrexate 
brainECF concentrations can be adequately predicted by CSF concentrations, one 
should first understand the mechanisms that determine the relationship between 
CSF concentrations and brainECF concentrations. 
 
Chapter 5 describes the application of the multiple microdialysis probes 
approach for continuous measurement and direct comparison of brainECF and 
CSF kinetics of methotrexate. To investigate the specific contribution of the 
various transporters, probenecid is co-administered as inhibitor of MRPs, OATs 
and OATPs. The previously developed SBPK model for acetaminophen and 
quinidine was adapted to allow the identification of the specific impact of 
MRP/OAT/OATP functionality on the basis of our methotrexate rat data. 
Furthermore, the developed SBPK model was also applied to extrapolate our 
data to other conditions, and other species, including human. 
 
In Chapter 6 the results presented in this thesis for the prediction of brain target 
site concentrations on the basis of CSF PK are discussed and future perspectives 
are given for predicting CNS drug effect in humans on the basis of preclinical 
data. 
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ABSTRACT 
 
One of the major challenges in the development of central nervous system 
(CNS) targeted drugs is predicting CNS exposure in human from preclinical 
data. In this study we present a methodology to investigate brain disposition in 
rats using a physiologically-based modeling approach aiming at improving the 
prediction of human brain exposure. We specifically focused on quantifying 
regional diffusion and fluid flow processes within the brain. 
Acetaminophen was used as a test compound as it is not subjected to active 
transport processes. Microdialysis probes were implanted in striatum, for 
sampling brain extracellular fluid (brainECF) concentrations, and in lateral 
ventricle (LV) and cisterna magna (CM), for sampling cerebrospinal fluid 
(CSF) concentrations. Serial blood samples were taken in parallel. These data, 
in addition to physiological parameters from literature, were used to develop a 
systems-based model to describe the regional brain pharmacokinetics of 
acetaminophen.  
The concentration-time profiles of brainECF, CSFLV and CSFCM indicate a 
rapid equilibrium with plasma. However, brainECF concentrations are on average 
4-fold higher than CSF concentrations, with average brain-to-plasma AUC0-240 
ratios of 121%, 28% and 35% for brainECF, CSFLV and CSFCM, respectively. 
It is concluded that for acetaminophen, a model compound for passive 
transport into, within and out of the brain, differences exist between the brainECF 
and the CSF pharmacokinetics. The systems-based pharmacokinetic (SBPK) 
modeling approach is important, as it allowed the prediction of human brainECF 
exposure on the basis of human CSF concentrations. 
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INTRODUCTION 
 
Central nervous system (CNS) disorders are currently estimated to affect 
hundreds of millions of people worldwide (World Health Organization, 2007). 
While established treatments are currently available for most of these disorders, 
significant unmet medical needs still remain, as currently available drugs are 
treating symptoms rather than curing the disease (Pangalos et al., 2007). 
Therefore, novel treatments or drugs with a different mechanism of action are 
needed. However, the failure rate of development of new CNS drugs is very 
high. The actual problem lies in the inability to predict human (wanted and 
unwanted) CNS drug effects.  
It is known that unbound plasma concentrations may not necessarily 
represent the unbound brain concentrations available for target interaction, due 
to distributional mechanisms (Chapter 1). In recent years much attention has 
been given to blood-brain barrier (BBB) permeability, as this is assumed to be 
the main determinant of CNS exposure (Abbott et al., 2008; Bickel, 2005; Feng, 
2002; Hammarlund-Udenaes et al., 2008; Jeffrey and Summerfield, 2010; Liu et 
al., 2008). However, even though BBB permeability is a very important 
determinant, it is not the only relevant process. The brain is a dynamic multi-
compartmental system, in which all processes of drug entry, within brain 
diffusion, metabolism, binding and elimination determine actual CNS target site 
concentrations (Chapter 1). To ultimately be able to predict CNS drug effects 
in humans, a more mechanistic understanding is needed of the individual 
contributions of the processes involved in brain target site distribution and 
ultimately drug effects.  
The use of cerebrospinal fluid (CSF) as a surrogate for unbound brain target 
site concentrations has been discussed previously in Chapter 1 and by De 
Lange and Danhof (2002), Shen et al. (2004) and Lin (2008). In short, it has 
been concluded that a generally applicable relationship between CSF 
concentrations and brain extracellular fluid (brainECF) concentrations does not 
exist due to qualitative and quantitative differences in processes that govern the 
pharmacokinetics (PK) at these sites. However, CSF concentrations are often 
considered the best available surrogate for brain target site concentrations in 
humans (Fridén et al., 2009; Kalvass and Maurer, 2002; Liu et al., 2006; Liu et 
al., 2009; Maurer et al., 2005). 
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In rats, the most common method for collecting a CSF sample is by a single 
puncture or the implantation of a cannula in either the lateral ventricle or the 
cisterna magna (Bouman and van Wimersma Greidanus, 1979; Cserr, 1965; 
Cserr, 1971; De Lange and Danhof, 2002; Nielsen et al., 1980). However, 
taking a CSF sample significantly affects the CSF volume, of which the impact 
is not yet known (De Lange et al., 1997). The intracerebral microdialysis 
technique can be used for monitoring CSF concentrations, with minimal 
disturbance of the normal CSF physiology, and the application of multiple 
microdialysis probes to single animals allows for direct comparison between 
unbound concentrations in brainECF, CSFLV and CSFCM. 
In this study we investigated the passive blood-brain transport processes that 
govern the relationship between the PK at different sites in the brain for 
acetaminophen, as a paradigm compound for passive transport (De Lange and 
Danhof, 2002; De Lange et al., 1994). Concentration-time profiles of 
acetaminophen were obtained by microdialysis at different sites in the brain 
(striatum, lateral ventricle, and cisterna magna) and by serial blood sampling 
parallel plasma kinetics were obtained.  
 
 
MATERIALS AND METHODS 
 
Chemicals and solutions 
 
Acetaminophen and saline were obtained from the Leiden University Medical 
Center Pharmacy (Leiden, the Netherlands). Sodium chloride, potassium 
chloride, calcium chloride, magnesium chloride, ethylenediaminetetraacetic 
acid (EDTA), perchloric acid, sodium acetate and L-(+)-Ascorbic acid were 
obtained from J.T. Baker (Deventer, the Netherlands). Disodium hydrogen 
phosphate dihydrate and sodium dihydrogen phosphate monohydrate were 
obtained from Merck (Amsterdam, the Netherlands). 3,4-Dihydroxy-
benzylamine hydrobromide (DHBA), L-cysteine and 1-octane-sulfonic acid 
(OSA) were obtained from Sigma (Zwijndrecht, the Netherlands). Methanol and 
acetic acid were obtained from Biosolve B.V. (Valkenswaard, the Netherlands). 
Microdialysis perfusion fluid was prepared as previously described (Stevens et 
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al., 2009), containing 140.3 mM sodium, 2.7 mM potassium, 1.2 mM calcium, 
1.0 mM magnesium and 147.7 mM chloride. 
 
Animals  
 
The study protocol was approved by the Animal Ethics Committee of Leiden 
University (UDEC nr. 07068) and all animal procedures were performed in 
accordance with Dutch laws on animal experimentation. A total of 36 Male 
Wistar WU rats (225-275 g, Charles River, Maastricht, the Netherlands) were 
randomly divided into two groups; the first group (n = 12) was used for the 
determination of the in vivo microdialysis probe recovery; the second group (n 
= 24) was used for brain disposition experiments. 
After arrival, all animals were housed in groups for 5-7 days (Animal 
Facilities, Gorlaeus Laboratories, Leiden, the Netherlands), under standard 
environmental conditions (ambient temperature 21°C; humidity 60%; 12/12 h 
light/dark cycle, background noise, daily handling), with ad libitum access to 
food (Laboratory chow, Hope Farms, Woerden, the Netherlands) and acidified 
water. Between surgery and experiments, the animals were kept individually in 
Makrolon type three cages for 7 days to recover from the surgical procedures. 
 
Surgery 
 
All surgical procedures were performed under isoflurane (2%) anesthesia, while 
maintaining the body temperature at 37°C by an electric heating pad 
(CMA/150, CMA/Microdialysis AB, Stockholm, Sweden). First, cannulas were 
implanted in the left femoral artery and vein for blood sampling and drug 
administration, respectively. The cannulas were disinfected with 0.1% 
benzalkoniumchloride for at least 24h prior to the implantation. The arterial 
cannula consisted of 4 cm of non-sterile polyethylene tubing (ID 0.28 mm and 
OD 0.61 mm, Portex Fine Bore polythene tubing, Smiths Medical International 
Ltd, Kent, England) connected to 16 cm of non-sterile polyethylene tubing (ID 
0.58 mm and OD 0.96 mm, Portex Fine Bore polythene tubing, Smiths Medical 
International Ltd, Kent, England). The thinner part of the cannula was inserted 4 
cm into the artery. The venous cannula consisted of 19 cm non-sterile 
polyethylene tubing (ID 0.58 mm and OD 0.96 mm) with a small silicon ring 
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round the tubing at 3 cm from the tip. The cannula was inserted 3 cm into the 
vein. Both cannulas were subcutaneously led to the back of the head and fixated 
in the neck with a rubber ring.  
Subsequently, after placing the rat in a stereotaxic frame (David Kopf 
Instruments, Tujunga, USA), the animals were chronically instrumented with 
two CMA/12 microdialysis guides (CMA/Microdialysis AB, Stockholm, 
Sweden) in different combinations of striatum (ST), for sampling in brainECF, 
and lateral ventricle (LV) and/or cisterna magna (CM) for sampling in CSF 
(ST+LV, ST+CM or LV+CM; each group with n = 8). For ST, the position of 
the microdialysis guide is: 1.0 mm anterior, 3.0 mm lateral, 3.4 mm ventral, 
relative to bregma. For LV, the position of the microdialysis guide is: 0.9 mm 
posterior, 1.6 mm lateral, 2.9 mm ventral, relative to the bregma. For CM, the 
position of the microdialysis guide is: 1.93 mm posterior, 3.15 mm lateral, 8.1 
mm ventral, at an angle of 25° from the dorsoventral axis (towards anterior) and 
18° lateral from the anteroposterior axis relative to lambda (figure 1). The 
microdialysis guides were secured to the skull with 3 anchor screws and dental 
cement. 
 
Figure 1. Graphical representation of the position of the microdialysis probes for ST, LV and CM 
 
After the surgery the animals received 0.03 ml Temgesic ® intramuscular 
(Schering-Plough, Amstelveen, the Netherlands) and 0.3 ml Ampicillan® 
(Alfasan B.V., Woerden, the Netherlands) subcutaneously. One day prior to the 
experiment, the microdialysis dummies were replaced by the microdialysis 
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probes (CMA/12, Polycarbonate membrane, molecular weight cut-off 20 kDa, 
CMA/Microdialysis AB, Stockholm, Sweden, with a semi-permeable 
membrane length of 4 mm for ST, and 1 mm for LV and CM). 
 
Experimental set-up 
 
All experiments started between 9.00 and 10.00 AM to minimize the influences 
of circadian rhythms. First, microdialysis vials were weighed prior to the 
experiment to be able to validate the probe perfusion rate (a maximal deviation 
of 5% was allowed for the sample to be included in the data). All microdialysis 
vials were then placed in a cooled fraction collector (Univentor 820 
Microsampler, AgnTho’s AB, Lidingö, Sweden) to collect the microdialysate 
samples. Microdialysis perfusion fluid was prepared as described above. The 
microdialysis probes were connected to FEP-tubing (CMA/Microdialysis AB, 
Stockholm, Sweden) with tubing adapters (CMA/Microdialysis AB, Stockholm, 
Sweden). Microdialysis probes were then continuously flushed with 
microdialysis perfusion fluid (2 μl/min, Bee-Hive, Bioanalytical Systems Inc., 
W-Lafayette, USA), being equilibrated for 60 min before acetaminophen 
administration.  
The in vivo microdialysis probe recovery of acetaminophen was determined 
on the basis of reverse dialysis (Ståhle et al., 1991). The concept of the reverse 
dialysis method assumes directional independence of the solute through the 
dialysis membrane and that recovery is independent of the perfused 
concentration (Le Quellec et al., 1995), as was true for acetaminophen under in 
vitro conditions. In short, the microdialysis probes in striatum, lateral ventricle 
and cisterna magna were perfused with different concentrations of 
acetaminophen (50, 200 and 1000 ng/ml) in perfusion fluid. The in vivo 
recovery for each microdialysis probe location is defined as the ratio of the 
concentration difference between the dialysate (Cdial) from striatum, lateral 
ventricle or cisterna magna and perfusion fluid (Cin) over the concentration in 
the perfusion fluid (equation 1) (Scheller and Kolb, 1991). 
 
𝑖𝑛 𝑣𝑖𝑣𝑜 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 = 𝐶𝑖𝑛−𝐶𝑑𝑖𝑎𝑙
𝐶𝑖𝑛
                   (1) 
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For the brain disposition experiments, the rats received an intravenous infusion 
of 15 mg/kg acetaminophen dissolved in saline (200 μl/min/kg for a period of 
10 minutes) with an automated pump (Pump 22 Multiple Syringe Pump, 
Harvard Apparatus, Holliston, USA). Start and duration of infusion was 
corrected for internal volume of the tubing so that infusion started at t=0 min. 
10 min interval samples were collected between t=−1 h and t=2 h, followed by 
20 min interval samples until t=4 h. After weighing the microdialysis vials they 
were stored at −80°C before analysis. 
For the determination of acetaminophen plasma concentrations, blood 
samples of 100 μl were taken, in parallel to the microdialysate samples, from 
the arterial cannula at t=−5 (blank), 2, 7, 10, 15, 30, 60, 120, 180, and 240 min. 
For the determination of plasma protein binding of acetaminophen, blood 
samples of 300 μl were taken at t=−30 (blank) and 30 min (with a concentration 
assumed to be approximately 50% of Cmax). After the blood sample at t=240 
min, an additional dose of 15 mg/kg in 10 minutes was given to be able to 
determine plasma protein binding at Cmax (at t=250 min). All blood samples 
were temporarily stored in heparin (10 IE) coated Eppendorf cups. The blank 
blood samples for the determination of plasma protein binding were spiked with 
acetaminophen to obtain a blood concentration of 150 ng/ml. The spiked blood 
samples were then incubated in a shaking water bath at 37°C for 30 minutes. All 
blood samples were centrifuged for 15 min at 5000 rpm and the plasma was 
pipetted into clean Eppendorf cups and stored at −20°C before analysis.  
At the end of the experiments the animals were sacrificed with an overdose 
of Nembutal (Ceva Sante Animale, Libourne, France).  
 
Plasma and microdialysate sample analysis 
 
Plasma protein binding was determined with Centrifree® ultrafiltration devices 
(Millipore BV, Etten-Leur, the Netherlands). All procedures were performed 
according to the user’s manual. The ultrafiltrate was diluted 10 times with saline 
before the analysis.  
Acetaminophen concentrations in plasma, micdrodialysate and ultrafiltrate 
were determined as described by Stevens et al. (2009). In short, acetaminophen 
concentrations in plasma, microdialysate and ultrafiltrate were determined using 
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High Pressure Liquid Chromatography with Electro-Chemical Detection 
(HPLC-ECD).  
To 50 μl of the plasma samples 50 μl purified Millipore water (resistivity 
18.2 MΩ·cm, Millipore B.V., Amsterdam, the Netherlands) and 25 μl internal 
standard (IS), containing 150 ng/ml DHBA, was added. Proteins were then 
precipitated by adding 100 μl 6% perchloric acid, followed by vortexing and 
centrifugation (10 min at 4000 rpm). The supernatant was then transferred into a 
clean glass tube, after which 150 μl sodium acetate (1M) was added. After 
vortexing, the samples were injected into the HPLC-ECD. To 20 µl of the 
microdialysate or diluted ultrafiltrate samples 20 μl IS was added, followed by 
vortexing before being directly injected into the HPLC-ECD system.  
Data acquisition and processing was performed using Empower® data 
acquisition software (Waters, Etten-Leur, the Netherlands). For constructing the 
calibration curve, linear regression analysis was applied using weight factor 
1/(y)2. Data analysis, statistical analysis, and plotting were performed using 
Microsoft® Office Excel 2003 (Microsoft Corporation, USA). 
 
Pharmacokinetic data analysis 
 
All plasma concentrations were converted to unbound plasma concentrations, 
by correction for plasma protein binding. All microdialysate concentrations 
from striatum, lateral ventricle and cisterna magna were converted into brainECF 
concentrations (CECF) or CSF concentrations (CCSF) by division of the dialysate 
concentrations by the average in vivo recovery as determined for each 
microdialysis probe location (equation 2).  
 
𝐶𝐸𝐶𝐹  𝑜𝑟 𝐶𝐶𝑆𝐹 = 𝐶𝑑𝑖𝑎𝑙𝑖𝑛 𝑣𝑖𝑣𝑜 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦                   (2) 
 
Areas under the curve from t=0 to t=240 min (AUC0-240) were calculated by 
the trapezoidal rule and tested for differences by single factor ANOVA. The 
population PK models were developed and fitted to the data by means of non-
linear mixed-effects modeling using the NONMEM software package (version 
6.2, Icon Development Solutions, Ellicott City, Maryland, USA) and analyzed 
using the statistical software package S-Plus® for Windows (version 6.2 
Professional, Insightful Corp., Seattle, USA).  
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Rather than applying a whole-body physiologically-based PK (PBPK) 
model, we focused on the brain physiology by implementing a systems-based 
approach. Here, the plasma kinetics were described by means of a 
compartmental approach, whereas the brain concentrations and the exchange 
between brainECF and CSF were described by means of a physiologically-based 
approach. In order to do so, the volumes of the different brain compartments 
were fixed to their physiological volumes, which were based on the following 
considerations: 
1. The brainECF volume in a 250g rat is about 290 µl (Cserr et al., 1981). 
2. The brain intracellular space (brainICS) is approximately 80% of the brain 
volume (Thorne et al., 2004). With an average brain weight of 1.8 g in a 
250 g rat (own observations), this results in a brainICS volume of 1.44 ml. 
3. The total CSF volume in a 250g rat is about 300 μl (Bass and Lundborg 
1973). The volume of the lateral ventricles is about 17% of the total CSF 
volume (Condon et al., 1986; Kohn et al., 1991). This results in a volume 
of the rat lateral ventricles of about 50 μl (0.17 × 300).  
4. The volume of the cisterna magna is about 5.7% of the total CSF volume 
(Adam and Greenberg, 1978; Robertson, 1949). This results in a volume of 
the rat cisterna magna of about 17 μl (0.057 × 300).  
5. The cranial subarachnoid space in rats is estimated to be about 60% of the 
total CSF volume (Bass and Lundborg, 1973; Levinger, 1971). This results 
in a volume of the cranial subarachnoid space of about 180 μl (0.60 × 300). 
6. The unaccounted for CSF volume (17%; 50 µl) is considered to be mainly 
located in the third and fourth ventricles (Levinger, 1971). 
7. The blood-brain transport is restricted by the presence of the BBB and the 
blood-CSF barrier (BCSFB), which is located at the choroid plexuses of 
the lateral, third and fourth ventricles (Chapter 1), as well as at the 
cisterna magna. 
8. The intra-brain distribution was restricted by the physiological flow paths 
of brainECF, in which brainECF flows towards the CSF compartments at a 
rate of 0.2 μl/min (Abbott, 2004; Cserr et al., 1981), and CSF flows from 
lateral ventricle, through the third and fourth ventricle, to the cisterna 
magna and subsequently to the subarachnoid space (cranial and spinal) and 
back into blood at a rate of 2.2 μl/min (Cserr, 1965).  
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Structural model selections for the systems-based PK (SBPK) model were 
based on the likelihood ratio test (p < 0.01), diagnostic plots (observed 
concentrations vs. individual and population predicted concentrations, weighted 
residuals vs. predicted time and concentrations), parameter correlations and 
precision in parameter estimates. The inter-animal variability in 
pharmacokinetic parameters was assumed to be log normally distributed. The 
residual error, which accounts for unexplained variability (e.g. measurement 
and experimental error and model-misspecification), was best described with a 
proportional error model.  
The validity of the SBPK model was investigated by means of a visual 
predictive check (Cox et al., 1999; Duffull and Aarons, 2000; Yano et al., 
2001). Using the final PK parameter estimates, 1000 curves were simulated. 
Subsequently, the median and the 5th and 95th percentile of the predicted 
concentrations were calculated, which represent the 90% prediction interval. 
These were then compared with the observations. 
In order to test the ruggedness of the model and estimate the precision of the 
parameters n=100 non-parametric (case resampling) bootstraps were performed. 
To create the bootstrapped datasets, specific rat data (plasma and microdialysate 
concentrations) were removed randomly from the datasets and replaced with 
randomly selected rat data from the complete original dataset. Each of these 
permutations of the original dataset were fitted with the final model determined 
based on the original dataset. This results in a series of model fits, each with its 
own set of parameters. These results were displayed graphically and the 
descriptive statistics of the parameters were compared to parameter estimates of 
the final model. Only bootstrap runs that successfully minimized were used in 
this analysis. 
 
Systems-based scaling 
 
The parameters of the rat SBPK model were extrapolated to humans to predict 
the human acetaminophen plasma, CSF and brainECF concentration-time 
profiles. These concentration-time profiles were then compared to observed 
acetaminophen concentrations in plasma and CSF from the subarachnoid space 
(CSFSAS), as presented by Bannwarth et al. (1992). To do so, the elimination 
clearance was scaled based on equation 3. 
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𝐶𝐿𝐸,ℎ𝑢𝑚𝑎𝑛 = 𝐶𝐿𝐸,𝑟𝑎𝑡 × �𝐵𝑊ℎ𝑢𝑚𝑎𝑛𝐵𝑊𝑟𝑎𝑡 �0.75    (3) 
 
Here, CLE,human and CLE,rat are the elimination clearances in humans and rats, 
respectively. BWhuman and BWrat are the human and rat bodyweights, 
respectively. The scaling factor of 0.75 is based on allometry (Boxenbaum, 
1982). Next, the transfer clearances between plasma and the different peripheral 
and brain compartments were scaled based on equations 4 and 5. 
 
𝐶𝐿𝑃𝐿−𝑃𝐸𝑅 = 𝐴𝑃𝐸𝑅 × (𝑉𝑃𝐸𝑅)0.67     (4) 
 
𝐶𝐿𝑃𝐿−𝐵𝑅 = 𝐴𝐵𝑅 × (𝑉𝐵𝑅)0.67     (5) 
 
Here, APER and ABR are scaling coefficients for periphery and brain, 
respectively, and both are estimated on the basis of the rat data (Hosseini-
Yeganeh and McLachlan, 2002). VPER represents the physiological volume of 
the (lumped) peripheral tissues. VBR represents the physiological volume of the 
different brain compartments. The scaling factor of 0.67 is based on the 
permeability surface area of the different brain compartments, which is related 
to the tissue weight (Kawai et al., 1994). The physiological parameters of the rat 
SBPK model were changed accordingly.  
 
 
RESULTS 
 
All results are presented as average values ± standard deviation, unless stated 
otherwise.  
 
Acetaminophen pharmacokinetics 
 
The experimental set-up allowed for direct comparison of plasma 
concentrations with brain concentrations on two distinct sites, including the 
direct comparison of brainECF concentrations with CSF concentrations within a 
single rat. Plasma protein binding was linear with concentration, at an extent of 
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19.5 ± 4.2 %. The average in vivo recoveries for the striatum, lateral ventricle 
and cisterna magna probes were 12.0 ± 3.3%, 8.1 ± 3.8% and 8.6 ± 4.7%, 
respectively. The average unbound acetaminophen concentrations for plasma, 
brainECF, CSF from lateral ventricle (CSFLV) and cisterna magna (CSFCM) is 
shown in figure 2. 
The unbound plasma concentration-time profile shows a short distribution 
phase of about 15 min. During the elimination phase (t > 15 min) the unbound 
plasma concentrations reach an apparent plateau from t = 120 min onward. The 
concentration-time profiles of brainECF, CSFLV and CSFCM show a pattern 
similar to the unbound plasma concentration-time profile, indicating a relatively 
rapid distribution. However, brainECF concentrations are on average 4-fold 
higher than CSF concentrations in both lateral ventricle and cisterna magna. The 
CSF concentration in both locations is similar. 
 
 
Figure 2. Observed data from the rat. Average (geometric mean ± S.E.M.) unbound 
acetaminophen concentration-time profile for plasma (n = 10), brainECF (n = 10), CSFLV (n = 14) 
and CSFCM (n = 8)  
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The concentration-time profile for the brainECF shows more similarities to the 
unbound plasma concentration-time profile than the concentration-time profiles 
of CSFLV or CSFCM. The acetaminophen concentration in brainECF is 
significantly higher (p < 0.05) than that in CSF from t = 0 to t = 80 min. As a 
result, the brainECF-to-unbound plasma AUC0-240 ratio is also higher than the 
CSF-to-unbound plasma AUC0-240 ratio with an average ratio of 121 ± 72%, 28 
± 10% and 35 ± 17% for brainECF, CSFLV and CSFCM, respectively. This 
indicates that brainECF-to-CSF exposure ratio is approximately 4. 
 
Compartmental modeling approach 
 
All data were subjected first to compartmental pharmacokinetic analysis. The 
compartmental pharmacokinetic analysis showed that the plasma concentrations 
were best described by a 2 compartment model that included inter-
compartmental clearance (Q), elimination clearance from the central 
compartment (CLE) and an additional zero-order drug input into the plasma 
compartment. This additional, infusion-like, drug input represents the fraction 
of the administered acetaminophen that is reabsorbed (Fabs) within the study 
duration (240 min), presumably because of enterohepatic circulation (Hjelle and 
Klaassen, 1984; Siegers et al., 1983; Watari et al., 1983). 
As the next step in the data analysis, to describe the concentrations in each of 
the brain compartments, a single brain compartment was added. Drug flow 
between the brain compartment and the plasma compartment was by a clearance 
in (CLin) and clearance out (CLout), rather than an intercompartmental clearance.  
Subsequently, the addition of a second and third brain compartment was 
explored for the description of the plasma data, as well as the brainECF, CSFLV 
and CSFCM data (results not shown). As it was our goal to investigate the 
relationship between brainECF and CSF pharmacokinetics, we have applied 
compartmental modeling to describe the relationships between brainECF and 
CSF at the two sites.  
However, this approach was without success, as the model had too much 
freedom to fit the plasma and brain data correctly. For this reason, and because 
of the improved value for extrapolation and prediction, we have applied a 
systems-based PK model to investigate the exchange between brainECF and CSF.  
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Systems-based modeling approach 
 
As CSF flows from lateral ventricle through the third and fourth ventricle, to the 
cisterna magna and subsequently to the subarachnoid space and back into blood, 
we added two CSF compartments that represent the combined third and fourth 
ventricle (CSFTFV) and the subarachnoid space (CSFSAS) to more adequately 
describe CSF physiology. Since we have no measurements of the concentrations 
in the third and fourth ventricle, the transfer clearance between plasma and third 
and fourth ventricle was assumed to be equal to the transfer clearance between 
plasma and lateral ventricle. For the correct representation of the brain 
physiology, we have also included the brainICS to the model. However, since we 
have no measurements of total brain concentrations, it was assumed that brainICS 
concentrations are equal to brainECF concentrations. Therefore, the brainICS 
volume is added to the brainECF volume to account for the total brain volume.  
 
Final SBPK model - The final SBPK model is shown in figure 3. The 
differential equations of this model can be found in the appendix. The final 
estimation of the PK parameters is summarized in table 1.  
Here, CLE is the elimination clearance from plasma, QPL-PER is the inter-
compartmental clearance between plasma and the peripheral compartment. 
Further, for transfer clearances between compartments (CLfrom comp-to comp), 
denotations of the compartments are: PL = plasma; ECF = brainECF; ICS = 
brainICS; LV = lateral ventricle; TFV = third and fourth ventricle; CM = cisterna 
magna and SAS = subarachnoid space. QECF is the flow rate of brainECF, QCSF is 
the flow rate of CSF. For the plasma and brain compartments V is the 
physiological volume; for the peripheral compartment V is the volume of 
distribution. Fabs is the fraction of the dose that is reabsorbed over time as a 
result of enterohepatic circulation, fup is the fraction unbound in plasma, ηi is 
the inter-individual variability of parameter i and εj is the residual error on the 
concentrations in compartment j.  
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Figure 3. Graphical representation of the SBPK model that was used to describe the intra-brain 
distribution in the rat. CLE is the elimination clearance from plasma, QPL-PER is the inter-
compartmental clearance between plasma and the peripheral compartment. Further, for transfer 
clearances between compartments (CLfrom comp-to comp), denotations of the compartments are:       
PL = plasma; ECF = brainECF; LV = lateral ventricle; TFV = third and fourth ventricle; and  
CM = cisterna magna. Fabs is the fraction of the dose that is reabsorbed over time as a result of 
enterohepatic circulation 
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The visual predictive check of the final model is given in figure 4. It can be 
seen that the final model describes the data very well within the 90% prediction 
interval, and also can cope with the large inter-individual variation in brain 
concentrations. This SBPK model was used to predict acetaminophen 
concentrations in rat CSFSAS, shown in figure 5. As a result of the CSF flow 
from lateral ventricle, through the third and fourth ventricle, to the cisterna 
magna and subsequently to the subarachnoid space, clear differences in the 
predicted concentration-time profiles of these CSF compartments can be 
observed.  
 
Extrapolation to humans 
The final SBPK model was used for the prediction of human brainECF 
concentrations by scaling of the rat parameters to humans. However, scaling of 
the elimination clearance based on allometry resulted in an underestimation of 
plasma and CSFSAS concentrations (results not shown). Therefore, it was 
decided to fit the plasma data to our model for estimating the elimination 
clearance in humans. This resulted in a reasonable prediction of plasma and 
CSFSAS concentrations (figure 6). The final human PK parameters are given in 
table 1. Predictions indicate that brainECF concentrations in humans are ~2-fold 
higher than plasma concentrations. 
By comparing the acetaminophen concentrations in plasma and CSFSAS 
between rats and humans (as presented by Bannwarth et al. (1992)), it can be 
seen that the kinetics in humans are slower compared to rats (figure 7). 
However, the peak concentrations in plasma appear to be similar, whereas the 
peak concentrations in CSFSAS in humans are ~8-fold higher compared to rats. 
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Figure 4. The visual predictive check of the final SBPK model. The dots represent the individual 
data points and the grey area represents the 90% prediction confidence interval. The x-axis 
represents the time in minutes, the y-axis represents the acetaminophen concentration in ng/ml. 
The different boxes represent the unbound plasma, brainECF, CSFLV and CSFCM data 
 
 
Figure 5. SBPK model predicted acetaminophen concentrations in rat plasma and the different 
brain compartments: brainECF, CSFLV, CSFCM and CSFSAS. Predictions are based on a 10 min i.v. 
infusion of 15 mg/kg acetaminophen in a 250 gr rat 
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Figure 6. Observed and SBPK model predicted human acetaminophen concentrations in humans. 
The dots represent the data as presented by Bannwarth et al. (1992) and the grey area represents 
the 90% prediction confidence interval. The x-axis represents the time in minutes, the y-axis 
represents the acetaminophen concentration in µg/ml. The different boxes represent the unbound 
plasma, brainECF, CSFLV, CSFCM and CSFSAS. Predictions are based on a 10 min i.v. infusion of 
15 mg/kg acetaminophen in a 70 kg human 
 
 
Figure 7. Observed and SBPK model predicted acetaminophen concentrations in rat and human 
plasma and CSFSAS. Predictions are based on a 10 min i.v. infusion of 15 mg/kg acetaminophen in 
a 250 gr rat and a 70 kg human 
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Table 1. Final estimation of the rat and human PK parameters (± standard error) 
Parameter Rat value Human value 
CLE 13.8 ± 1.0 ml/min 299 ml/min 
QPL-PER 45.1 ± 5.8 ml/min 1100 ml/min 
CLPL-ECF 165 ± 39 µl/min 14.9 ml/min 
CLECF-PL 198 ± 24 µl/min 17.8 ml/min 
CLPL-LV 2.9 ± 1.3 µl/min 0.17 ml/min 
CLLV-PL 5.0 ± 2.1 µl/min 0.05 ml/min 
CLPL-TFV 2.9 ± 1.3 µl/min 0.17 ml/min 
CLTFV-PL 5.0 ± 2.1 µl/min 0.05 ml/min 
CLPL-CM 0.8 ± 0.4 µl/min 0.05 ml/min 
CLCM-PL 4.5 ± 0.9 µl/min 0.27 ml/min 
QECF 0.2 µl/min 1,2 0.175 ml/min 12,13 
QCSF 2.2 µl/min 3 0.4 ml/min 14 
VPL 10.6 ml 4 2.9 l 15 
VPER 188 ± 11 ml 51.6 l 
VICS 1440 µl 5 960 ml 5 
VECF 290 µl 1 240 ml 12 
VLV 50 µl 6,7 22.5 ml 6,7,16 
VTFV 50 µl 8 22.5 ml 8 
VCM 17 µl 9,10 7.5 ml 9,10 
VSAS 180 µl 8,11 90 ml 17 
Fabs 0.025 %/min N.A. 
fup 80.5 ± 4.2% 95% 18 
ηCL E 0.03 ± 0.01 N.A. 
ηCL PL-ECF 0.45 ± 0.25 N.A. 
ηCL PL-LV 0.28 ± 0.13 N.A. 
ηCL PL-CM 1.11 ± 0.54 N.A. 
εPL 0.08 ± 0.02 0.06 
εECF 0.14 ± 0.03 N.A. 
εCSF LV 0.19 ± 0.05 N.A. 
εCSF CM 0.18 ± 0.04 N.A. 
εCSF SAS N.A. N.A. 
 
Parameter values in italic are derived from literature. CLE is the elimination clearance from 
plasma, QPL-PER is the inter-compartmental clearance between plasma and the peripheral 
compartment. Further, for transfer clearances between compartments (CLfrom comp-to comp), 
denotations of the compartments are: PL = plasma; ECF = brainECF; LV = lateral ventricle;  
TFV = third and fourth ventricle; and CM = cisterna magna. For plasma and brain 
compartments V is the physiological volume; for peripheral compartment V is the volume of 
distribution. ηi = inter-individual variability of parameter i; εj = residual error on concentrations 
in compartment j. 
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Notes to table 1 continued: 1 Cserr et al., 1981; 2 Abbott, 2004; 3 Cserr, 1965; 4 Lee and Blaufox, 
1985; 5 Thorne et al., 2004; 6 Condon et al., 1986; 7 Kohn et al., 1991; 8 Levinger, 1971;               
9 Robertson, 1949; 10 Adam and Greenberg, 1978; 11 Bass and Lundborg, 1973; 12 Begley, 2000; 
13 Kimelberg, 2004; 14 Nilsson et al., 1992; 15 Frank and Gray, 1953; 16 Dickey et al., 2000;         
17 Pardridge, 2011; 18 Bailey and Briggs, 2004. 
 
 
DISCUSSION 
 
In the development of CNS targeted drugs, the prediction of human CNS target 
exposure is a big challenge. Often it is assumed that CSF concentrations are 
more or less equal to unbound brain concentrations, and the most common 
method for collecting a CSF sample from humans is by a lumbar puncture (Hill 
et al., 1999). However, the brain is a dynamic multi-compartmental system, in 
which all processes of entry, diffusion, metabolism, binding and elimination 
determine local CNS concentrations. Not much is currently known about the 
impact of these processes on brain disposition of different drugs. Here we 
present a methodology to investigate brain disposition in rats using a systems-
based modeling approach aiming at improving the prediction of human brain 
exposure.  
In this study we compared the unbound concentration-time profiles of 
acetaminophen, as a paradigm compound for passive transport, obtained from 
the brain striatum and different sites of CSF. To that end we have used the 
multiple microdialysis probes approach, with probes placed into different sites 
of the brain. Thus, the PK information is obtained by the same technique, 
without the need of taking CSF samples that influences brain physiology. Our 
hypothesis was that acetaminophen would distribute homogeneously over the 
brain. 
Since the inter-individual variation in brain concentrations is reasonably 
large, the statistical significance of the results could be questioned. However, 
the variability in brain concentrations is most likely the result of the large 
variation in in vivo recovery, which is the sum of the intra-individual variation, 
the analytical error and the true inter-individual variability.  
With an assumed log-normal distribution of the inter-individual variability 
and the residual error, it can be assumed that the observed differences between 
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brainECF and CSF concentrations are the result of actual differences, rather than 
a result of the variability in the in vivo recoveries. 
Preferably, the in vivo recovery should have been determined in the same 
animals in which the brain disposition experiments were performed to eliminate 
the inter-individual variability. However, we decided to perform these 
experiments in a separate group of animals to keep the duration of experiments 
within realistic limits. 
With in vivo recoveries of approximately 10%, we are working at the limit of 
the methodology. Therefore, in retrospect, the level of in vivo recovery could 
have been increased by decreasing the microdialysis perfusion flow rate. 
However, as our analytical method required a certain sample volume we 
decided to use a flow rate of 2 µl/min. Furthermore, we have used 10 minute 
sample intervals to reveal the initial rate of brain distribution, which is crucial 
information for estimating clearance values into and out of the different brain 
compartments.  
Even though the final resulting variability of the brain disposition data was 
high, the modeling does take into consideration this variability by means of the 
inter-individual variability in plasma to brainECF, plasma to CSFLV and plasma 
to CSFCM clearance, as well as a residual error on the brainECF, CSFLV and 
CSFCM data. 
Acetaminophen PK in plasma, together with brainECF PK or CSF PK, has 
been studied before (De Lange et al., 1994; De Lange et al., 1995; Hjelle and 
Klaassen, 1984; Morrison et al., 1991; Siegers et al., 1983; Stevens et al., 2009; 
van Bree et al., 1989; Watari et al., 1983), but brainECF PK and CSF PK have 
never been directly related to each other. The plasma concentration-time profile 
obtained in this study shows great similarities with those reported previously. 
For example, Morrison et al. (1991), showed a distribution phase of 
approximately 20 minutes, after an i.v. bolus dose of 15 mg/kg, followed by an 
elimination phase until the end of the experiment at t = 120 min. Watari et al. 
(1983), reported a distribution phase of 15 min and that the disposition of 
acetaminophen was best described by a 2-compartment model. As in previous 
studies from our group (De Lange et al., 1994; Stevens et al., 2009; van Bree et 
al., 1989), we observed in this study a plateau in plasma concentrations at time 
points later than 120 min. The plateau of the plasma concentrations is 
presumably caused by enterohepatic circulation of acetaminophen. This has 
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been described by Watari et al. (1983), Siegers et al. (1983), and Hjelle and 
Klaassen (1984). Acetaminophen is metabolized / biotransformed in the liver 
into acetaminophen-sulfate and acetaminophen-glucuronide. Acetaminophen-
sulfate is subsequently transported both into the bile and into the bloodstream, 
after which it is mainly excreted via urine. Acetaminophen-glucuronide is 
mainly transported into bile, which is then released in the intestines. After the 
release in the small intestine, the acetaminophen-sulfate and acetaminophen-
glucuronide can be hydrolyzed into acetaminophen, which is then re-absorbed. 
The time course of the re-uptake of acetaminophen spans several hours (Hjelle 
and Klaassen, 1984; Siegers et al., 1983; Watari et al., 1983), which therefore 
could explain the plateau in plasma concentrations from t = 120 min onward. 
It is often assumed that CSF concentrations equilibrate readily with brainECF 
concentrations due to the lack of a physical barrier between the two (Lee et al., 
2001). The rate of equilibration between CSF concentrations and brainECF 
concentrations by passive diffusion through brain tissue is dependent on the 
lipophilicity of the compound (De Lange et al., 1995). For acetaminophen, 
which is a moderately lipophilic compound with known fast equilibrium 
between blood and brain, and no indication of active transport at the BBB or 
BCSFB, we expected the brainECF and CSF concentrations to be similar. 
However, we have observed that brainECF concentrations are approximately 4-
fold higher than CSF concentrations. This can probably be explained by the 
relatively high turnover rate of CSF. With a total CSF volume of 300 μl, and a 
flow rate of 2.2 μl/min, the total CSF volume is replaced every 2.5 h. However, 
the volumes of the lateral ventricle and cisterna magna are calculated to be 50 
and 17 μl, respectively. This indicates that the CSF in the lateral ventricle and 
cisterna magna is replaced every 23 and 8 minutes, respectively. Due to the 
slow distribution from the brain tissue to the CSF, the CSF acts as a sink, 
causing the observed concentration gradient within the brain. This has been 
observed for other passively transported compounds as well (Kielbasa and 
Stratford Jr, 2012). 
Several studies have reported acetaminophen concentration-time profiles in 
brainECF (De Lange et al., 1994; Morrison et al., 1991; Stevens et al., 2009), and 
CSF (De Lange et al., 1995). We have found more or less similar unbound 
plasma and brainECF concentration-time profiles, while in literature brainECF 
concentrations have been reported that were several-fold lower than plasma 
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concentrations. Importantly, in the previous studies, brainECF concentrations 
were estimated on the basis of in vitro recovery, while in this study it was based 
on in vivo recovery correction. We found an in vitro recovery value of 
acetaminophen of 31.9 ± 5.2%, for a 4 mm microdialsyis membrane, which is 
~3 fold higher than the in vivo recovery of 12.0 ± 3.3% estimated in this study. 
This might be an explanation for the discrepancy between earlier reports and the 
current one. Assuming the same ratio between in vitro and in vivo recoveries 
(~factor 3), it would indicate a concentration-time profile in brainECF that is 
more similar to unbound plasma concentrations than to CSF.  
On the other hand, using serial CSF sampling – from the cisterna magna, van 
Bree et al. (1989) have found that acetaminophen slowly distributed into and 
out of CSF, resulting in a delayed maximum concentration in CSF, and a slower 
elimination. We think that the sampling of CSF jeopardizes brain fluid 
homeostasis, as it causes a decrease in CSF pressure that normally serves as a 
trigger for elimination of CSF into blood via the basal cisterns and subarachnoid 
spaces (Kazama et al., 1994). 
Calculations of brain distribution are often performed by modeling the brain 
compartment as an effect compartment (Hammarlund-Udenaes et al., 1997; 
Sheiner et al., 1979). Here, the plasma concentration is the driving force for 
brain concentrations, without the uptake into or elimination from the brain 
influencing the concentration-time profile in blood. However, for a more 
realistic approach in describing the data we have included the brain 
compartment in the mass balance of acetaminophen disposition. Rather than 
applying a whole-body PBPK model, we implemented a systems-based 
approach where the plasma kinetics were described by means of a 
compartmental approach, while the brain concentrations, and the exchange 
between brainECF and CSF, were described by means of a physiologically-based 
approach. In order to do so, the volumes of the different brain compartments 
were fixed to their physiological volumes. Since the physiological volumes of 
the different brain compartments are over 35-fold lower than that of plasma, 
only a small fraction of the amount of acetaminophen in plasma is transported 
into brain tissue.  
Interestingly, the clearance values between plasma and brainECF are over 40-
fold higher than the clearance values between plasma and CSF. This indicates 
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that the transport across the BBB is more substantial compared to transport 
across the BCSFB. 
Given that CSF concentrations are considered to be the best available 
surrogate for brainECF concentrations in humans (Fridén et al., 2009; Kalvass 
and Maurer, 2002; Liu et al., 2006; Liu et al., 2009; Maurer et al., 2005), we 
have focused on the prediction of human brainECF concentrations based on 
human CSF concentrations. Bannwarth and colleagues have measured 
acetaminophen concentrations in plasma and CSF following a 3 min i.v. 
infusion of 2 g propacetamol, a prodrug which is hydrolysed to acetaminophen 
within 7 minutes (Bannwarth et al., 1992). The dosage used corresponded to 
~15 mg/kg acetaminophen in 10 minutes, which is equal to the dose used in this 
study. The observed plasma and spinal CSFSAS concentration-time profile in 
humans are similarly shaped as the observed acetaminophen plasma 
concentration-time profile and the predicted CSFSAS concentration-time profile 
in rat. However, the kinetics in humans are different from that in rats.  
For the prediction of human brainECF exposure on the basis of human CSF 
concentrations the SBPK modeling approach is important, as it allowed the 
extrapolation of our rat data. This was done by changing the different 
physiological parameters of the rat to the human values and systems-based 
scaling of the brain clearances. A similar approach has been applied by Kielbasa 
and Stratford (2012), where brain compartmental volumes were fixed to their 
physiological volumes and human brain PK parameters were predicted on the 
basis of allometric scaling of rat brain PK parameters. These predictions were 
then compared to clinical PK parameters based on human plasma or CSF 
concentrations. 
As the possibility to validate human predictions of brainECF exposure on the 
basis of direct measurement of brainECF concentrations in human is highly 
restricted, there is the need for more mechanistic understanding of the processes 
involved in the causal path from drug dosing to CNS drug effects. This will 
possibly allow the validation of predictions on the basis of appropriate 
biomarkers in human CSF or plasma samples. To that end, the physiological 
brain disposition model presented here will be extended on the basis of brain 
disposition measurements of a series of other drugs with different 
physicochemical properties in order to fully characterize the processes involved 
in brain disposition. For drugs that are known to be actively transported into or 
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out of the brain, a cross-compare designed study with or without the inhibition 
of the specific transporter will be informative on the contribution of the specific 
transporter in blood-brain transport. By adding this information to the current 
SBPK model, together with quantitative information on the transporter 
expression levels in animals and humans, the SBPK model will serve as a basis 
for extrapolation of preclinical findings and ultimately only in vitro 
determinations of physicochemical properties of drugs, to the human situation. 
 
 
CONCLUSION 
 
Even for acetaminophen, a drug without active transport processes into, within 
and out of the brain, significant differences exist between the striatal brainECF 
and the CSF concentrations after acute dosing. 
With the ultimate goal of being able to predict CNS drug effects in humans, 
a more mechanistic understanding of the relative importance of the processes 
involved in brain target site distribution can be obtained in vivo by applying the 
intracerebral microdialysis technique in combination with physiologically based 
pharmacokinetic modeling. 
 
 
APPENDIX 
 
Differential equations 
 
The mass balance equations describing the final SBPK model were expressed as 
follows: 
 
Plasma: 
 
𝑑𝐴𝑃𝐿,𝑢
𝑑𝑡
= 𝑑𝑜𝑠𝑒 − 𝑘𝑃𝐿−𝑃𝐸𝑅 × 𝐴𝑃𝐿,𝑢 + 𝑘𝑃𝐸𝑅−𝑃𝐿 × 𝐴𝑃𝐸𝑅 − 𝑘𝑃𝐿−𝐸𝐶𝐹 × 𝐴𝑃𝐿,𝑢 +𝑘𝐸𝐶𝐹−𝑃𝐿 × 𝐴𝐸𝐶𝐹 − 𝑘𝑃𝐿−𝐿𝑉 × 𝐴𝑃𝐿,𝑢 + 𝑘𝐿𝑉−𝑃𝐿 × 𝐴𝐿𝑉 − 𝑘𝑃𝐿−𝑇𝐹𝑉 × 𝐴𝑃𝐿,𝑢 +𝑘𝑇𝐹𝑉−𝑃𝐿 × 𝐴𝑇𝐹𝑉 − 𝑘𝑃𝐿−𝐶𝑀 × 𝐴𝑃𝐿,𝑢 + 𝑘𝐶𝑀−𝑃𝐿 × 𝐴𝐶𝑀 + �𝑄𝐶𝑆𝐹𝑉𝑆𝐴𝑆 � × 𝐴𝑆𝐴𝑆 
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−𝑘𝐸 × 𝐴𝑃𝐿,𝑢 + 𝐹𝑎𝑏𝑠 × 𝑑𝑜𝑠𝑒 
 
𝐶𝑃𝐿,𝑢 = 𝐴𝑃𝐿,𝑢𝑉𝑃𝐿  
 
Periphery: 
 
𝑑𝐴𝑃𝐸𝑅
𝑑𝑡
= 𝑘𝑃𝐿−𝑃𝐸𝑅 × 𝐴𝑃𝐿,𝑢 − 𝑘𝑃𝐸𝑅−𝑃𝐿 × 𝐴𝑃𝐸𝑅 
 
𝐶𝑃𝐸𝑅 = 𝐴𝑃𝐸𝑅𝑉𝑃𝐸𝑅  
 
BrainECF: 
 
𝑑𝐴𝐸𝐶𝐹
𝑑𝑡
= 𝑘𝑃𝐿−𝐸𝐶𝐹 × 𝐴𝑃𝐿,𝑢 − 𝑘𝐸𝐶𝐹−𝑃𝐿 × 𝐴𝐸𝐶𝐹 − �𝑄𝐸𝐶𝐹𝑉𝐸𝐶𝐹� × 𝐴𝐸𝐶𝐹 
 
𝐶𝐸𝐶𝐹 = 𝐴𝐸𝐶𝐹𝑉𝐸𝐶𝐹  
 
CSFLV: 
 
𝑑𝐴𝐿𝑉
𝑑𝑡
= 𝑘𝑃𝐿−𝐿𝑉 × 𝐴𝑃𝐿,𝑢 − 𝑘𝐿𝑉−𝑃𝐿 × 𝐴𝐿𝑉 + �𝑄𝐸𝐶𝐹𝑉𝐸𝐶𝐹� × 𝐴𝐸𝐶𝐹 − �𝑄𝐶𝑆𝐹𝑉𝐿𝑉 � × 𝐴𝐿𝑉 
 
𝐶𝐿𝑉 = 𝐴𝐿𝑉𝑉𝐿𝑉  
 
CSFTFV: 
 
𝑑𝐴𝑇𝐹𝑉
𝑑𝑡
= 𝑘𝑃𝐿−𝑇𝐹𝑉 × 𝐴𝑃𝐿,𝑢 − 𝑘𝑇𝐹𝑉−𝑃𝐿 × 𝐴𝑇𝐹𝑉 + �𝑄𝐶𝑆𝐹𝑉𝐿𝑉 � × 𝐴𝐿𝑉 − �𝑄𝐶𝑆𝐹𝑉𝑇𝐹𝑉� × 𝐴𝑇𝐹𝑉 
 
𝐶𝑇𝐹𝑉 = 𝐴𝑇𝐹𝑉𝑉𝑇𝐹𝑉  
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CSFCM: 
 
𝑑𝐴𝐶𝑀
𝑑𝑡
= 𝑘𝑃𝐿−𝐶𝑀 × 𝐴𝑃𝐿,𝑢 − 𝑘𝐶𝑀−𝑃𝐿 × 𝐴𝐶𝑀 + �𝑄𝐶𝑆𝐹𝑉𝑇𝐹𝑉� × 𝐴𝑇𝐹𝑉 − �𝑄𝐶𝑆𝐹𝑉𝐶𝑀 � × 𝐴𝐶𝑀 
 
𝐶𝐶𝑀 = 𝐴𝐶𝑀𝑉𝐶𝑀  
 
CSFSAS: 
 
𝑑𝐴𝑆𝐴𝑆
𝑑𝑡
= �𝑄𝐶𝑆𝐹
𝑉𝐶𝑀
� × 𝐴𝐶𝑀 − �𝑄𝐶𝑆𝐹𝑉𝑆𝐴𝑆 � × 𝐴𝑆𝐴𝑆 
 
𝐶𝑆𝐴𝑆 = 𝐴𝑆𝐴𝑆𝑉𝑆𝐴𝑆  
 
Where: 
 
𝑘𝐸 = 𝐶𝐿𝐸𝑉𝑃𝐿  
𝑘𝑃𝐿−𝑃𝐸𝑅 = 𝑄𝑃𝐿−𝑃𝐸𝑅𝑉𝑃𝐿   
𝑘𝑃𝐸𝑅−𝑃𝐿 = 𝑄𝑃𝐿−𝑃𝐸𝑅𝑉𝑃𝐸𝑅   
𝑘𝑃𝐿−𝐸𝐶𝐹 = 𝐶𝐿𝑃𝐿−𝐸𝐶𝐹𝑉𝑃𝐿   
𝑘𝐸𝐶𝐹−𝑃𝐿 = 𝐶𝐿𝐸𝐶𝐹−𝑃𝐿𝑉𝐸𝐶𝐹   
𝑘𝑃𝐿−𝐿𝑉 = 𝐶𝐿𝑃𝐿−𝐿𝑉𝑉𝑃𝐿   
𝑘𝐿𝑉−𝑃𝐿 = 𝐶𝐿𝐿𝑉−𝑃𝐿𝑉𝐿𝑉   
𝑘𝑃𝐿−𝑇𝐹𝑉 = 𝐶𝐿𝑃𝐿−𝑇𝐹𝑉𝑉𝑃𝐿   
𝑘𝑇𝐹𝑉−𝑃𝐿 = 𝐶𝐿𝑇𝐹𝑉−𝑃𝐿𝑉𝑇𝐹𝑉   
𝑘𝑃𝐿−𝐶𝑀 = 𝐶𝐿𝑃𝐿−𝐶𝑀𝑉𝑃𝐿   
𝑘𝐶𝑀−𝑃𝐿 = 𝐶𝐿𝐶𝑀−𝑃𝐿𝑉𝐶𝑀   
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NOMENCLATURE 
 
Ai  Amount of acetaminophen in compartment i (ng) 
Ci  Concentration of acetaminophen in compartment i (ng/ml) 
k rate constant (min-1) 
Q flow rate (ml/min) 
CL clearance (ml/min) 
V volume (ml) 
 
Subscripts 
 
PL plasma 
PL,u unbound acetaminophen in plasma 
PER peripheral compartment 
ECF brainECF 
CSF CSF 
LV lateral ventricle 
TFV third and fourth ventricle 
CM cisterna magna 
SAS subarachnoid space 
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ABSTRACT 
 
In the development of central nervous system (CNS)-targeted drugs, the 
prediction of human CNS target exposure is a big challenge. Cerebrospinal fluid 
(CSF) concentrations have often been suggested as a ‘good enough’ surrogate 
for brain extracellular fluid (brainECF, brain target site) concentrations in 
humans. However, brain anatomy and physiology indicates prudence.  
We have applied a multiple microdialysis probes approach in rats, for 
continuous measurement and direct comparison of quinidine kinetics in 
brainECF, CSF, and plasma.  
The data obtained indicated important differences between brainECF and CSF 
kinetics, with brainECF kinetics being most sensitive to P-gp inhibition. To 
describe the data we developed a systems-based pharmacokinetic (SBPK) 
model. Our findings indicated that: 1) brainECF- and CSF-to-unbound plasma 
AUC0-360 ratios were all over 100%; 2) P-gp also restricts brain intracellular 
exposure; 3) a direct transport route of quinidine from plasma to brain cells 
exists; 4) P-gp-mediated efflux of quinidine at the blood-brain barrier (BBB) 
seems to result of combined efflux enhancement and influx hindrance; 5) P-gp 
at the blood-CSF barrier (BCSFB) either functions as an efflux transporter or is 
not functioning at all. 
It is concluded that in parallel obtained data on unbound brainECF, CSF and 
plasma concentrations, under dynamic conditions, is a complex but most valid 
approach to reveal the mechanisms underlying the relationship between brainECF 
and CSF concentrations. This relationship is significantly influenced by the 
activity of P-gp. Therefore, information on the activity of P-gp is required for 
the prediction of human brain target site concentrations of P-gp substrates on 
the basis of human CSF concentrations. 
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INTRODUCTION 
 
To be able to predict desired or undesired central nervous system (CNS) drug 
effects in humans, a mechanistic understanding is needed of the individual 
contributions of the processes involved in brain target site distribution and 
ultimately drug effects. With the unbound drug concentrations at the brain target 
site being responsible for the (un)wanted effect it is important to be able to 
determine or predict unbound drug concentrations at their site of action.  
During the preclinical phase of drug development several techniques can be 
applied to determine or predict brain target site concentrations, which are often 
closely linked, or equal, to brain extracellular fluid (brainECF) concentrations 
(De Lange et al., 2000; Hammarlund-Udenaes, 2009). However, most of the 
preclinical techniques have very limited applicability in the extrapolation of 
preclinical findings to the human situation (Chapter 1; De Lange et al., 1997; 
Hammarlund-Udenaes et al., 2009).  
Cerebrospinal fluid (CSF) concentrations are often considered to be the best 
available surrogate for brain target site concentrations in humans (Fridén et al., 
2009; Kalvass and Maurer, 2002; Liu et al., 2006; Liu et al., 2009; Maurer et 
al., 2005). It is often assumed that CSF concentrations readily equilibrate with 
brainECF concentrations due to the lack of a physical barrier between these sites 
(Lee et al., 2001). However, due to qualitative and quantitative differences in 
processes that govern the pharmacokinetics (PK) of drugs in the brain, a 
generally applicable relationship between CSF concentrations and brainECF 
concentrations does not exist (Chapter 1; De Lange and Danhof, 2002; Lin, 
2008; Shen et al., 2004).  
Transport of drugs into and out of the brain is not solely governed by the 
blood-brain barriers (the blood-brain barrier (BBB) and the blood-CSF barrier 
(BCSFB)), but also by the anatomy of the brain and physiological processes. In 
combination with drug specific properties (Danhof et al., 2007; Keep and Jones, 
1990; Mayer et al., 1959; Oldendorf, 1979), this determines the concentrations 
of a drug within a specific part of the CNS, including the target site 
concentrations, which we are ultimately interested in.  
We have previously shown that even for acetaminophen, a model compound 
for passive transport into, within and out of the brain, differences exist between 
CSF and brainECF kinetics (Chapter 3). For compounds subjected to active 
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transport at the level of the brain barriers, such as by P-gp, differences between 
brainECF and CSF are anticipated to be larger. With P-gp localized at both the 
luminal and abluminal membranes of capillary endothelial cells, as well as to 
adjacent pericytes and astrocytes (Bendayan et al., 2006), this suggests that P-
gp may regulate drug transport processes in the entire brain at both the cellular 
and subcellular level. In contrast, P-gp presence and localization at the BCSFB 
is still subject of debate, with the only report of presence at the apical surface of 
the choroid plexus epithelial cells in the rat by Rao et al. (1999). Furthermore, it 
has been well established that P-gp functions as an efflux transporter at the BBB 
(Schinkel, 1999), whereas, there has been some evidence that P-gp could 
function as an influx transporter at the BCSFB (Kassem et al., 2007; Rao et al., 
1999). This could result in significant differences between concentrations at the 
brain target site and in CSF for compounds that are substrates for P-gp mediated 
transport. 
The presence of P-gp at multiple sites, with in part a yet uncertain transport 
direction, could have major implications for the predictability of human brainECF 
concentrations on the basis of human CSF concentrations for compounds that 
are substrates for active (e.g. P-gp-mediated) transport. Consequently, to be able 
to predict human brainECF concentrations on the basis of human CSF 
concentrations, one should first understand the mechanisms that determine the 
relationship between CSF concentrations and brainECF concentrations.  
Previous studies have indicated that, under steady-state conditions, CSF 
concentrations were comparable to steady-state brainECF concentrations for 
compounds that freely diffuse across the BBB and BCSFB, but may differ for 
compounds that are substrate for the various active transport systems at the 
BBB and BCSFB (Fridén et al., 2009; Kalvass and Maurer, 2002; Liu et al., 
2006; Liu et al., 2009; Maurer et al., 2005). CSF and brainECF concentration 
ratios were considered comparable if smaller than 3-fold, and assumed to be of 
little pharmacological consequence.  
However, we have previously questioned this arbitrary threefold range in 
ratio of CSF and brainECF (target site) kinetics, especially with regard to the 
unknown impact of the steady-state situation versus the more realistic multiple 
dosing conditions (troughs and peaks), the unknown of the changes therein in 
disease conditions as well as the unknown impact of this range on 
pharmacodynamics (Chapter 1). These unknowns need to be investigated 
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before we can really predict human target site pharmacokinetics and finally 
CNS effects.  
Using the multiple intracerebral microdialysis probes approach (striatum, 
lateral ventricle, and cisterna magna) with parallel blood sampling, continuous 
measurement and direct comparison of changes in concentrations in plasma, 
brainECF and CSF kinetics of quinidine could be assessed. Quinidine, a well-
known P-gp substrate (Doran et al., 2005; Kusuhara et al., 1997; Syvänen et al., 
2012; Sziráki et al., 2011; Varma and Panchagnula, 2005), was administered by 
means of a short infusion of 10 mg/kg and 20 mg/kg, with and without co-
administration of the P-gp blocker tariquidar (Fox and Bates, 2007; Kurnik et 
al., 2008). Mathematical modeling was applied to the data to result in a number 
of key findings. 
 
 
MATERIALS AND METHODS 
 
Chemicals and solutions 
 
Quinidine, quinidine sulfate dehydrate, quinidine hemi sulfate and quinine hemi 
sulfate were obtained from Sigma Aldrich (Zwijndrecht, the Netherlands). 
Tariquidar (XR9576) was obtained from Xenova Group PLC (Cambridge, 
England) or API Services Inc. (Westford, USA). Triethyl amine was obtained 
from J.T. Baker (Deventer, the Netherlands). Boric acid and orthophosphoric 
acid 85% were obtained from Merck (Darmstadt, Germany). Methyl tert-butyl 
ether was obtained from Biosolve B.V. (Valkenswaard, the Netherlands). 
Isoﬂurane was obtained from Pharmachemie B.V. (Haarlem, the Netherlands). 
Saline and 5% glucose were obtained from the Leiden University Medical 
Centre pharmacy (Leiden, the Netherlands). Microdialysis perfusion fluid was 
prepared as previously described (Chapter 3), containing 140.3 mM sodium, 
2.7 mM potassium, 1.2 mM calcium, 1.0 mM magnesium and 147.7 mM 
chloride. 
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Animals 
 
The study protocol was approved by the Animal Ethics Committee of Leiden 
University (UDEC nr. 07142) and all animal procedures were performed in 
accordance with Dutch laws on animal experimentation. A total of 60 male 
Wistar WU rats (225-275 g, Charles River, Maastricht, the Netherlands) were 
randomly divided into two groups; the first group (n = 12) was used for the 
determination of the in vivo microdialysis probe recovery; the second group (n 
= 48) was used for brain disposition experiments. This second group was further 
divided into four subgroups, designated for 10 or 20 mg/kg quinidine without or 
with co-administration of tariquidar (10-, 10+, 20- and 20+, respectively). 
After arrival, all animals were housed in groups for 5-7 days (Animal 
Facilities, Gorlaeus Laboratories, Leiden, the Netherlands), under standard 
environmental conditions (ambient temperature 21°C; humidity 60%; 12/12 h 
light/dark cycle, background noise, daily handling), with ad libitum access to 
food (Laboratory chow, Hope Farms, Woerden, the Netherlands) and acidified 
water. Between surgery and experiments, the animals were kept individually in 
Makrolon type three cages for 7 days to recover from the surgical procedures. 
 
Surgery  
 
All surgical procedures were performed as described in Chapter 3. In short, 
cannulas were implanted in the left femoral artery and vein for blood sampling 
and drug administration, respectively. Both cannulas were subcutaneously led to 
the back of the head and fixated in the neck with a rubber ring. Subsequently, 
the animals were chronically instrumented with two CMA/12 microdialysis 
guides (CMA/Microdialysis AB, Stockholm, Sweden) in different combinations 
of striatum (ST), for sampling in brainECF, and lateral ventricle (LV) and/or 
cisterna magna (CM) for sampling in CSF (ST+LV, ST+CM or LV+CM). For 
ST, the position of the microdialysis guide is: 1.0 mm anterior, 3.0 mm lateral, 
3.4 mm ventral, relative to bregma. For LV, the position of the microdialysis 
guide is: 0.9 mm posterior, 1.6 mm lateral, 2.9 mm ventral, relative to the 
bregma. For CM, the position of the microdialysis guide is: 1.93 mm posterior, 
3.15 mm lateral, 8.1 mm ventral, at an angle of 25° from the dorsoventral axis 
(towards anterior) and 18° lateral from the anteroposterior axis relative to 
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lambda. The microdialysis guides were secured to the skull with 3 anchor 
screws and dental cement. 
After the surgery the animals received 0.03 ml Temgesic ® intramuscularly 
(Schering-Plough, Amstelveen, the Netherlands) and 0.3 ml Ampicillan® 
(Alfasan B.V., Woerden, the Netherlands) subcutaneously. One day prior to the 
experiment, the microdialysis dummies were replaced by the microdialysis 
probes (CMA/12 Elite, Polyarylethersulfone membrane, molecular weight cut-
off 20 kDa, CMA/Microdialysis AB, Stockholm, Sweden, with a semi-
permeable membrane length of 4 mm for ST, and 1 mm for LV and CM). 
 
Experimental set-up 
 
All experiments were performed as described in Chapter 3 with some 
modifications. In short, the in vivo microdialysis probe recovery of quinidine 
was determined on the basis of reverse dialysis (Ståhle et al., 1991). The 
microdialysis probes in striatum, lateral ventricle and cisterna magna were 
perfused with different concentrations of quinidine (50, 200 and 1000 ng/ml) in 
perfusion fluid. To evaluate the potential effect of co-administration of 
tariquidar on the in vivo recovery of quinidine, several animals received an 
intravenous infusion of 15 mg/kg in 5% glucose solution (100 µl/min/kg for a 
period of 10 minutes) with an automated pump (Pump 22 Multiple Syringe 
Pump, Harvard Apparatus, Holliston, USA) 30 minutes prior to the start of the 
reverse dialysis experiment. Control animals received an intravenous infusion of 
vehicle (100 µl/min/kg for a period of 10 minutes). 
The in vivo recovery is defined as the ratio of the concentration difference 
between the dialysate (Cdial) and perfusion fluid (Cin) over the concentration in 
the perfusion fluid (equation 1) (Scheller and Kolb, 1991).  
 
𝑖𝑛 𝑣𝑖𝑣𝑜 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 = 𝐶𝑖𝑛−𝐶𝑑𝑖𝑎𝑙
𝐶𝑖𝑛
                    (1) 
 
For the brain disposition experiments, the rats first received an intravenous 
infusion of 15 mg/kg tariquidar in 5% glucose solution or vehicle 30 minutes 
prior to the administration of 10 or 20 mg/kg quinidine in saline (100 µl/min/kg 
for a period of 10 minutes). The start and duration of the infusion was corrected 
for internal volume of the tubing so that infusion started at t=0 min. 10 min 
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interval samples were collected between t=−1 h and t=4 h, followed by 20 min 
interval samples until t=6 h. After weighing the microdialysis vials they were 
stored at −80°C before analysis. 
For the determination of quinidine plasma concentrations, blood samples of 
100 μl were taken, in parallel to the microdialysate samples, from the arterial 
cannula at t=−5 (blank), 2, 7, 10, 12, 17, 30, 60, 140, 240, and 360 min. All 
blood samples were temporarily stored in heparin (10 IU) coated Eppendorf 
cups before being centrifuged for 15 min at 5000 rpm. The plasma was then 
pipetted into clean Eppendorf cups and stored at −20°C before analysis. 
At the end of the experiments the animals were sacrificed with an overdose 
of Nembutal (Ceva Sante Animale, Libourne, France). The animals were then 
perfused and decapitated to isolate the brain. After cleaning with saline, 
weighing, and freezing in liquid nitrogen, the brain was stored at -80˚C before 
analysis. 
 
Plasma protein binding 
 
For the determination of plasma protein binding of quinidine, blood samples of 
300 μl were taken at t=−30 (blank) and 60 min (with a concentration assumed to 
be approximately 50% of Cmax (Harashima et al., 1985)). After the blood sample 
at t=360 min, an additional dose of 10 or 20 mg/kg in 10 minutes was given to 
be able to determine plasma protein binding at Cmax (at t=370 min). All blood 
samples were temporarily stored in heparin (10 IU) coated Eppendorf cups. The 
blank blood samples were spiked with quinidine to obtain a blood concentration 
of 100 ng/ml for the 10 mg/kg dose group and 200 ng/ml for the 20 mg/kg dose 
group. The spiked blood samples were then incubated in a shaking water bath at 
37°C for 30 minutes. All blood samples were centrifuged for 15 min at 5000 
rpm and the plasma was pipetted into clean Eppendorf cups and stored at −20°C 
before analysis.  
Plasma protein binding was determined with Centrifree® ultrafiltration 
devices (Millipore BV, Etten-Leur, the Netherlands). All procedures were 
performed according to the user’s manual. The ultrafiltrate was diluted 10 times 
with saline before the analysis.  
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Concentration analysis 
 
Quinidine concentrations in plasma, plasma ultrafiltrate, microdialysate, and 
total brain were determined as described by Syvänen et al. (2012), using High 
Pressure Liquid Chromatography (HPLC) with fluorescence detection. In short, 
to 20 μl of plasma, 50 μl internal standard (IS; 500 ng/ml quinine) was added. 
After homogenization with 200 μl borate buffer pH 10, 5 ml of methyl tert-butyl 
ether was added. After vortexing, centrifugation, and freezing of the aqueous 
layer, the organic phase was evaporated to dryness. The extracts were 
reconstituted in 100 μl of mobile phase and centrifuged at 4000 g during 5 min. 
The clean plasma extracts were injected using a mobile phase with an 
acetonitrile/buffer ratio of 1:6. 
To 20 µl of the plasma ultrafiltrate or microdialysate samples 20 μl IS was 
added, followed by vortexing before being directly injected into the HPLC 
system.  
Quinidine concentration in brain tissue was analyzed by the following steps: 
whole brain was homogenized in 50 mM phosphate buffer at pH 7.4. To 600 µl 
of the homogenate 100 µl IS and 100 µl 1M sodium hydroxide was added. 5 ml 
methyl tert-butyl ether was then added, followed by vortexing and 
centrifugation. 4 ml of the supernatant was then transferred to a clean glass tube 
and 100 μL of 30 mM phosphoric acid was added. After vortexing and 
centrifugation, the supernatants were aspirated and discarded. The remaining 
aqueous phase was centrifuged for 10 min at 11000 g. An aliquot of 50 μl was 
then transferred to clean glass vials and 20 μl was injected into the HPLC 
system.  
Data acquisition and processing was performed using Empower® data 
acquisition software (Waters, Etten-Leur, the Netherlands). For constructing the 
calibration curve, linear regression analysis was applied using weight factor 
1/(y)2. Data analysis, statistical analysis, and plotting were performed using 
Microsoft® Office Excel 2003 (Microsoft Corporation, USA). 
 
Pharmacokinetic data analysis 
 
All plasma concentrations were converted to unbound plasma concentrations, 
by correction for plasma protein binding. All microdialysate concentrations 
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from striatum, lateral ventricle and cisterna magna were converted into brainECF 
concentrations (CECF) or CSF concentrations (CCSF) by division of the dialysate 
concentrations by the average in vivo recovery as determined for each 
microdialysis probe location (equation 2).  
 
𝐶𝐸𝐶𝐹  𝑜𝑟 𝐶𝐶𝑆𝐹 = 𝐶𝑑𝑖𝑎𝑙𝑖𝑛 𝑣𝑖𝑣𝑜 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦                    (2) 
 
Areas under the curve from t=0 to t=360 min (AUC0-360) were calculated by 
the trapezoidal rule and tested for differences by single factor ANOVA. The 
population PK models were developed and fitted to the data by means of non-
linear mixed-effects modeling using the NONMEM software package (version 
6.2, Icon Development Solutions, Ellicott City, Maryland, USA) and analyzed 
using the statistical software package S-Plus® for Windows (version 6.2 
Professional, Insightful Corp., Seattle, USA).  
The pharmacokinetic model for quinidine plasma and brain concentrations 
was based on the systems-based PK (SBPK) approach we have previously 
applied to investigate the exchange between brainECF and CSF of acetaminophen 
(Chapter 3). For this approach, the volumes of the different brain 
compartments were fixed to their physiological volumes. The rat brain 
intracellular space and brainECF volume were assumed to be 1.44 ml (Thorne et 
al., 2004), and 290 µl (Cserr et al., 1981), respectively. With a total CSF 
volume of 300 µl in the rat (Bass and Lundborg 1973), the volumes of the 
lateral ventricles, third and fourth ventricles, cisterna magna and subarachnoid 
space were assumed to be 50 µl (Condon et al., 1986; Kohn et al., 1991), 50 µl 
(Levinger, 1971), 17 µl (Adam and Greenberg, 1978; Robertson, 1949), and 
180 µl (Bass and Lundborg, 1973; Levinger, 1971), respectively. The intra-
brain distribution was restricted by the physiological flow paths of brainECF, in 
which brainECF flows towards the CSF compartments at a rate of 0.2 μl/min 
(Abbott, 2004; Cserr et al., 1981), and CSF flows from lateral ventricle, through 
the third and fourth ventricle, to the cisterna magna and subsequently to the 
subarachnoid space (cranial and spinal) and back into blood at a rate of 2.2 
μl/min (Cserr, 1965). 
Structural model selections for the SBPK model were based on the 
likelihood ratio test (p < 0.01), diagnostic plots (observed concentrations vs. 
individual and population predicted concentrations, weighted residuals vs. 
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predicted time and concentrations), parameter correlations and precision in 
parameter estimates. The inter-animal variability in pharmacokinetic parameters 
was assumed to be log normally distributed. The residual error, which accounts 
for unexplained variability (e.g. measurement and experimental error and 
model-misspecification), was best described with a proportional error model.  
The validity of the SBPK model was investigated by means of a visual 
predictive check (Cox et al., 1999; Duffull and Aarons, 2000; Yano et al., 
2001). Using the final PK parameter estimates, 1000 curves were simulated. 
Subsequently, the median and the 5th and 95th percentile of the predicted 
concentrations were calculated, which represent the 90% prediction interval. 
These were then compared with the observations. 
In order to test the ruggedness of the model and estimate the precision of the 
parameters n=100 non-parametric (case resampling) bootstraps were performed. 
To create the bootstrapped datasets, specific rat data (plasma and microdialysate 
concentrations) were removed randomly from the datasets and replaced with 
randomly selected rat data from the complete original dataset. Each of these 
permutations of the original dataset were fitted with the final model determined 
based on the original dataset. This results in a series of model fits, each with its 
own set of parameters. These results were displayed graphically and the 
descriptive statistics of the parameters were compared to parameter estimates of 
the final model. Only bootstrap runs that successfully minimized were used in 
this analysis. 
 
 
RESULTS 
 
All results are presented as average values ± standard error of the mean, unless 
stated otherwise.  
 
Quinidine pharmacokinetics 
 
The average unbound plasma (plasmau), brainECF, lateral ventricle (CSFLV) and 
cisterna magna (CSFCM) quinidine concentrations following the 10 and 20 
mg/kg dose with or without co-administration of tariquidar are shown in figure 
1. Plasma protein binding of quinidine was linear at an extent of 86.5 ± 5.5 %. It 
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was not affected by co-administration of tariquidar. The co-administration of 
tariquidar slightly reduced the plasma elimination rate of plasmau for both 10 
and 20 mg/kg dose of quinidine. Data obtained by microdialysis from the 
brainECF, CSFLV and CSFCM were corrected for in vivo recovery. The average in 
vivo recoveries for the quinidine concentrations in striatum, lateral ventricle and 
cisterna magna probes were not influenced by co-administration of tariquidar 
and were determined to be 9.1 ± 0.5%, 2.9 ± 0.5% and 3.5 ± 0.5%, respectively.  
 
 
Figure 1. Average (geometric mean ± S.E.M.) unbound quinidine concentration-time profiles 
following intravenous administration of quinidine, with (+) or without (-) co-administration of 
tariquidar (15/mg/kg). (A) 10 mg/kg quinidine dose: for plasma (n = 11 (-) and 6 (+)), brainECF 
(n = 6 (-) and 4 (+)), CSFLV (n = 4 (-) and 3 (+)) and CSFCM (n = 4 (-) and 4 (+). (B) 20 mg/kg 
quinidine dose. Plasma (n = 9 (-) and 11 (+)), brainECF (n = 5 (-) and 6 (+)), CSFLV (n = 4 (-) 
and 4 (+)) and CSFCM (n = 6 (-) and 6 (+)) 
 
It can be seen that a higher dose of quinidine leads to higher quinidine 
concentrations in all brain compartments, but not to the same extent. Tariquidar 
increased quinidine concentrations significantly (p < 0.01) in all brain 
compartmens, but most pronouncedly for brainECF. The effect of tariquidar was 
dependent on the quinidine dose; at the higher dose of quinidine, the increase in 
quinidine concentrations in all brain compartments was less profound, as can be 
seen by the average brainu-to-plasmau AUC0-360 ratios (table 1). However, the 
difference between the unbound brain (brainu)-to-plasmau AUC0-360 ratios for 
the 10 and 20 mg/kg dose with co-administration of tariquidar was only 
significant (p < 0.05) for brainECF. The brainECF-to-CSF concentrations ratios 
were also very much dependent on tariquidar, and on average were increased 
from 0.77 ± 0.19 to 2.41 ± 0.56 and from 0.67 ± 0.21 to 2.02 ± 0.52, for the 10 
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and 20 mg/kg dose, respectively (table 2). Significant differences in AUC ratios 
and concentrations between brainECF and CSF (either from lateral ventricle or 
cisterna magna) were only observed for the groups that received the co-
administration of tariquidar. 
 
Table 1. Brainu-to-plasmau AUC0-360 ratios for brainECF, CSFLV and CSFCM for the 10 mg/kg and 
20 mg/kg dose without (-) and with (+) co-administration of tariquidar 
Brainu-to-plasmau 
AUC0-360 ratios 
10- 10+ 20- 20+ 
BrainECF 135 ± 17% 1265 ± 213%**‡ 150 ± 16%‡ 864 ± 64%**‡† 
CSFLV 177 ± 39% 624 ± 41%** 257 ± 24% 498 ± 74%** 
CSFCM 167 ± 16% 479 ± 76%** 184 ± 15% 383 ± 33%** 
 
** Significantly (p < 0.01) different from the group without co-administration of tariquidar 
‡ Significantly (p < 0.05) different from the CSF-to-plasmau AUC0-360 ratios 
† Significantly (p < 0.05) different from the 10 mg/kg dose group with co-administration of 
tariquidar 
 
Table 2. BrainECF-to-CSF concentration ratios for the 10 mg/kg and 20 mg/kg dose without (-) 
and with (+) co-administration of tariquidar 
BrainECF-to-CSF 
concentration ratios 10
- 10+ 20- 20+ 
BrainECF-to-CSFLV 0.75 ± 0.09* 2.13 ± 0.47* 0.56 ± 0.18* 1.81 ± 0.57 
BrainECF-to-CSFCM 0.79 ± 0.25 2.70 ± 0.51* 0.78 ± 0.17 2.23 ± 0.37* 
BrainECF-to-CSFaverage 0.77 ± 0.19 2.41 ± 0.56* 0.67 ± 0.21 2.02 ± 0.52* 
 
* Significantly (p < 0.05) different from 1 
 
Also, end-of-experiment total brain concentrations (braintotal) were obtained. 
These data were corrected for corresponding brainECF concentrations to 
represent deep brain (braindeep) concentrations. The braindeep concentrations were 
determined to be on average 3.6 ± 1.6-fold higher than final brainECF 
concentrations for the control group and 6.3 ± 1.5-fold higher for the animals 
that received a co-administration of tariquidar (not significantly different). This 
indicates that P-gp also influences brain intracellular exposure.  
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Compartmental modeling approach 
 
All data were subjected first to compartmental pharmacokinetic analysis. It was 
shown that the plasma concentrations were best described by a three 
compartment model with inter-compartmental clearance (Q), and elimination 
clearance from the central compartment (CLE). The effect of the co-
administration of tariquidar on the elimination clearance was found to be 
significant (p < 0.01, objective function value reduction of 6.63 units). 
To describe the concentrations in each of the brain compartments, four brain 
compartments were added (brainECF, CSFLV, CSFCM and braindeep). Drug 
transport between the plasma and the different brain compartments was 
determined by a transfer clearance between plasma and each of the brain 
compartments (CLPL-BR) and vice versa (CLBR-PL). In this model (figure 2) it was 
not possible to include drug transport between the different brain compartments 
because each brain compartment then has multiple routes of entry. The model 
was not able to identify the specific contribution of each route, resulting in 
transfer clearance value estimations near 0, which is not realistic. Therefore, we 
decided to remove the transport between the different brain compartments. 
 
Distinction between passive and active transport clearances - The effect of P-
gp on the different transfer clearances between plasma and the brain 
compartments was determined by comparing the parameter estimations for the 
rats that did to those rats that did not receive the co-administration of tariquidar. 
Thus, a distinction could be made between the passive and the active 
component of the transfer clearances. 
The data were best described by a model in which P-gp reduced the transfer 
clearance from plasma to the brain compartments (i.e. influx hindrance; 
equation 3) and increased the transfer clearance from the brain compartments to 
plasma (i.e. efflux enhancement; equation 4). The transfer clearances between 
plasma and the different brain compartments that could be assigned to P-gp 
were incorporated into the model as previously described by Syvänen et al. 
(2006):  
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𝐶𝐿𝑃𝐿−𝐵𝑅 = 𝐶𝐿𝑃𝐿−𝐵𝑅,𝑝 − 𝐶𝐿𝑃𝐿−𝐵𝑅,𝑃−𝑔𝑝                  (3) 
 
𝐶𝐿𝐵𝑅−𝑃𝐿 = 𝐶𝐿𝐵𝑅−𝑃𝐿,𝑝 + 𝐶𝐿𝐵𝑅−𝑃𝐿,𝑃−𝑔𝑝                  (4) 
 
Where the subscript ‘p’ denotes passive transport and ‘P-gp’ denotes P-gp-
mediated transport. 
 
Modeling quinidine concentration-dependent P-gp-mediated transport - Since 
P-gp-mediated transport is an active (saturable) process we have also tried to 
identify the maximal transport rate (Tm) and the blood- or brain concentration 
for half-maximal transport (Km) as follows: 
 
𝐶𝐿𝑃𝐿−𝐵𝑅,𝑃−𝑔𝑝 = 𝑇𝑚,𝑃𝐿−𝐵𝑅𝐾𝑚,𝑃𝐿−𝐵𝑅+𝐶𝑃𝐿,𝑢                   (5) 
 
𝐶𝐿𝐵𝑅−𝑃𝐿,𝑃−𝑔𝑝 = 𝑇𝑚,𝐵𝑅−𝑃𝐿𝐾𝑚,𝐵𝑅−𝑃𝐿+𝐶𝐵𝑅                   (6) 
 
Where CPL,u is the unbound plasma concentration and CBR is the concentration 
in one of the brain compartments. The parameter estimations of Tm and Km 
resulted in high values for both Tm and Km (results not shown), indicating that 
the plasma and brain concentrations in this study are not sufficiently high for 
saturating P-gp-mediated transport. The parameter estimations of Tm and Km 
also resulted in too large coefficients of variation. Thus, our data were 
insufficient to determine the values of these parameters, and for the next 
modeling steps, P-gp-mediated transport had to be incorporated by means of a 
single clearance value, rather than by Tm and Km. 
 
Modeling deep brain concentrations - Braindeep concentrations were determined 
for samples obtained at the end-of-experiment time point. Based on previous 
studies in our lab with male Wistar WU rats (unpublished results), it was found 
that the braindeep-to-brainECF concentration ratio of quinidine was constant 
throughout the entire experimental period. We used this information to estimate 
braindeep concentrations during the experiment.  
 
 
Chapter 4 
116 
 
 
Figure 2. Diagram of the compartmental model that was used to describe the brain distribution of 
quinidine in the rat. CLE is the elimination clearance from plasma, QPL-PERx is the inter-
compartmental clearance between plasma and the first (x=1) or second (x=2) peripheral 
compartment. Further, for transfer clearances between compartments (CLfrom comp-to comp), 
denotations of the compartments are: PL = plasma; DBR = braindeep; ECF = brainECF;             
LV = lateral ventricle; and CM = cisterna magna 
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Final compartmental model - The final estimation of the PK parameters of the 
compartmental model is summarized in table 3. The visual predictive check of 
the final compartmental model is given in figure 3. It can be seen that the 
compartmental model describes the data very well within the 90% prediction 
interval, and also can cope with the large inter-individual variation as observed 
in the different brain concentrations.  
 
 
Figure 3. The visual predictive check of the compartmental model. The dots represent the 
individual data points and the gray area represents the 90% prediction confidence interval. The 
different boxes represent the plasma, brainECF, CSFLV, CSFCM and braindeep data 
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Table 3. Final estimation of the rat PK parameters for the compartmental model (± standard 
error) 
Parameter Value 
CLE 158 ± 11 ml/min 
P-gp effect on CLE 1.2 ± 0.1-fold increase 
QPL-PER1 822 ± 95 ml/min 
QPL-PER2 171 ± 28 ml/min 
CLPL-DBR,p 1430 ± 188 µl/min 
CLPL-DBR,P-gp 1270 ± 165 µl/min 
CLDBR-PL,p 16.1 ± 1.3 µl/min 
CLDBR-PL,P-gp 17.3 ± 2.4 µl/min 
CLPL-ECF,p 36.6 ± 3.9 µl/min 
CLPL-ECF,P-gp 25.8 ± 3.7 µl/min 
CLECF-PL,p 3.2 ± 0.2 µl/min 
CLECF-PL,P-gp 4.4 ± 0.7 µl/min 
CLPL-LV,p 3.4 ± 0.7 µl/min 
CLPL-LV,P-gp 1.1 ± 0.3 µl/min 
CLLV-PL,p 0.4 ± 0.09 µl/min 
CLLV-PL,P-gp 0.5 ± 0.2 µl/min 
CLPL-CM,p 0.7 ± 0.08 µl/min 
CLPL-CM,P-gp 0.07 ± 0.02 µl/min 
CLCM-PL,p 0.1 ± 0.02 µl/min 
CLCM-PL,P-gp 0.2 ± 0.06 µl/min 
VPL 10.6 ml 1 
VPER1 5.9 ± 0.5 l 
VPER2 11.7 ± 1.6 l 
VDBR 1.44 ml 2 
VECF 290 µl 3 
VLV 50 µl 4,5 
VCM 17 µl 6,7 
ηCLE 0.08 ± 0.02 
εPL 0.13 ± 0.02 
εDBR 0.06 ± 0.01 
εECF 0.05 ± 0.01 
εLV 0.09 ± 0.02 
εCM 0.07 ± 0.01 
 
Parameter values in italic are derived from literature. CLE is the elimination clearance from 
plasma, QPL-PERx is the inter-compartmental clearance between plasma and the first (x=1) or 
second (x-=2) peripheral compartment. Further, for transfer clearances between compartments 
(CLfrom comp-to comp), denotations of the compartments are: PL = plasma; ECF = brainECF;        
DBR = braindeep; LV = lateral ventricle; and CM = cisterna magna. For plasma and brain 
compartments V is the physiological volume; for peripheral compartments V is the volume of 
distribution. ηi = inter-individual variability of parameter i; εj = residual error on concentrations 
in compartment j. 
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Notes to table 3 continued: The additional subscripts ‘p’ and ‘P-gp’ denote passive transport and 
P-gp-mediated transport, respectively.  
1 Lee and Blaufox, 1985; 2 Thorne et al., 2004; 3 Cserr et al., 1981; 4 Condon et al., 1986; 5 Kohn 
et al., 1991; 6 Adam and Greenberg, 1978; 7 Robertson, 1949. 
 
Systems-based modeling approach 
 
As it was our goal to investigate the relationship between brainECF and CSF 
pharmacokinetics, we have applied a SBPK modeling approach. To more 
adequately describe CSF physiology, we have added two CSF compartments 
that represent the combined third and fourth ventricle (CSFTFV) and the 
subarachnoid space (CSFSAS), like we did previously for analysis of 
acetaminophen regional brain distribution (Chapter 3). Since we have no 
measurements of the concentrations in the third and fourth ventricle, the transfer 
clearance between plasma and third and fourth ventricle was assumed to be 
equal to the transfer clearance between plasma and lateral ventricle. 
 
Modeling CSF flow - In our first attempt of the SBPK approach the values of 
the brainECF flow (QECF) and CSF flow (QCSF) were fixed to their physiological 
values. However, it appeared that this value for QCSF was too high for proper 
description of quinidine concentration in the CSF compartments. Therefore the 
CSF production rate was estimated. To do so, the clearance from CSFLV to 
plasma was fixed to 0, as otherwise QCSF was estimated to be 0. Thereby, the 
model was ‘forced’ to estimate the QCSF, being 0.52 ± 0.25 µl/min. This value of 
QCSF was much lower than the physiological one (2.2 µl/min). An explanation 
for the reduced QCSF was searched for. It was found that quinidine is capable of 
inhibiting Na+-K+-ATPase activity (Ball et al., 1981), which is an enzyme at the 
apical membrane of the choroid plexus that leads to the formation of CSF 
(Brown et al., 2004; Ernst et al., 1986). A potential influence of quinidine 
reducing CSF flow was investigated by a CSF quinidine concentration (CCSF)-
dependent inhibition of QCSF by means of an Emax model (equation 7), in which 
QCSF,EF was the effective CSF flow.  
 
𝑄𝐶𝑆𝐹,𝐸𝐹 = 𝑄𝐶𝑆𝐹 × �1 − 𝐶𝐶𝑆𝐹𝐶𝐶𝑆𝐹+𝐼𝐶50�                    (7) 
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The resulting estimated IC50 of quinidine was 209 ± 66 ng/ml. This value was 
143-fold lower than reported (~30 µg/ml (Ball et al., 1981)) and therefore not 
considered realistic. As an alternative, we needed to fix the QCSF to its 
physiological value and to define the rate of transfer of quinidine from blood to 
CSFLV and vice versa being equal.  
 
Modeling P-gp-mediated transport - P-gp has been well described as an efflux 
transporter at the BBB. However, the mechanism by which P-gp can exert its 
effect could be by so-called efflux enhancement or influx hindrance or both. 
The data were best described by the model with P-gp function solely as influx 
hindrance or combined influx hindrance and efflux enhancement. The 
observation that in vivo probe recovery of quinidine was not affected by 
tariquidar would be an indication that quinidine is transported by P-gp only via 
the influx hindrance mechanism (Kusuhara et al., 1997; Stein et al., 1994; Sun 
et al., 2001). However, as the largest reduction in the objective function value in 
the model was observed for a combined influx hindrance and efflux 
enhancement, this indicates that this model is most probably the best. 
Based on the suggestion that P-gp functions as an influx transporter at the 
BCSFB (Kassem et al., 2007; Rao et al., 1999), the effect of P-gp on the 
clearance values between plasma and CSF was described as such. However, 
with our data we could not identify P-gp influx at the BCSFB. Therefore, we 
have tested models in which P-gp was considered to be an efflux transporter at 
the BCSFB or not present at the BCSFB at all. The data were best described by 
a model with P-gp as an efflux transporter at the BCSFB for lateral ventricle, 
whereas it was absent for cisterna magna. 
Again, we have tried to identify Tm and Km values for P-gp-mediated 
transport of the SBPK model, but without success (results not shown). 
Therefore, P-gp-mediated transport had to be incorporated by means of a single 
clearance value, rather than by Tm and Km. 
 
Modeling deep brain concentrations - Our assumption was that compounds, 
after passing the BBB and BCSFB would first enter brainECF, before reaching 
the braindeep compartment. However, since the braindeep concentrations are much 
higher than the brainECF concentrations, and the physiological volume of the 
braindeep compartment is much larger than the brainECF compartment, the mass 
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transfer of quinidine from plasma, via the brainECF compartment, to the deep 
brain needs to be quite substantial. This route did not result in a model that 
could adequately describe the data. In contrast, a direct mass transfer from 
plasma into the braindeep compartment did. Actually, the direct route through 
lipid membranes seems a rather plausible explanation for a lipohilic drug like 
quinidine, which has a logP of 2.36 in its neutral form (Machatha and 
Yalkowsky, 2005).  
 
Final SBPK model - The final SBPK model is shown in figure 4. The 
differential equations of this model can be found in the appendix. The final 
estimation of the PK parameters is summarized in table 4. Here, the parameters 
are the same as for table 3, with the addition of the following: CLPL-TFV is the 
clearance from plasma to CSFTFV, CLTFV-PL is the clearance from CSFTFV to 
plasma, QECF is the flow rate of brainECF, QCSF is the flow rate of CSF, VTFV is 
the volume of the third and fourth ventricle combined and VSAS is the volume of 
the subarachnoid space.  
The visual predictive check of the final model is given in figure 5. It can be 
seen that the final model describes the data very well within the 90% prediction 
interval, and also can cope with the large inter-individual variation in brain 
concentrations.  
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Figure 4 (left). Diagram of the SBPK model that was used to describe the intra-brain distribution 
in the rat. CLE is the elimination clearance from plasma, QPL-PERx is the inter-compartmental 
clearance between plasma and the first (x=1) or second (x=2) peripheral compartment. Further, 
for transfer clearances between compartments (CLfrom comp-to comp), denotations of the 
compartments are: PL = plasma; DBR = braindeep; ECF = brainECF; LV = lateral ventricle; TFV 
= third and fourth ventricle; CM = cisterna magna and SAS = subarachnoid space. QECF is the 
flow rate of brainECF, QCSF is the flow rate of CSF  
 
 
 
Figure 5. The visual predictive check of the final SBPK model. The dots represent the individual 
data points and the gray area represents the 90% prediction confidence interval. The x-axis 
represents the time (min) and the y-axis represents the quinidine concentrations (ng/ml). The 
different boxes represent the plasma, brainECF, CSFLV, CSFCM and braindeep data, respectively 
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Table 4. Final estimation of the rat PK parameters for the different SBPK models (± standard 
error) 
Parameter efflux enhancement influx hindrance efflux enhancement and influx hindrance 
Objective function 
value 18105 18030 17969 
CLE 81.6 ± 11.4 ml/min 87.4 ± 10.5 ml/min 95.9 ± 11.0 ml/min 
P-gp effect on CLE 1.9 ± 0.2-fold increase 2.1 ± 0.3-fold increase 1.9 ± 0.2-fold increase 
QPL-PER1 1520 ± 177 ml/min 1150 ± 138 ml/min 1190 ± 135 ml/min 
QPL-PER2 84.2 ± 57.6 ml/min 360 ± 105 ml/min 333 ± 94 ml/min 
CLPL-DBR,p 1540 ± 182 µl/min 2670 ± 501 µl/min 2180 ± 384 µl/min 
CLPL-DBR,P-gp N.A. 2430 ± 466 µl/min 1900 ± 373 µl/min 
CLDBR-PL,p 17.8 ± 1.5 µl/min 48.5 ± 9.6 µl/min 37.2 ± 7.2 µl/min 
CLDBR-PL,P-gp 253 ± 40.4 µl/min N.A. 19.6 ± 10.9 µl/min 
CLPL-ECF,p 48.6 ± 6.3 µl/min 68.4 ± 9.1 µl/min 50.2 ± 5.0 µl/min 
CLPL-ECF,P-gp N.A. 54.8 ± 8.1 µl/min 33.8 ± 5.1 µl/min 
CLECF-PL,p 7.1 ± 1.2 µl/min 9.3 ± 1.4 µl/min 6.3 ± 0.8 µl/min 
CLECF-PL,P-gp 33.1 ± 8.1 µl/min N.A. 5.3 ± 1.7 µl/min 
CLPL-LV,p 7.2 ± 0.8 µl/min 8.4 ± 0.8 µl/min 9.0 ± 0.9 µl/min 
CLPL-LV,P-gp N.A. 3.0 ± 0.7 µl/min 3.8 ± 0.8 µl/min 
CLLV-PL,p 0.03 ± 0.01 µl/min 0.04 ± 0.01 µl/min 0.04 ± 0.01 µl/min 
CLLV-PL,P-gp 1.2 ± 0.4 µl/min N.A. 0 µl/min 
CLPL-CM,p 1.3 ± 0.3 µl/min 1.1 ± 0.3 µl/min 1.1 ± 0.3 µl/min 
CLPL-CM,P-gp N.A. 0 µl/min 0 µl/min 
CLCM-PL,p 3.7 ± 0.5 µl/min 4.0 ± 0.5 µl/min 4.1 ± 0.5 µl/min 
CLCM-PL,P-gp 0 µl/min N.A. 0 µl/min 
QECF 0.2 µl/min 1,2 0.2 µl/min 1,2 0.2 µl/min 1,2 
QCSF 2.2 µl/min 3 2.2 µl/min 3 2.2 µl/min 3 
VPL 10.6 ml 4 10.6 ml 4 10.6 ml 4 
VPER1 13.2 ± 1.8 l 6.4 ± 1.6 l 6.8 ± 1.7 l 
VPER2 5.8 ± 2.6 l 13.9 ± 2.0 l 13.3 ± 2.2 l 
VDBR 1.44 ml 5 1.44 ml 5 1.44 ml 5 
VECF 290 µl 6 290 µl 6 290 µl 6 
VLV 50 µl 7,8 50 µl 7,8 50 µl 7,8 
VTFV 50 µl 9 50 µl 9 50 µl 9 
VCM 17 µl 10,11 17 µl 10,11 17 µl 10,11 
VSAS 180 µl 9,12 180 µl 9,12 180 µl 9,12 
ηCLE 0.20 ± 0.09 0.16 ± 0.08 0.14 ± 0.06 
εPL 0.29 ± 0.04 0.22 ± 0.02 0.22 ± 0.03 
εDBR 0.06 ± 0.01 0.07 ± 0.02 0.07 ± 0.02 
εECF 0.07 ± 0.01 0.07 ± 0.01 0.06 ± 0.01 
εLV 0.10 ± 0.01 0.10 ± 0.01 0.11 ± 0.02 
εCM 0.06 ± 0.01 0.07 ± 0.01 0.08 ± 0.02 
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Notes to table 4: Parameter values in italic are derived from literature; N.A. implicates that the 
parameter is not available in the specific model. CLE is the elimination clearance from plasma, 
QPL-PERx is the inter-compartmental clearance between plasma and the first (x=1) or second      
(x-=2) peripheral compartment. Further, for transfer clearances between compartments     
(CLfrom comp-to comp), denotations of the compartments are: PL = plasma; ECF = brainECF;        
DBR = braindeep; LV = lateral ventricle; and CM = cisterna magna. For plasma and brain 
compartments, V = physiological volume; for peripheral compartments, V = volume of 
distribution. ηi = inter-individual variability of parameter i; εj = residual error on concentrations 
in compartment j. The additional subscripts ‘p’ and ‘P-gp’ denote passive transport and             
P-gp-mediated transport, respectively. 
1 Abbott, 2004; 2 Cserr et al., 1981; 3 Cserr, 1965; 4 Lee and Blaufox, 1985; 5 Thorne et al., 2004; 
6 Cserr et al., 1981; 7 Condon et al., 1986; 8 Kohn et al., 1991; 9 Levinger, 1971; 10 Adam and 
Greenberg, 1978; 11 Robertson, 1949; 12 Bass and Lundborg, 1973. 
 
 
DISCUSSION 
 
In the development of CNS-targeted drugs, the prediction of human CNS target 
exposure is a big challenge. While CSF concentrations are often considered to 
be the best available surrogate for brain target site concentrations in humans, a 
generally applicable relationship between CSF concentrations and brainECF 
concentrations does not exist (Chapter 1; De Lange and Danhof, 2002; Lin, 
2008; Shen et al., 2004). Previous studies have indicated that, at steady-state 
conditions, CSF to brainECF concentration ratios were between 3-fold (either 
higher or lower) for compounds that freely diffuse across the BBB and BCSFB, 
while for compounds being brain barrier transporter substrates the difference 
may be higher (Fridén et al., 2009; Kalvass and Maurer, 2002; Liu et al., 2006; 
Liu et al., 2009; Maurer et al., 2005). Combining their data showed that 24% 
(21/89) of the P-gp substrates had a CSF/brainECF concentration ratio larger than 
3. Then, prediction of brainECF concentrations on the basis of CSF 
concentrations gets inadequate. This indicates that we need to improve our 
understanding of the impact of P-gp functionality at the brain barriers in order 
to be able to predict human CNS brainECF concentrations. 
By using the multiple microdialysis probes approach (Chapter 3), we 
investigated the direct relationships between brain striatum concentrations and 
those in different CSF locations, and unbound plasma concentrations in the rat. 
We have focused on P-gp-mediated efflux transport functionality at the BBB, 
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whereas it has been reported to function as an influx transporter at the BCSFB 
(Kassem et al., 2007; Rao et al., 1999). This could have major implications for 
the relationship between CSF concentrations and brainECF concentrations for 
compounds that are substrates for P-gp-mediated transport. To investigate the 
specific contribution of P-gp-mediated transport, quinidine was used as a 
paradigm P-gp substrate, with inhibition of P-gp by co-administration of 
tariquidar. Tariquidar is known to inhibit P-gp with a half-maximum inhibition 
constant (IC50) of approximately 25 ng/ml (Mistry et al., 2001). Previous work 
by Bankstahl et al. (2008), and Syvänen et al. (2011) have indicated that a 15 
mg/kg dose of tariquidar results in plasma and brain concentrations over 50-fold 
higher than the IC50 value up to 3 hours after administration. Therefore, it is 
plausible to assume that the dose of tariquidar is sufficient to fully inhibit P-gp 
throughout the entire experimental period. Advanced mathematical modeling 
was used to finally determine the interaction between systems physiology and 
quinidine. Our key findings indicated that: 1) brainECF- and CSF-to-unbound 
plasma AUC0-360 ratios were all over 100%, indicating influx transport by using 
unbound concentrations; 2) P-gp also restricts brain intracellular exposure; 3) a 
direct transport route of quinidine from plasma to brain cells exists; 4) P-gp-
mediated efflux of quinidine at the BBB seems to result of combined efflux 
enhancement and influx hindrance; 5) P-gp at the BCSFB at the level of the 
lateral ventricle functions as an efflux transporter or, at the cisterna magna, is 
not functioning at all. 
In previous studies brainECF concentrations were estimated on the basis of 
total brain concentrations and the brain unbound fraction, determined by 
equilibrium dialysis of drug-spiked brain homogenates (Kalvass and Maurer, 
2002; Liu et al., 2006; Maurer et al., 2005). However, brain tissue 
homogenization destroys cell structures unmasking binding sites that are 
normally not accessible to a drug (Liu et al., 2009), potentially leading to 
underestimation of the in vivo brain unbound fraction. The use of the brain slice 
technique is an improvement (Kakee et al., 1996). Liu et al. (2006), and Fridén 
et al. (2009), have applied this technique to calculate the brain unbound 
fraction, being further used to estimate brainECF concentrations. Comparison of 
the brain homogenate method with brain slice technique indicated that the brain 
unbound fraction was over 50% different for 5 out of 7 compounds (Liu et al., 
2006). Liu et al. (2009) have later applied the microdialysis technique for direct 
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measurement of unbound brainECF concentrations and compared those to CSF 
concentrations sampled at steady-state. They found that the ratio of CSF over 
brainECF concentrations was larger for 1 out of the 7 P-gp substrates.  
To our surprise, we found that unbound quinidine concentrations in brain 
were significantly higher than unbound concentrations in plasma. This appears 
to be in contrast to previous studies by Liu et al. (2009), and Kodaira et al. 
(2011), in which unbound brain-to-unbound plasma (brainu/plasmau) 
concentration ratios at assumed steady state were well below unity. While our 
results were quite comparable to the results of Liu et al. (2009), and Kodaira et 
al. (2011), a substantial difference was found for the (calculated) unbound brain 
(ECF) concentrations between these studies, and ours. Liu et al. (2009) 
determined the brain free fraction with the brain homogenate method and found 
an unbound brain fraction comparable to the unbound brain fraction that was 
found by Kodaira et al. (2011) by the brain slice technique (3.6% and 2.4%, 
respectively). In contrast, the unbound brain fraction in our study was calculated 
to be 28% (brainECF concentration divided by the total brain concentration). 
However, Liu et al. (2009) reported a 3-fold difference in the brainu 
concentrations when calculated on the basis of the brain homogenate free 
fraction, compared to using microdialysis data when corrected for in vitro 
recovery. We measured both in vitro (33%) and in vivo recovery (9%), and 
found that the in vivo recovery was 3.5-fold lower. If we would calculate the 
brainECF/plasmau concentration ratio at maximal concentrations, like Liu et al. 
did, and assume that for Liu also a 3.5-fold lower in vivo recovery would apply, 
then the brainECF/plasmau concentration ratio would be comparable to ours.  
For the brainECF/plasmau AUC0-360 ratios, we found values significantly 
larger than unity as in the elimination phase the rate of decline in plasma 
concentrations was larger than those observed in CSF and brainECF. We cannot 
compare these findings with Kodaira and Liu because their studies did not 
include an elimination phase. 
Therefore, based on our data, it appears that quinidine is also transported by 
other transporters at the BBB and BCSFB, in the direction of the brain. 
However, there is no direct information in literature to support this. We could 
only find the following potential contributions: Van Montfoort et al. (2001) 
reported that quinidine is transported by organic cation transporters (OCTs). 
This observation was made in an in vitro study, and was found to occur for a pH 
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of 6, but not significantly at pH 7.4. The question remains how this relates to the 
in vivo situation, like ours. Giacomini et al. (2010) stated that quinidine is a 
potential inhibitor of OCTs. OCTs have been localized both at the BBB (Lin et 
al., 2010), as well as at the BCSFB (Choudhuri et al., 2003). Thus, the 
possibility of active influx transport for quinidine at the BBB and BCSFB 
remains to be further investigated. Alternatively, it could reflect a passive “ion-
trapping” process, governed by lower pH values in brainECF (pH=~7.3) than in 
plasma (pH=~7.4). However, as quinidine is a diprotic base with pKas 4.2 and 
7.9 (Varma and Panchagnula, 2005), the low difference between the % ionized 
at pH=7.3 (80%) and pH=7.4 (76%) does not seem to explain our findings. 
According to the “smaller than 3-fold concentration ratio paradigm” (Maurer 
et al., 2005), differences between brainECF and CSF concentrations of quinidine 
as found in this study (on average 0.72 ± 0.20) would be considered 
pharmacokinetically irrelevant. However, upon co-administration of tariquidar 
this ratio increased 3.1-fold (to the value of 2.22 ± 0.57). This means that P-gp 
functionality and variations thereof may have an important effect on the 
brainECF-CSF ratio and the extrapolation from rats to humans, as is discussed by 
De Lange (2013a; 2013b). However, quinidine is a strong P-gp substrate and it 
remains to be investigated what the impact of P-gp functionality on the brainECF-
CSF concentration relationships would be for weaker substrates.  
Several different models for P-gp-mediated transport have been suggested 
(Higgins and Gottesman, 1992; Kusuhara et al., 1997; Sahrom, 1997; Sharom, 
2006; Stein et al., 1994; Sun et al., 2001; Syvänen et al., 2006). The first model 
is described as the “classical pump model” in which a P-gp substrate is 
transported from the cytosol to the extracellular space against a concentration 
gradient (so-called “efflux enhancement”) (Higgins and Gottesman, 1992; 
Sharom, 1997; Sharom, 2006; Stein et al., 1994; Syvänen et al., 2006). The 
second model can be described as a “vacuum cleaner model” in which a 
lipophilic compound that is diffusing across the cellular membrane, is 
interacting with P-gp within the lipid bilayer of the cellular membrane and is 
then transported back into the extracellular space (Higgins and Gottesman, 
1992; Kusuhara et al., 1997; Sharom, 1997; Sharom, 2006). The third model is 
described as the “flippase model” in which a lipophilic compound within the 
lipid bilayer at the cytosolic side is flipped to the extracellular side where it 
diffuses back into the extracellular space (Higgins and Gottesman, 1992; 
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Sharom, 1997; Sharom, 2006; Stein et al., 1994; Sun et al., 2001; Syvänen et 
al., 2006). In the second and third model P-gp prevents the entry of compounds 
to the brain by a process which is called “influx hindrance”. Based on the SBPK 
modeling results, it appears that for quinidine P-gp acts via combined influx 
hindrance and efflux enhancement. This is in line with the localization of P-gp 
at both the luminal and abluminal membrane of the BBB (Bendayan et al., 
2006). 
For the potential role of P-gp at the BCSFB, there have been some 
indications that P-gp could function as an influx transporter at the BCSFB 
(Kassem et al., 2007; Rao et al., 1999). We anticipated this to be among our 
findings, however, with our data we could not identify P-gp influx at the level 
of the BCSFB. Instead, the results of the SBPK modeling suggest that P-gp at 
the BCSFB functions as an efflux transporter (lateral ventricle) or is not 
functioning at all (cisterna magna). 
Then, interestingly, the co-administration of tariquidar results in an increase 
of the total brain-to-brainECF concentration ratio, which has also been observed 
in an earlier study on quinidine at our lab by Syvänen et al. (2012). This 
indicates that P-gp is also located beyond the BBB at the parenchymal and 
perivascular astrocytes, which is in line with several reports (Declèves et al., 
2000; Golden and Pardridge, 2000; Pardridge et al., 1997; Seegers et al., 2002a; 
Seegers et al., 2002b; Volk et al., 2005).  
In our current study we obtained in parallel brain striatum, CSF and plasmau 
concentration-time profiles, under dynamic conditions, included corrections for 
in vivo probe recoveries, and plasma protein binding to finally obtain unbound 
concentrations in these body compartments. It is anticipated that this approach, 
combined with advanced mathematical modeling, will further improve 
revealing the mechanisms underlying the relationship between brainECF and CSF 
concentrations than will steady-state and/or single end-of-experiment CSF 
concentrations (Kielbasa et al., 2009). Having information on concentration-
time profiles following a single administration is relevant as we need time-
dependent data to decipher the rate and extent of processes of drug transport 
into, within, and out of the brain (Hammarlund-Udenaes et al., 2008). It 
provides the best basis to further explore the multiple dose regimens as used in 
the clinic, for which it is know that a true steady state condition is actually not 
reached.  
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Finally, in striving towards reduction on the use of animals on one hand, and 
the fact that systematic studies on the inter-relationship of plasma PK, BBB 
transport and intra-brain distribution, cannot be performed in human, the use of 
the multiple microdialysis probes approach, obtaining a total of 84 samples per 
animal, results in a great reduction in the number of animals required for these 
type of studies compared to the single time point measurements. 
 
 
CONCLUSION 
 
It is concluded that in parallel obtained data on unbound brainECF, CSF and 
plasmau concentrations, under dynamic conditions, combined with advanced 
mathematical modeling is a most valid approach to reveal the mechanisms 
underlying the relationship between brainECF and CSF concentrations, which is 
significantly influenced by activity of P-gp. This indicates that information on 
functionality of P-gp is important for the prediction of human brain target site 
concentrations of P-gp substrates on the basis of human CSF concentrations, 
and provides further guide to unravelling mechanisms and drug properties that 
govern the transport into, within, and out of the brain, for translational purposes. 
 
 
APPENDIX 
 
DIFFERENTIAL EQUATIONS 
 
The mass balance equations describing the final SBPK model were expressed as 
follows: 
 
Plasma: 
 
𝑑𝐴𝑃𝐿,𝑢
𝑑𝑡
= 𝑑𝑜𝑠𝑒 − 𝑘𝑃𝐿−𝑃𝐸𝑅1 × 𝐴𝑃𝐿,𝑢 + 𝑘𝑃𝐸𝑅1−𝑃𝐿 × 𝐴𝑃𝐸𝑅1 − 𝑘𝑃𝐿−𝑃𝐸𝑅2 × 𝐴𝑃𝐿,𝑢 +𝑘𝑃𝐸𝑅2−𝑃𝐿 × 𝐴𝑃𝐸𝑅2 − 𝑘𝑃𝐿−𝐷𝐵𝑅 × 𝐴𝑃𝐿,𝑢 + 𝑘𝐷𝐵𝑅−𝑃𝐿 × 𝐴𝐷𝐵𝑅 − 𝑘𝑃𝐿−𝐸𝐶𝐹 × 𝐴𝑃𝐿,𝑢 +𝑘𝐸𝐶𝐹−𝑃𝐿 × 𝐴𝐸𝐶𝐹 − 𝑘𝑃𝐿−𝐿𝑉 × 𝐴𝑃𝐿,𝑢 + 𝑘𝐿𝑉−𝑃𝐿 × 𝐴𝐿𝑉 − 𝑘𝑃𝐿−𝑇𝐹𝑉 × 𝐴𝑃𝐿,𝑢 
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+𝑘𝑇𝐹𝑉−𝑃𝐿 × 𝐴𝑇𝐹𝑉 − 𝑘𝑃𝐿−𝐶𝑀 × 𝐴𝑃𝐿,𝑢 + 𝑘𝐶𝑀−𝑃𝐿 × 𝐴𝐶𝑀 + �𝑄𝐶𝑆𝐹𝑉𝑆𝐴𝑆 �× 𝐴𝑆𝐴𝑆 − 𝑘𝐸 × 𝐴𝑃𝐿,𝑢 
 
𝐶𝑃𝐿,𝑢 = 𝐴𝑃𝐿,𝑢𝑉𝑃𝐿  
 
Periphery: 
 
𝑑𝐴𝑃𝐸𝑅1
𝑑𝑡
= 𝑘𝑃𝐿−𝑃𝐸𝑅1 × 𝐴𝑃𝐿,𝑢 − 𝑘𝑃𝐸𝑅1−𝑃𝐿 × 𝐴𝑃𝐸𝑅1 
 
𝐶𝑃𝐸𝑅1 = 𝐴𝑃𝐸𝑅1𝑉𝑃𝐸𝑅1  
 
𝑑𝐴𝑃𝐸𝑅2
𝑑𝑡
= 𝑘𝑃𝐿−𝑃𝐸𝑅2 × 𝐴𝑃𝐿,𝑢 − 𝑘𝑃𝐸𝑅2−𝑃𝐿 × 𝐴𝑃𝐸𝑅2 
 
𝐶𝑃𝐸𝑅2 = 𝐴𝑃𝐸𝑅2𝑉𝑃𝐸𝑅2  
 
Braindeep: 
 
𝑑𝐴𝐷𝐵𝑅
𝑑𝑡
= 𝑘𝑃𝐿−𝐷𝐵𝑅 × 𝐴𝑃𝐿,𝑢 − 𝑘𝐷𝐵𝑅−𝑃𝐿 × 𝐴𝐷𝐵𝑅 
 
𝐶𝐷𝐵𝑅 = 𝐴𝐷𝐵𝑅𝑉𝐷𝐵𝑅  
 
BrainECF: 
 
𝑑𝐴𝐸𝐶𝐹
𝑑𝑡
= 𝑘𝑃𝐿−𝐸𝐶𝐹 × 𝐴𝑃𝐿,𝑢 − 𝑘𝐸𝐶𝐹−𝑃𝐿 × 𝐴𝐸𝐶𝐹 − �𝑄𝐸𝐶𝐹𝑉𝐸𝐶𝐹 �× 𝐴𝐸𝐶𝐹 
 
𝐶𝐸𝐶𝐹 = 𝐴𝐸𝐶𝐹𝑉𝐸𝐶𝐹  
 
CSFLV: 
 
𝑑𝐴𝐿𝑉
𝑑𝑡
= 𝑘𝑃𝐿−𝐿𝑉 × 𝐴𝑃𝐿,𝑢 − 𝑘𝐿𝑉−𝑃𝐿 × 𝐴𝐿𝑉 + �𝑄𝐸𝐶𝐹𝑉𝐸𝐶𝐹� × 𝐴𝐸𝐶𝐹 − �𝑄𝐶𝑆𝐹𝑉𝐿𝑉 �× 𝐴𝐿𝑉 
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𝐶𝐿𝑉 = 𝐴𝐿𝑉𝑉𝐿𝑉  
 
CSFTFV: 
 
𝑑𝐴𝑇𝐹𝑉
𝑑𝑡
= 𝑘𝑃𝐿−𝑇𝐹𝑉 × 𝐴𝑃𝐿,𝑢 − 𝑘𝑇𝐹𝑉−𝑃𝐿 × 𝐴𝑇𝐹𝑉 + �𝑄𝐶𝑆𝐹𝑉𝐿𝑉 �× 𝐴𝐿𝑉 − �𝑄𝐶𝑆𝐹𝑉𝑇𝐹𝑉�× 𝐴𝑇𝐹𝑉 
 
𝐶𝑇𝐹𝑉 = 𝐴𝑇𝐹𝑉𝑉𝑇𝐹𝑉  
 
CSFCM: 
 
𝑑𝐴𝐶𝑀
𝑑𝑡
= 𝑘𝑃𝐿−𝐶𝑀 × 𝐴𝑃𝐿,𝑢 − 𝑘𝐶𝑀−𝑃𝐿 × 𝐴𝐶𝑀 + �𝑄𝐶𝑆𝐹𝑉𝑇𝐹𝑉�× 𝐴𝑇𝐹𝑉 − �𝑄𝐶𝑆𝐹𝑉𝐶𝑀 �× 𝐴𝐶𝑀 
 
𝐶𝐶𝑀 = 𝐴𝐶𝑀𝑉𝐶𝑀  
 
CSFSAS: 
 
𝑑𝐴𝑆𝐴𝑆
𝑑𝑡
= �𝑄𝐶𝑆𝐹
𝑉𝐶𝑀
�× 𝐴𝐶𝑀 − �𝑄𝐶𝑆𝐹𝑉𝑆𝐴𝑆 �× 𝐴𝑆𝐴𝑆 
 
𝐶𝑆𝐴𝑆 = 𝐴𝑆𝐴𝑆𝑉𝑆𝐴𝑆  
 
Where: 
 
𝑘𝐸 = 𝐶𝐿𝐸,𝑝+𝐶𝐿𝐸,𝑃−𝑔𝑝𝑉𝑃𝐿    
𝑘𝑃𝐿−𝑃𝐸𝑅1 = 𝑄𝑃𝐿−𝑃𝐸𝑅1𝑉𝑃𝐿    
𝑘𝑃𝐸𝑅1−𝑃𝐿 = 𝑄𝑃𝐿−𝑃𝐸𝑅1𝑉𝑃𝐸𝑅1   
𝑘𝑃𝐿−𝑃𝐸𝑅2 = 𝑄𝑃𝐿−𝑃𝐸𝑅2𝑉𝑃𝐿   
𝑘𝑃𝐸𝑅2−𝑃𝐿 = 𝑄𝑃𝐿−𝑃𝐸𝑅2𝑉𝑃𝐸𝑅2   
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𝑘𝑃𝐿−𝐷𝐵𝑅 = 𝐶𝐿𝑃𝐿−𝐷𝐵𝑅,𝑝−𝐶𝐿𝑃𝐿−𝐷𝐵𝑅,𝑃−𝑔𝑝𝑉𝑃𝐿   
𝑘𝐷𝐵𝑅−𝑃𝐿 = 𝐶𝐿𝐷𝐵𝑅−𝑃𝐿,𝑝+𝐶𝐿𝐷𝐵𝑅−𝑃𝐿,𝑃−𝑔𝑝𝑉𝐷𝐵𝑅   
𝑘𝑃𝐿−𝐸𝐶𝐹 = 𝐶𝐿𝑃𝐿−𝐸𝐶𝐹,𝑝−𝐶𝐿𝑃𝐿−𝐸𝐶𝐹,𝑃−𝑔𝑝𝑉𝑃𝐿   
𝑘𝐸𝐶𝐹−𝑃𝐿 = 𝐶𝐿𝐸𝐶𝐹−𝑃𝐿,𝑝+𝐶𝐿𝐸𝐶𝐹−𝑃𝐿,𝑃−𝑔𝑝𝑉𝐸𝐶𝐹   
𝑘𝑃𝐿−𝐿𝑉 = 𝐶𝐿𝑃𝐿−𝐿𝑉,𝑝−𝐶𝐿𝑃𝐿−𝐿𝑉,𝑃−𝑔𝑝𝑉𝑃𝐿   
𝑘𝐿𝑉−𝑃𝐿 = 𝐶𝐿𝐿𝑉−𝑃𝐿,𝑝+𝐶𝐿𝐿𝑉−𝑃𝐿,𝑃−𝑔𝑝𝑉𝐿𝑉   
𝑘𝑃𝐿−𝑇𝐹𝑉 = 𝐶𝐿𝑃𝐿−𝑇𝐹𝑉,𝑝−𝐶𝐿𝑃𝐿−𝑇𝐹𝑉,𝑃−𝑔𝑝𝑉𝑃𝐿   
𝑘𝑇𝐹𝑉−𝑃𝐿 = 𝐶𝐿𝑇𝐹𝑉−𝑃𝐿,𝑝+𝐶𝐿𝑇𝐹𝑉−𝑃𝐿,𝑃−𝑔𝑝𝑉𝑇𝐹𝑉   
𝑘𝑃𝐿−𝐶𝑀 = 𝐶𝐿𝑃𝐿−𝐶𝑀,𝑝−𝐶𝐿𝑃𝐿−𝐶𝑀,𝑃−𝑔𝑝𝑉𝑃𝐿   
𝑘𝐶𝑀−𝑃𝐿 = 𝐶𝐿𝐶𝑀−𝑃𝐿,𝑝+𝐶𝐿𝐶𝑀−𝑃𝐿,𝑃−𝑔𝑝𝑉𝐶𝑀   
 
NOMENCLATURE 
 
Ai  Amount of quinidine in compartment i (ng) 
Ci  Concentration of quinidine in compartment i (ng/ml) 
k rate constant (min-1) 
Q flow rate (ml/min) 
CL clearance (ml/min) 
V volume (ml) 
 
Subscripts 
 
PL plasma 
PL,u unbound quinidine in plasma 
PERi peripheral compartment i 
DBR braindeep 
ECF brainECF 
CSF CSF 
LV lateral ventricle 
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TFV third and fourth ventricle 
CM cisterna magna 
SAS subarachnoid space 
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ABSTRACT 
 
Children and adults with malignant diseases have a high risk of prevalence of 
the tumor in the central nervous system (CNS). As prophylaxis treatment 
methotrexate is often given. In order to monitor methotrexate exposure in the 
CNS, cerebrospinal fluid (CSF) concentrations are often measured. However, 
the question is in how far we can rely on CSF concentrations of methotrexate as 
appropriate surrogate for brain target site concentrations, especially under 
disease conditions. 
In this study, we have investigated the spatial distribution of unbound 
methotrexate in healthy rat brain by parallel microdialysis, with or without 
inhibition of Mrp/Oat/Oatp-mediated active transport processes by a co-
administration of probenecid. Specifically, we have focused on the relationship 
between brain extracellular fluid (brainECF) and CSF concentrations. The data 
were used to develop a systems-based pharmacokinetic (SBPK) brain 
distribution model for methotrexate. This model was subsequently applied on 
literature data on methotrexate brain distribution in other healthy and diseased 
rats (brainECF), healthy dogs (CSF) and diseased children (CSF) and adults 
(brainECF and CSF). 
Important differences between brainECF and CSF kinetics were found, but we 
have found that inhibition of Mrp/Oat/Oatp-mediated active transport processes 
does not significantly influence the relationship between brainECF and CSF 
methotrexate concentrations. 
The prediction of methotrexate data obtained in other healthy rats and dogs 
works reasonably well, provided that information on the different elimination 
routes, or the lack thereof, is included in the systems-based scaling approach. 
The prediction of data from diseased rats and humans, together with SBPK 
model-based simulations, indicates that disease conditions significantly affect 
brain distribution.  
It is concluded that in parallel obtained data on unbound brainECF, CSF and 
plasma concentrations, under dynamic conditions, combined with advanced 
mathematical modeling is a most valid approach to develop SBPK models that 
allow revealing the mechanisms underlying the relationship between brainECF 
and CSF concentrations in health and disease. 
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INTRODUCTION 
 
Methotrexate was introduced into the treatment of malignant diseases more than 
50 years ago (Hertz et al., 1956). Today, many treatment protocols for 
malignant diseases, like acute lymphoblastic leukemia, have established the 
combination of high-dose methotrexate (to decrease the fraction of plasma 
protein binding), combined with leucovorin rescue (Djerassi et al., 1967; Moe 
and Holen, 2000). Before the use of central nervous system (CNS) prophylaxis, 
the CNS was the most frequently reported site of initial recurrence in children 
with acute lymphoblastic leukemia, accounting for up to 75% of cases (Bleyer 
and Poplack, 1985; Evans et al., 1970). However, in the treatment of acute 
lymphoblastic leukemia, prophylactic CNS therapy effectively reduced the rate 
of CNS relapses (Balis and Poplack, 1989; Blaney and Poplack, 1996, Clarke et 
al., 2003; Smith et al., 1996). Still, CNS recurrence remains a major limitation 
to achieving complete cure, accounting for 30–40% of recurrences in some 
pediatric clinical trials (Hutchinson et al., 2003; Lange et al., 2002). 
The use of cranial irradiation for CNS prophylaxis is effective but associated 
with severe late effects (Clarke et al., 2003; Ochs and Mulhern, 1994). Today, 
the combination of high-dose methotrexate and intrathecal methotrexate, 
employed to reduce such treatment-related late effects, has successfully 
replaced cranial irradiation as CNS prophylaxis in most patients (about 80 to 
90%) of acute lymphoblastic leukemia (Cáp et al., 1998; Pui et al., 2009). 
However, the intrathecal methotrexate procedure is susceptible to complications 
and stressful for the patient, especially for children (Keidan et al., 2005). 
Therefore, it has been suggested that the use of high-dose intravenous 
methotrexate alone could be sufficient for CNS prophylaxis (Niemann et al., 
2010). 
On the basis of in vitro testing, a methotrexate concentration of 0.45 µg/ml 
at the target site is commonly acknowledged as effective in killing tumor cells 
(Hryniuk and Bertino, 1969). With the CNS being the target site for CNS 
prophylaxis, it is the aim to have the appropriate methotrexate concentration in 
the brain extracellular fluid (brainECF). However, as blood-brain barrier (BBB) 
transport is highly restricted for methotrexate, plasma concentrations need to be 
far higher than the 0.45 µg/ml to be able to reach appropriate concentrations in 
the CNS. As a result, the exposure of the rest of the body to cytotoxic 
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concentrations is quite substantial (Chabner and Young, 1973; Ferreri et al., 
2004).  
The information on the relationship between plasma and CNS methotrexate 
concentrations appears to be inconsistent, with linear relationships reported by 
Borsi and Moe (1987), Jönsson et al. (2007), Millot et al. (1994), whereas 
Milano et al. (1990), Thyss et al. (1987) and Vassal et al. (1990) reported non-
linear relationships. Therefore, CNS concentrations are often monitored for 
appropriate dose selection (Niemann et al., 2010). To that end, CSF 
concentrations are used, since brainECF concentrations are not readily 
measurable in humans. CSF concentrations are considered to be the best 
available surrogate (Fridén et al., 2009; Kalvass and Maurer, 2002; Liu et al., 
2006; Liu et al., 2009; Maurer et al., 2005), with the assumption that CSF 
concentrations readily equilibrate with brainECF concentrations due to the lack of 
a physical barrier between these sites (Lee et al., 2001). However, due to 
qualitative and quantitative differences between processes that govern the 
pharmacokinetics (PK) of drugs in the brainECF versus CSF, a generally 
applicable relationship between the PK at these two sites does not exist and 
needs evaluation (Chapter 1; De Lange and Danhof, 2002; Lin, 2008; Shen et 
al., 2004).  
We have previously shown that even for acetaminophen, investigated as 
model compound for passive transport into, within and out of the brain, 
differences exist between CSF and brainECF kinetics (Chapter 3). Furthermore, 
we have also shown that for quinidine, a model compound for P-gp mediated 
transport, differences exist between CSF and brainECF kinetics, which are very 
much dependent on P-gp functionality (Chapter 4). With methotrexate being a 
substrate for a wide variety of transporters that are all located at the BBB and 
BCSFB (including the reduced folate carrier 1 (RFC1) (Hinken et al., 2011), 
breast cancer resistance protein (BCRP) (Breedveld et al., 2007), multidrug 
resistance-associated proteins (MRP) 2, 3 and 4 (Vlaming et al., 2011), organic 
anion transporter (OAT) 1 and 3 (Takeda et al., 2002), and organic anion-
transporting polypeptides (OATP) A (Badagnani et al., 2006) and OATP B (van 
de Steeg et al., 2009)), this could have major implications for the predictability 
of brainECF methotrexate concentrations on the basis of CSF concentrations. 
Consequently, to be able to know whether methotrexate brainECF concentrations 
can be adequately predicted by CSF concentrations, one should first understand 
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the mechanisms that determine the relationship between CSF concentrations 
and brainECF concentrations. 
In this study we have used the parallel intracerebral microdialysis probes 
approach (striatum, lateral ventricle, and cisterna magna (Chapter 3)) in 
conjunction with parallel blood sampling, for continuous measurement and 
direct comparison of changes in concentrations in plasma, brainECF and CSF 
kinetics of methotrexate. To investigate the specific contribution of the various 
transporters, probenecid is co-administered as inhibitor of MRPs (Bakos et al., 
2000), OATs (Sugiyama et al., 2001) and OATPs (Kis et al., 2013). Advanced 
mathematical modeling is applied to extrapolate the data to other conditions, 
and other species, including human. 
 
 
MATERIALS AND METHODS 
 
Chemicals and solutions 
 
Methotrexate solution for injection (Emthexate PF) and isoflurane were 
obtained from Pharmachemie B.V. (Haarlem, the Netherlands). Methotrexate 
(powder), aminopterin and ammonium formate were from Sigma-Aldrich 
(Zwijndrecht, the Netherlands). Probenecid, 5% glucose and saline were 
obtained from the Leiden University Medical Centre pharmacy (Leiden, the 
Netherlands). Acetonitrile (HPLC-S grade), methanol (ULC-grade) and formic 
acid (ULC grade) were from Biosolve (Valkenswaard, the Netherlands). 
Ammonium hydroxide (25%), magnesium chloride, sodium acetate, sodium 
chloride, calcium chloride and perchloric acid, were obtained from Baker 
(Deventer, the Netherlands). Potassium chloride was from Merck (Darmstadt, 
Germany). All other chemicals were of analytical grade. Microdialysis 
perfusion fluid was prepared as previously described (Chapter 3), containing 
140.3 mM sodium, 2.7 mM potassium, 1.2 mM calcium, 1.0 mM magnesium 
and 147.7 mM chloride.  
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Animals  
 
The study protocol was approved by the Animal Ethics Committee of Leiden 
University (UDEC nr. 10094). All animal procedures were performed in 
accordance with Dutch laws on animal experimentation. A total of 40 male 
Wistar WU rats (225-275 g, Charles River, Maastricht, the Netherlands) were 
randomly divided into two groups; the first group (n = 8) was used for the 
determination of the in vivo microdialysis probe recovery; the second group (n 
= 32) was used for brain disposition experiments. This second group was further 
divided into four subgroups, designated for 40 or 80 mg/kg methotrexate 
without or with co-administration of probenecid (denoted as 40-, 40+, 80- and 
80+, respectively). 
After arrival, all animals were housed in groups for 5-7 days (Animal 
Facilities, Gorlaeus Laboratories, Leiden, the Netherlands), under standard 
environmental conditions (ambient temperature 21°C; humidity 60%; 12/12 h 
light/dark cycle, background noise, daily handling), with ad libitum access to 
food (Laboratory chow, Hope Farms, Woerden, the Netherlands) and acidified 
water. Between surgery and experiments, the animals were kept individually in 
Makrolon type three cages for 7 days to recover from the surgical procedures. 
 
Surgery  
 
All surgical procedures were performed as described in Chapter 3. In short, 
cannulas were implanted in the left femoral artery and vein for blood sampling 
and drug administration, respectively. Both cannulas were subcutaneously led to 
the back of the head and fixated in the neck with a rubber ring. Subsequently, 
the animals were chronically instrumented with two CMA/12 microdialysis 
guides (CMA/Microdialysis AB, Stockholm, Sweden) in different combinations 
of striatum (ST), for sampling in brainECF, and lateral ventricle (LV) and/or 
cisterna magna (CM) for sampling in CSF (ST+LV, ST+CM or LV+CM). For 
ST, the position of the microdialysis guide is: 1.0 mm anterior, 3.0 mm lateral, 
3.4 mm ventral, relative to bregma. For LV, the position of the microdialysis 
guide is: 0.9 mm posterior, 1.6 mm lateral, 2.9 mm ventral, relative to the 
bregma. For CM, the position of the microdialysis guide is: 1.93 mm posterior, 
3.15 mm lateral, 8.1 mm ventral, at an angle of 25° from the dorsoventral axis 
Prediction of methotrexate CNS distribution in different species – influence of disease conditions 
147 
 
(towards anterior) and 18° lateral from the anteroposterior axis relative to 
lambda. The microdialysis guides were secured to the skull with 3 anchor 
screws and dental cement. 
After the surgery the animals received 0.03 ml Temgesic ® intramuscularly 
(Schering-Plough, Amstelveen, the Netherlands) and 0.3 ml Ampicillan® 
(Alfasan B.V., Woerden, the Netherlands) subcutaneously. One day prior to the 
experiment, the microdialysis dummies were replaced by the microdialysis 
probes (CMA/12 Elite, Polyarylethersulfone membrane, molecular weight cut-
off 20 kDa, CMA/Microdialysis AB, Stockholm, Sweden, with a semi-
permeable membrane length of 4 mm for ST, and 1 mm for LV and CM). 
 
Experimental set-up 
 
All experiments were performed as described in Chapter 4, with some 
modifications. In short, the in vivo microdialysis probe recovery of methotrexate 
was determined on the basis of reverse dialysis (Ståhle et al., 1991). The 
microdialysis probes in striatum, lateral ventricle and cisterna magna were 
perfused with different concentrations of methotrexate (50, 200 and 1000 
ng/ml) in perfusion fluid. To evaluate the potential effect of co-administration 
of probenecid on the in vivo recovery of methotrexate, several animals received 
an intravenous infusion of 150 mg/kg probenecid in 5% NaHCO3 in saline (150 
µl/min/kg for a period of 10 minutes) with an automated pump (Pump 22 
Multiple Syringe Pump, Harvard Apparatus, Holliston, USA) 30 minutes prior 
to the start of the reverse dialysis experiment. Control animals received an 
intravenous infusion of vehicle (150 µl/min/kg, for a period of 10 minutes). 
The in vivo recovery is defined as the ratio of the concentration difference 
between the dialysate (Cdial) and perfusion fluid (Cin) over the concentration in 
the perfusion fluid (equation 1) (Scheller and Kolb, 1991).  
 
𝑖𝑛 𝑣𝑖𝑣𝑜 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 = 𝐶𝑖𝑛−𝐶𝑑𝑖𝑎𝑙
𝐶𝑖𝑛
     (1) 
 
For the brain disposition experiments, the rats first received an intravenous 
infusion of 150 mg/kg probenecid in 5% NaHCO3 in saline or vehicle (150 
µl/min/kg, for a period of 10 minutes) 30 minutes prior to the administration of 
40 or 80 mg/kg methotrexate in saline (200 µl/min/kg for a period of 10 
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minutes). The start and duration of the infusion was corrected for internal 
volume of the tubing so that infusion started at t=0 min. 10 min interval samples 
were collected between t=−1 h and t=5 h. After weighing the microdialysis vials 
they were stored at −80°C before analysis. 
For the determination of methotrexate plasma concentrations, blood samples 
of 100 μl were taken, in parallel to the microdialysate samples, from the arterial 
cannula at t=−5 (blank), 2, 7, 9, 10, 12, 17, 30, 90, 180, and 300 min. All blood 
samples were temporarily stored in heparin (10 IU) coated Eppendorf cups 
before being centrifuged for 15 min at 5000 rpm. The plasma was then pipetted 
into clean Eppendorf cups and stored at −20°C before analysis. 
At the end of the experiments the animals were sacrificed with an overdose 
of Nembutal (Ceva Sante Animale, Libourne, France).  
 
Plasma protein binding 
 
For the determination of plasma protein binding of methotrexate, plasma 
samples of different time points were pooled (combining t = 2 and 7; t = 9 and 
10; t = 12 and 17; t = 30 and 90; t = 180 and 300) to span the entire 
concentration range. Plasma protein binding was determined with Centrifree® 
ultrafiltration devices (Millipore BV, Etten-Leur, the Netherlands). All 
procedures were performed according to the user’s manual. The ultrafiltrate was 
diluted 10 times with saline before the analysis.  
 
Concentration analysis 
 
Methotrexate concentrations in plasma, plasma ultrafiltrate and microdialysate 
were quantified using an on-line solid phase extraction (SPE) with liquid 
chromatography-tandem mass spectrometry (LC/MS/MS) system, based on 
previous work by Rule et al. (2001) and Guo et al. (2007).  
To 20 µl of plasma and plasma ultrafiltrate, 20 µl internal standard (10 
µg/ml aminopterin) was added. After mixing with 40 µl of 6% perchloric acid 
and centrifugation for 10 minutes at 10000 g, 60 µl of the supernatant was 
thoroughly mixed with 40 µl of 1 M sodium acetate. 20 µl was then injected on 
the SPE column. 
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To 15 µl of the microdialysate samples, 15 µl of the internal standard (250 
ng/ml aminopterin) was added. After mixing, 10 µl was injected on the SPE 
column. 
HySphere™ SPE cartridges and a cartridge holder from Spark (Emmen, the 
Netherlands) were used in combination with the divert/inject valve of the mass 
spectrometer to prevent salt entering the mass spectrometer. After flushing 
under acidic conditions, the SPE was switched onto the LC system and 
methotrexate and its internal standard were eluted from the SPE to the LC 
column. For plasma precipitates, C-8 HD SE cartridges were used, while for 
microdialysate samples C-18 cartridges were used. After injection of the sample 
on the SPE column, salts from either precipitated plasma or microdialysate 
samples were flushed to waste before analysis on the HPLC column. A 
quaternary gradient HPLC pump (P580) from Dionex (Breda, the Netherlands) 
was used for the on-line SPE method, while a Surveyor pump (Thermo 
Scientific, Breda, the Netherlands) served as delivery unit for the HPLC 
column. 
The VisionHT® C-18B column (Grace Alltech, Breda, the Netherlands) was 
thermostatted at 37°C. The mobile phase consisted of 21% methanol and 79% 
lab water, derived from a PURELAB Ultra system (Veolia Water Solutions, 
Ede, the Netherlands), containing 0.2% formic acid and 1 mM ammonium 
formate. After isocratic elution of the peaks of methotrexate and internal 
standard, the column was flushed with 90% methanol and 10% lab water 
containing 0.2% formic acid and 1mM ammonium formate 7–9.5 minutes after 
injection.  
Sample analysis was performed on a Finnigan TSQ Quantum Ultra Mass 
Spectrometer System (Thermo Scientific, Breda, the Netherlands). Electrospray 
ionization was used in the positive mode at 3500V. Methotrexate was quantified 
using selected reaction monitoring (SRM) with the transition 455–308 (m/z). 
The internal standard, aminopterin, had a SRM transition of 441–294 (m/z). The 
collision energy used was 18 V, scan width was set at 0.7 m/z and both Q1 and 
Q3 were set to 0.70 full width at half maximum (FWHM). The scan time was 
0.11 seconds. Argon served as the collision gas. 
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Pharmacokinetic data analysis 
 
All plasma concentrations were converted to unbound plasma concentrations, 
by correction for plasma protein binding. All microdialysate concentrations 
from striatum, lateral ventricle and cisterna magna were converted into brainECF 
concentrations (CECF) or CSF concentrations (CCSF) by division of the dialysate 
concentrations by the average in vivo recovery as determined for each 
microdialysis probe location (equation 2).  
 
𝐶𝐸𝐶𝐹  𝑜𝑟 𝐶𝐶𝑆𝐹 = 𝐶𝑑𝑖𝑎𝑙𝑖𝑛 𝑣𝑖𝑣𝑜 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦     (2) 
 
Areas under the curve from t=0 to t=300 min (AUC0-300) were calculated by 
the trapezoidal rule and tested for differences by single factor ANOVA. The 
population PK models were developed and fitted to the data by means of non-
linear mixed-effects modeling using the NONMEM software package (version 
6.2, Icon Development Solutions, Ellicott City, Maryland, USA) and analyzed 
using the statistical software package S-Plus® for Windows (version 6.2 
Professional, Insightful Corp., Seattle, USA).  
The pharmacokinetic model for methotrexate plasma and brain 
concentrations was based on the systems-based PK (SBPK) approach we have 
previously applied to investigate the exchange between brainECF and CSF of 
acetaminophen (Chapter 3) and quinidine (Chapter 4). For this approach, the 
volumes of the different brain compartments were fixed to their physiological 
volumes. The rat brain intracellular space and brainECF volume were assumed to 
be 1.44 ml (Thorne et al., 2004) and 290 µl (Cserr et al., 1981), respectively. 
With a total CSF volume of 300 µl in the rat (Bass and Lundborg, 1973), the 
volumes of the lateral ventricles, third and fourth ventricles, cisterna magna and 
subarachnoid space were assumed to be 50 µl (Condon et al., 1986; Kohn et al., 
1991), 50 µl (Levinger, 1971), 17 µl (Adam and Greenberg, 1978; Robertson, 
1949) and 180 µl (Bass and Lundborg, 1973; Levinger, 1971), respectively. The 
intra-brain distribution was restricted by the physiological flow paths of 
brainECF, in which brainECF flows towards the CSF compartments at a rate of 0.2 
μl/min (Abbott, 2004; Cserr et al., 1981), and CSF flows from lateral ventricle, 
through the third and fourth ventricle, to the cisterna magna and subsequently to 
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the subarachnoid space (cranial and spinal) and back into blood at a rate of 2.2 
μl/min (Cserr, 1965). 
Structural model selections for both the blood and brain PK model were 
based on the likelihood ratio test (p < 0.01), diagnostic plots (observed 
concentrations vs. individual and population predicted concentrations, weighted 
residuals vs. predicted time and concentrations), parameter correlations and 
precision in parameter estimates. The inter-animal variability in 
pharmacokinetic parameters was assumed to be log normally distributed. The 
residual error, which accounts for unexplained variability (e.g. measurement 
and experimental error and model-misspecification), was best described with a 
proportional error model.  
The validity of the pharmacokinetic models was investigated by means of a 
visual predictive check. (Cox et al., 1999; Duffull and Aarons, 2000; Yano et 
al., 2001) Using the final PK parameter estimates, 1000 curves were simulated. 
Subsequently, the median and the 5th and 95th percentile of the predicted 
concentrations were calculated, which represent the 90% prediction interval. 
These were then compared with the observations. 
In order to test the ruggedness of the model and estimate the precision of the 
parameters n=100 non-parametric (case resampling) bootstraps were performed. 
To create the bootstrapped datasets, specific rat data (plasma and microdialysate 
concentrations) were removed randomly from the datasets and replaced with 
randomly selected rat data from the complete original dataset. Each of these 
permutations of the original dataset was fitted with the final model determined 
based on the original dataset. This results in a series of model fits, each with its 
own set of parameters. These results were displayed graphically and the 
descriptive statistics of the parameters were compared to parameter estimates of 
the final model. Only bootstrap runs that successfully minimized were used in 
this analysis. 
 
Systems-based scaling 
 
The SBPK model was first used to predict the methotrexate plasma and brainECF 
concentration-time profiles of brain tumor-bearing rats (De Lange et al., 1995), 
to investigate the impact of disease-status on the kinetics of methotrexate. Next, 
the parameters of the rat SBPK were extrapolated to healthy dogs (Neuwelt et 
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al., 1985), to investigate the validity of using this approach for interspecies 
scaling. To do so, the elimination clearance was first divided into renal 
clearance and hepatic clearance, with renal clearance assumed to be identical to 
the glomerular filtration rate (Brcakova et al., 2009) and the remaining 
clearance assigned to hepatic clearance. The hepatic clearance was then scaled 
to the number of hepatocytes in rat or dog liver. Next, the transfer clearances 
between plasma and the different peripheral and brain compartments were 
scaled based on  
 
𝐶𝐿𝑃𝐿−𝑃𝐸𝑅 = 𝐴𝑃𝐸𝑅 × (𝑉𝑃𝐸𝑅)0.67     (3) 
 
𝐶𝐿𝑃𝐿−𝐵𝑅 = 𝐴𝐵𝑅 × (𝑉𝐵𝑅)0.67     (4) 
 
In which APER and ABR are scaling coefficients for periphery and brain, 
respectively, and both are estimated on the basis of the rat data (Hosseini-
Yeganeh and McLachlan, 2002). VPER represents the physiological volume of 
the (lumped) peripheral tissues for rapid (including muscle, kidney, intestine 
and liver) and slow equilibration (including adipose, skin, heart, bone and 
remaining tissue). VBR represents the physiological volume of the different brain 
compartments. The scaling factor of 0.67 is based on the permeability surface 
area of the different brain compartments, which is related to the tissue weight 
(Kawai et al., 1994). The physiological parameters of the rat SBPK model were 
changed accordingly.  
Finally, the parameters of the rat SBPK were extrapolated to the human 
setting, which included adults and children with different disease-states, using 
the same approach as applied for extrapolation to dogs. 
 
 
RESULTS 
 
All results are presented as average values ± standard error of the mean, unless 
stated otherwise.  
 
 
 
Prediction of methotrexate CNS distribution in different species – influence of disease conditions 
153 
 
Methotrexate pharmacokinetics 
 
The average unbound plasma (plasmau), brainECF, lateral ventricle (CSFLV) and 
cisterna magna (CSFCM) methotrexate concentrations following the 40 and 80 
mg/kg dose with or without co-administration of probenecid are shown in figure 
1. Plasma protein binding of methotrexate was linear at an extent of 55.2 ± 
7.7%. It was not affected by co-administration of probenecid. The co-
administration of probenecid slightly altered the distribution phase for both the 
40 and 80 mg/kg dose of methotrexate. Data obtained by microdialysis from the 
brainECF, CSFLV and CSFCM were corrected for in vivo recovery. The average in 
vivo recoveries for the methotrexate concentrations in striatum, lateral ventricle 
and cisterna magna probes were influenced by co-administration of probenecid 
and were determined to be 22.1 ± 2.0%, 28.1 ± 2.9% and 35.9 ± 2.5%, for the 
control group and 7.1 ± 0.9%, 16.9 ± 1.7% and 21.6 ± 5.6% for the probenecid 
group, respectively.  
It can be seen that a higher dose of methotrexate leads to higher 
methotrexate concentrations in all brain compartments, but not to the same 
extent. Probenecid increased methotrexate concentrations significantly (p < 
0.01) in all brain compartments. The effect of probenecid was dependent on the 
methotrexate dose; at the higher dose of methotrexate, the increase in 
methotrexate concentrations was more profound for brainECF and CSFLV, as can 
be seen by the average unbound brain (brainu)-to-plasmau AUC0-300 ratios (table 
1). However, the dose-dependency was not significant. The relationship 
between brainECF-to-CSF concentration ratios was not significantly affected by 
probenecid co-administration, and was on average 7.7 ± 3.7 (table 2).  
 
Table 1. Brainu-to-plasmau AUC0-360 ratios for brainECF, CSFLV and CSFCM for the 40 mg/kg and 
80 mg/kg dose without (-) and with (+) co-administration of probenecid 
Brainu-to-plasmau 
AUC0-300 ratios 
40- 40+ 80- 80+ 
BrainECF 2.5 ± 1.7%‡ 5.9 ± 1.1%*‡ 2.5 ± 0.3%‡ 9.8 ± 3.3%*‡ 
CSFLV 0.6 ± 0.1% 1.6 ± 1.0% 0.5 ± 0.3% 3.5 ± 0.4%* 
CSFCM 0.4 ± 0.1% 0.8 ± 0.1% 0.7 ± 0.4% 0.9 ± 0.5% 
 
* Significantly (p < 0.05) different from the group without co-administration of probenecid 
‡ Significantly (p < 0.05) different from the CSF-to-plasmau AUC0-300 ratios 
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Figure 1. Average (geometric mean ± S.E.M.) unbound methotrexate concentration-time profiles 
following intravenous administration of methotrexate, with (+) or without (-) co-administration of 
probenecid (150 mg/kg). (A) 40 mg/kg methotrexate dose: for plasma (n = 7 (-) and 6 (+)), 
brainECF (n = 5 (-) and 4 (+)), CSFLV (n = 4 (-) and 3 (+)) and CSFCM (n = 3 (-) and 4 (+). (B) 80 
mg/kg methotrexate dose. Plasma (n = 7 (-) and 7 (+)), brainECF (n = 4 (-) and 5 (+)), CSFLV (n = 
5 (-) and 4 (+)) and CSFCM (n = 6 (-) and 3 (+)) 
 
Table 2. BrainECF-to-CSF concentration ratios for the 40 mg/kg and 80 mg/kg dose without (-) 
and with (+) co-administration of probenecid. (No significant differences were found). 
BrainECF-to-CSF 
concentration ratios 40
- 40+ 80- 80+ 
BrainECF-to-CSFLV 9.6 ± 5.0 6.0 ± 2.9 11.6 ± 7.0 5.2 ± 2.4 
BrainECF-to-CSFCM 11.5 ± 5.5 8.3 ± 1.6 6.0 ± 2.3 12.7 ± 3.0 
BrainECF-to-CSFaverage 10.2 ± 4.8 6.8 ± 2.1 7.6 ± 3.3 7.2 ± 2.7 
 
Systems-based modeling approach 
 
As it was our goal to investigate the relationship between brainECF and CSF 
pharmacokinetics, we have applied a SBPK modeling approach like we did 
previously for analysis of regional brain distribution of acetaminophen 
(Chapter 3) and quinidine (Chapter 4). To adequately describe CSF 
physiology, we have used four CSF compartments that represent the CSFLV, the 
combined third and fourth ventricle (CSFTFV), the CSFCM and the subarachnoid 
space (CSFSAS). Since we have no measurements of the concentrations in the 
third and fourth ventricle, the transfer clearance between plasma and third and 
fourth ventricle was assumed to be equal to the transfer clearance between 
plasma and lateral ventricle. 
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Distinction between passive and active transport clearances - The active 
component of the different transfer clearances between plasma and the brain 
compartments was determined by comparing the parameter estimations for the 
rats that did to those rats that did not receive the co-administration of 
probenecid. Even though methotrexate is transported by a wide variety of 
transporters, the co-administration of the Mrp-, Oat- and Oatp-inhibitor 
probenecid allowed us to investigate the impact of combined Mrp-, Oat- and 
Oatp-mediated transport. The active component of the transfer clearances 
between plasma and the different brain compartments was incorporated into the 
model as previously described by Syvänen et al. (2006):  
 
𝐶𝐿𝑃𝐿−𝐵𝑅 = 𝐶𝐿𝑃𝐿−𝐵𝑅,𝑝 − 𝐶𝐿𝑃𝐿−𝐵𝑅,𝑎    (5) 
 
𝐶𝐿𝐵𝑅−𝑃𝐿 = 𝐶𝐿𝐵𝑅−𝑃𝐿,𝑝 + 𝐶𝐿𝐵𝑅−𝑃𝐿,𝑎    (6) 
 
Where the subscript ‘p’ denotes passive transport and ‘a’ denotes active 
transport. For the animals that received a co-administration of probenecid, both 
CLPL-BR,a and CLBR-PL,a were considered to be 0. 
 
Modeling Mrp-, Oat- and Oatp-mediated transport - Both Mrps, Oats, as well 
as Oatps have been well described as efflux transporters at the BBB and BCSFB 
(Graff and Pollack, 2004). However, the mechanism by which Mrps, Oats and 
Oatps can exert their effect could be by reducing the transfer clearance from 
plasma to the brain compartments (i.e. influx hindrance; equation 5) or by 
increasing the transfer clearance from the brain compartments to plasma (i.e. 
efflux enhancement; equation 6) or both. The data were best described by the 
model with Mrp, Oat and Oatp functioning solely by influx hindrance. 
Interestingly, the observation that in vivo probe recovery of methotrexate was 
affected by probenecid indicates that methotrexate is transported by Mrps, Oats 
and Oatps via the efflux enhancement mechanism (Syvänen et al., 2006). 
However, estimation of the active components when Mrp, Oat and Oatp were 
considered to function by efflux enhancement resulted in too large coefficients 
of variation. Also, the estimation of the active component in the transfer 
between plasma and cisterna magna resulted in too large coefficients of 
variation and was therefore assumed to be absent.  
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Modeling methotrexate concentration-dependent Mrp-, Oat- or Oatp-
mediated transport - Since Mrp-, Oat- or Oatp-mediated transport is an active 
(saturable) process we have also tried to identify the maximal transport rate (Tm) 
and the blood- or brain concentration for half-maximal transport (Km) as 
follows: 
 
𝐶𝐿𝑃𝐿−𝐵𝑅,𝑎 = 𝑇𝑚,𝑃𝐿−𝐵𝑅𝐾𝑚,𝑃𝐿−𝐵𝑅+𝐶𝑃𝐿,𝑢     (7) 
 
𝐶𝐿𝐵𝑅−𝑃𝐿,𝑎 = 𝑇𝑚,𝐵𝑅−𝑃𝐿𝐾𝑚,𝐵𝑅−𝑃𝐿+𝐶𝐵𝑅      (8) 
 
Where CPL,u is the unbound plasma concentration and CBR is the concentration 
in one of the brain compartments. The parameter estimations of Tm and Km 
resulted in high values for both Tm and Km (results not shown), indicating that 
the plasma and brain concentrations in this study are not sufficiently high for 
saturating Mrp-, Oat- or Oatp-mediated transport. The parameter estimations of 
Tm and Km also resulted in too large coefficients of variation. Thus, our data 
were insufficient to determine the values of these parameters. Therefore, Mrp-, 
Oat- or Oatp-mediated transport had to be incorporated by means of a single 
active transport clearance value, rather than by Tm and Km. 
 
Final SBPK model - The final SBPK model is shown in figure 2. The 
differential equations of this model can be found in the appendix. The final 
estimation of the PK parameters is summarized in table 3. Interestingly, no 
active component on the elimination clearance could be identified, whereas this 
was the case for the compartmental pharmacokinetic analysis of the plasma 
concentrations only (results not shown). 
According to Brcakova et al. (2009), the rate of renal clearance of unbound 
methotrexate in rats equals the rate of renal creatinine clearance, which is a 
measure of the glomerular filtration rate (GFR; 1.4 ml/min in the rat (Atherton, 
1983)). Consequently, the remaining methotrexate clearance is hepatically. 
Based on our results, the rate of hepatic clearance is therefore 7.35 ml/min in 
the rat. With a total hepatic blood flow of approximately 11.8 ml/min (Davies 
and Morris, 1993), this results in a hepatic extraction ratio of 62%, which is 
comparable to the 53% reported previously by Kates and Tozer (1976). 
Prediction of methotrexate CNS distribution in different species – influence of disease conditions 
157 
 
 
Figure 2. Diagram of the SBPK model that was used to describe the intra-brain distribution of 
methotrexate in the rat. CLE is the elimination clearance from plasma. Further, for transfer 
clearances between compartments (CLfrom comp-to comp), denotations of the compartments are:       
PL = plasma; PER,rapid = rapidly equilibrating periphery; PER,slow = slowly equilibrating 
periphery; ECF = brainECF; LV = lateral ventricle; TFV = third and fourth ventricle;               
CM = cisterna magna and SAS = subarachnoid space. QECF is the flow rate of brainECF, QCSF is 
the flow rate of CSF. The subscript ‘p’ denotes passive transport and ‘a’ denotes active transport. 
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The visual predictive check of the final model is given in figure 3. It can be 
seen that the final model describes the data very well within the 90% prediction 
interval, and also can cope with the large inter-individual variation in brain 
concentrations.  
 
Figure 3. The visual predictive check of the final SBPK model. The dots represent the individual 
data points and the gray area represents the 90% prediction confidence interval. The different 
boxes represent the plasmau, brainECF, CSFLV and CSFCM data 
 
Systems-based scaling 
 
The physiological and PK parameters of the rat, dog and human children and 
adults that were used for the extrapolation are given in table 3.  
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Table 3. Final estimation of the rat PK parameters of methotrexate for the SBPK model 
(± standard error) and predicted dog and human parameters.  
Parameter Rat value Dog value (20-25 
kg) 
Human child 
value  
(9 year old, 30 
kg bodyweight) 
Human adult 
value 
fu,p 44.8 ± 7.7 % 60% 13 67.7% 19 67.7% 19  
CLE,p 8.75 ± 0.85 
ml/min 
88.2 ml/min 
(based on 
1.1*GFR) 13 
163.2 ml/min 
(based on 
2*GFR) 20 
250 ml/min 
(based on 
2*GFR) 20 
GFR 1.4 ml/min 1 80.2 ml/min 14 81.6 ml/min 21 125 ml/min 6 
CLE,a N.A. N.A. N.A. N.A. 
CLPL-PER,rapid 31.5 ± 4.9 
ml/min 
748.2 ml/min 606.0 ml/min 1047.2 ml/min 
CLPER,rapid-PL 2.45 ± 0.34 
ml/min 
582.0 ml/min 471.3 ml/min 814.5 ml/min 
CLPL-PER,slow 2.94 ± 0.91 
ml/min 
38.1 ml/min 72.6 ml/min 146.5 ml/min 
CLPER,slow-PL 0.25 ± 0.04 
ml/min 
32.4 ml/min 61.8 ml/min 124.5 ml/min 
CLPL-ECF,p 1.81 ± 0.48 
µl/min 
29.8 µl/min 176.6 µl/min 180.9 µl/min 
CLPL-ECF,a 1.29 ± 0.41 
µl/min 
21.3 µl/min 125.8 µl/min 128.9 µl/min 
CLECF-PL 17.0 ± 4.4 µl/min 280.2 µl/min 1658.3 µl/min 1699.2 µl/min 
CLPL-LV,p 0.12 ± 0.04 
µl/min 
2.18 µl/min 5.55 µl/min 7.19 µl/min 
CLPL-LV,a 0.09 ± 0.03 
µl/min 
1.64 µl/min 4.17 µl/min 5.39 µl/min 
CLLV-PL 3.69 ± 1.57 
µl/min 
67.2 µl/min 170.8 µl/min 221.1 µl/min 
CLPL-TFV,p 0.12 ± 0.04 
µl/min 
2.18 µl/min 5.55 µl/min 7.19 µl/min 
CLPL-TFV,a 0.09 ± 0.03 
µl/min 
1.64 µl/min 4.17 µl/min 5.39 µl/min 
CLTFV-PL 3.69 ± 1.57 
µl/min 
67.2 µl/min 170.8 µl/min 221.1 µl/min 
CLPL-CM,p 0.017 ± 0.007 
µl/min 
0.24 µl/min 0.81 µl/min 1.01 µl/min 
CLPL-CM,a N.A. N.A. N.A. N.A. 
CLCM-PL 4.37 ± 1.81 
µl/min 
62.4 µl/min 207.4 µl/min 258.4 µl/min 
QECF 0.2 µl/min 2,3 10.5 µl/min 
(based on 0.11 
µl/min/g brain) 3 
0.1 ml/min 
(based on 50% of 
QCSF) 22 
0.175 ml/min 22 
QCSF 2.2 µl/min 4 63 µl/min 15 0.2 ml/min 23 0.4 ml/min 29 
VPL 10.6 ml 5 1112 ml 16 1600 ml 24 2900 ml 30 
VPER,rapid 49.7% of 
bodyweight 6 
64.1% of 
bodyweight 6 
36.1% of 
bodyweight 25 
35.0% of 
bodyweight 25 
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Table 3 Continued. 
VPER,slow 45.5% of 
bodyweight 6 
26.2% of 
bodyweight 6 
48.0% of 
bodyweight 25 
58.6% of 
bodyweight 25 
VECF 290 µl 3 19 ml (based on 
95.5 gr brain) 15 
270 ml 26 (based 
on 1350 gr 
brain) 27 
280 ml 26 (based 
on 1400 gr 
brain) 27 
VCSF,total 300 µl 7 15.6 ml 17 90 ml 28 140 ml 22 
VLV 50 µl 8,9 3.8 ml (24% of 
total CSF 
volume) 18 
15.3 ml (17% of 
total CSF 
volume) 8,9 
22.5 ml 8,9,31 
VTFV 50 µl 10 1.3 ml (8% of 
total CSF 
volume) 18 
15.3 ml (17% of 
total CSF 
volume) 8,9 
22.5 ml 8,9 
VCM 17 µl 11,12 0.9 ml (6% of 
total CSF volume 
(human value)) 
11,12 
5.1 ml (5.7% of 
total CSF 
volume) 11,12 
7.5 ml 11,12 
VSAS 180 µl 7,10 9.0 ml (60% of 
total CSF volume 
(human value)) 
7,10 
54 ml (60% of 
total CSF 
volume) 7,10 
90 ml 32 
ηCLE 0.11 ± 0.02 0.11 0.11 0.11 
εPL 0.18 ± 0.03 0.18 0.18 0.18 
εST 0.07 ± 0.02 0.07 0.07 0.07 
εLV 0.31 ± 0.09 0.31 0.31 0.31 
εCM 0.25 ± 0.06 0.25 0.25 0.25 
 
Parameter values in italic are derived from literature. Fu,p is the fraction unbound in plasma,  
CLE is the elimination clearance from plasma. For transfer clearances between compartments 
(CLfrom comp-to comp), denotations of the compartments are: PL = plasma; PER,rapid = rapidly 
equilibrating peripheral tissues; PER,slow = slowly equilibrating peripheral tissues;               
ECF = brainECF; LV = lateral ventricle; TFV = third and fourth ventricle; CM = cisterna magna; 
and SAS = subarachnoid space. V is the physiological volume. ηi = inter-individual variability of 
parameter i; εj = residual error on concentrations in compartment j. The additional subscripts ‘p’ 
and ‘a’ denote passive and active transport, respectively. N.A. implicates that the parameter is 
not available in the specific model. 
1 Atherton, 1983; 2 Abbott, 2004; 3 Cserr et al., 1981; 4 Cserr, 1965; 5 Lee and Blaufox, 1985;      
6 Davies and Morris, 1993; 7 Bass and Lundborg, 1973; 8 Condon et al, 1986; 9 Kohn et al., 
1991; 10 Levinger, 1971; 11 Adam and Greenberg, 1978; 12 Robertson, 1949; 13 Henderson et al., 
1965; 14 Von Hendy-Willson and Pressler, 2011; 15 Bering, 1959; 16 Visser et al., 1982; 17 Löfgren 
et al., 1973; 18 Vladic et al 2009; 19 Skibińska et al., 1990; 20 Hendel and Brodthagen, 1984;        
21 Schwartz et al., 1976; 22 Kimelberg, 2004; 23 Yasuda et al., 2002; 24 Linderkamp et al., 1977;   
25 ICRP, 2002; 26 Thorne et al., 2004; 27 Dekaban and Sadowsky, 1978; 28 Troncin and Dadure, 
2009; 29 Nilsson et al., 1992; 30 Frank and Gray, 1953; 31 Dickey et al., 2000; 32 Pardridge, 2011. 
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Extrapolation to other healthy and to diseased rats 
 
We have applied the final SBPK model to investigate the impact of disease-
status on the PK of methotrexate in plasmau and brainECF of brain tumor-bearing 
rats, compared to healthy control rats (De Lange et al., 1995). By using the 
same PK parameter values that were estimated based on our data (table 3), there 
appears to be a small underestimation of the elimination from plasma as well as 
a small underestimation of the initial brainECF concentrations for the control rats 
(figure 4A) (but both plasmau and brainECF data are in general still within the 
range of 5-95% of the model prediction of the data). However, for the group of 
rats with measurement of plasma and ipsilateral brainECF concentrations at 11 
days post-tumor implantation, the concentration-time profiles in brainECF in 
brain tumor were substantially higher than was the case for the healthy situation 
(figure 4B). Presence and size of tumor were determined histologically after the 
end of the experiment. Simulations indicated that these higher brainECF 
concentrations are most likely caused by an increased plasma-to-brainECF 
clearance rate in brain tumor conditions (results not shown). 
 
 
Figure 4. Observed and SBPK model predicted methotrexate plasmau and brainECF 
concentrations in (A) control rats (plasmau, n=5; brainECF, n=6); (B) tumor implanted rats with 
ipsilateral brainECF measurement after 11 days (plasmau, n=6; brainECF, n=6) (De Lange et al., 
1995). Note that the two lowest concentration-time profiles in (B) represent animals in which no 
tumor was present on subsequent histological examinations. The dots represent the individual 
data points and the gray area represents the 90% prediction confidence interval. The different 
boxes represent the plasmau and brainECF data 
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Extrapolation to healthy dogs 
 
We have also tried to predict the plasmau and CSF kinetics of methotrexate in 
healthy dogs by systems-based scaling of our rat data. Predictions were then 
compared to literature data presented by Neuwelt et al. (1985). Plasma 
concentrations were first corrected for the level of protein binding, which was 
assumed to be 40% (Henderson et al., 1965). The rate of renal clearance was 
assumed to equal the glomerular filtration rate (80.2 ml/min (Von Hendy-
Willson and Pressler, 2011)). Systems-based scaling of our data initially 
resulted in a 10-to-100-fold underestimation of dog plasmau and CSFCM 
concentrations, whereas the CSFCM-to-plasmau concentration ratio was 
predicted correctly. The underestimation of the plasmau and CSFCM 
concentrations was primarily caused by an overestimation of the plasma 
elimination clearance. As the number of hepatocytes per gram liver in dogs is 
twice as much compared to rats (Bayliss et al., 1999), the rate of hepatic 
clearance was scaled to the liver weight and then multiplied by 2. With an 
assumed liver weight of 720 g in the dog (Davies and Morris, 1993), the rate of 
hepatic clearance was estimated to be 1094 ml/min. However, in the rat, 
methotrexate is eliminated both via the kidneys as well as the liver, whereas in 
dogs methotrexate is eliminated primarily via the kidneys (Henderson et al., 
1965). This indicates that the estimation of the hepatic clearance rate in dogs 
was much too high. For healthy dogs, with a hepatic clearance being 
approximately 10% of the renal clearance (Henderson et al., 1965), using the 
physiological and adapted PK parameters presented in table 3, the prediction 
was much improved and resulted in a slight underestimation of plasmau and 
CSFCM concentrations (figure 5). Yet the CSFCM-to-plasmau concentration ratio 
was still predicted correctly.  
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Figure 5. Observed and SBPK model predicted methotrexate plasmau and CSFCM concentrations 
in (healthy) dogs (plasmau, n=12; CSFCM, n=4). The dots represent the average data points as 
could be obtained from Neuwelt et al. (1985) and the gray area represents the 90% prediction 
confidence interval. The different boxes represent the plasmau and CSFCM data. The hepatic 
clearance was assumed to be 10% of the renal clearance for the final SBPK predictions 
 
Extrapolation to diseased human adults and children 
 
The only available human brainECF concentration-time profiles were derived 
from Blakeley et al. (2009), from 2 adult patients with supratentorial glioma. 
Other data included human plasma and CSFLV concentration-time profiles in 
adults with meningeal leukemia or meningeal carcinomatosis (n = 21, Shapiro 
et al., 1975), primary tumor (n = 16, Glantz et al., 1998), or only plasma 
concentration-time profiles in adults with small-cell lung carcinoma (n = 9, 
Creaven et al., 1976), various neoplastic diseases (n = 8, Bore et al., 1987) or 
rheumatoid arthritis (n = 56, Herman et al., 1989; Stewart et al., 1990). Also 
included were plasma and CSFCM concentration-time profiles from children 
with medulloblastoma or ependymoblastoma (n = 4, Chatelut et al., 1991), 
plasma and CSFSAS concentration-time profiles from children with non-
Hodgkin’s lymphoma (n = 29, Vassal et al., 1990), or only plasma 
concentration-time profiles from children with acute lymphoblastic leukemia (n 
= 49, Aumente et al., 2006) or osteosarcoma (n = 14, Colom et al., 2009). For 
constructing the adult and child plasma, CSFLV, CSFCM and CSFSAS dataset, 
either the individual or average data points from the different references were 
used, when available. Otherwise, simulations were performed based on the PK 
parameters presented in the different references. 
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All plasma concentrations were first corrected for the level of protein binding, 
which was assumed to be 32% for high dose methotrexate (Skibińska et al., 
1990). Systems-based scaling of our data initially resulted in a 100-fold 
underestimation of human plasmau, brainECF and CSF concentrations for both 
adults and children (results not shown). Again, the underestimation of the 
plasmau, brainECF and CSF concentrations was primarily caused by an 
overestimation of the elimination clearance. For the systems-based scaling of 
the elimination clearance of methotrexate it was assumed that the rate of human 
renal clearance equals the glomerular filtration rate (125 ml/min in adults 
(Davies and Morris, 1993) and approximately 80 ml/min in 9 year-old children 
(the average age of the available datasets)). As the number of hepatocytes per 
gram liver is equal between rats and humans (Bayliss et al., 1999), the rate of 
hepatic clearance is scaled to the liver weight. With an assumed liver weight of 
10 g in the rat (Davies and Morris, 1993), 780 g in 9 year old children and 1820 
g in adults (ICRP, 2002), the rate of hepatic clearance is estimated to be 593 
ml/min and 1380 ml/min in 9 years old children and adults, respectively. 
However, due to the extensive enterohepatic circulation of methotrexate in 
humans, the hepatic elimination rate is effectively reduced to the same level as 
the renal elimination rate (Hendel and Brodthagen, 1984). So, when taking into 
account that the hepatic clearance rate of methotrexate in humans is much lower 
than the extrapolated value, i.e. equal to the renal clearance rate, the predicted 
human plasmau concentrations are comparable to the observed concentrations 
(figure 6). However, even though the human plasmau concentrations can be 
predicted reasonably well with systems-based scaling of our rat data and 
adaption of the hepatic clearance rate to those reported for human (table 3), this 
approach still results in an up to 10-fold underestimation of brainECF, CSFCM and 
CSFLV concentrations in both children and adults, respectively. Scaling of the 
blood-to-brain clearance values on the basis of the total surface area of the BBB 
(150 cm2 in rats (Gjedde, 1981; Keep and Jones, 1990a); 200,000 cm2 in human 
adults (Pardridge, 2002)) and BCSFB (75 cm2 in rats (Keep and Jones, 1990b), 
2000-100,000 cm2 in human adults (Dohrmann, 1970)), rather than to the tissue 
weight to the power 0.67, did not improve the predictions (results not shown). 
BrainECF and CSFLV concentrations in adults, as shown in figure 6a, were not 
obtained in parallel, but from different subjects, also having other diseases. 
However, these are the only data available to make a comparison between these 
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two unbound brain concentrations. Both brainECF and CSFLV concentrations are 
higher than predicted by the SBPK model, while the observed brainECF-to-
CSFLV concentration ratio is in accordance with the predicted brainECF-to-CSFLV 
concentration ratio. It therefore seems that the plasma-to-brain concentration 
ratio is increased by disease conditions. Specifically, simulations indicated that 
the brainECF-to-CSF concentration ratio in diseased adults and children is equal 
to 2.6, which is approximately 3-fold lower than the brainECF-to-CSF 
concentration ratio observed in healthy rats, being most likely caused by an 
overestimation of the brainECF-to-plasma clearance rate. It indicates that under 
disease conditions there is a decreased active efflux from the brainECF to plasma 
(results not shown). On the other hand, simulations indicated that the 
underestimation of CSF concentrations in disease conditions is most likely 
caused by an overestimation of the CSF flow. This is in line with the 
observation that several adult patients had an obstruction to normal CSF flow 
(Glantz et al., 1998) (results not shown).  
Overall, the observed and SBPK model predicted plasmau, brainECF, CSFLV, 
CSFCM and CSFSAS concentration-time profiles in healthy and diseased rats, 
dogs, children and adults are summarized in figure 7. 
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Figure 6. (A) Observed and predicted methotrexate plasma, CSFLV and CSFSAS concentrations in 
(diseased) children; (B) observed and SBPK model predicted methotrexate plasma, brainECF and 
CSFLV concentrations in (diseased) adults. Plasma data from adults and children were collected 
from different studies (see text and table 4). Adult brainECF data were obtained from 2 patients 
with supratentorial glioma (Blakeley et al., 2009). Adult CSFLV data were obtained from 21 
patients with meningeal leukemia or meningeal carcinomatosis (Shapiro et al., 1975) or 16 
patients with primary tumor (Glantz et al., 1998). Child CSFLV data were obtained from 4 
patients (serial sampling) with medulloblastoma or ependymoblastoma (Chatelut et al., 1991). 
Child CSFSAS data were obtained from 29 patients (single sample) with non-Hodgkin’s lymphoma 
(Vassal et al., 1990). The dots represent the individual data points and the gray area represents 
the 90% prediction confidence interval. The different boxes represent the plasmau, brainECF, 
CSFLV and CSFSAS data. The hepatic clearance was assumed to be equal to the renal clearance 
for the final SBPK predictions 
 
 
DISCUSSION 
 
By using the parallel microdialysis probes approach, we have previously shown 
that, even for acetaminophen, a model compound for passive transport into, 
within and out of the brain, differences exist between CSF and brainECF kinetics 
(Chapter 3). Furthermore, we have also shown that for quinidine, a model 
compound for P-gp mediated transport, differences exist between CSF and 
brainECF kinetics, which are very much dependent of P-gp functionality 
(Chapter 4). With methotrexate being a substrate for a wide variety of 
transporters that are all located at the BBB and BCSFB, including RFC1 
(Hinken et al., 2011), BCRP (Breedveld et al., 2007), MRP 2, 3 and 4 (Vlaming 
et al., 2011), OAT 1 and 3 (Takeda et al., 2002), and OATP A (Badagnani et 
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al., 2006) and OATP B (van de Steeg et al., 2009), this could have major 
implications for the predictability of brainECF methotrexate concentrations on 
the basis of CSF methotrexate concentrations.  
In this study, the parallel microdialysis probes approach was used to 
investigate methotrexate distribution to and within the brain, and the specific 
contribution of the various transporters on the brain distribution of 
methotrexate. Probenecid was co-administered as inhibitor of Mrps (Bakos et 
al., 2000), Oats (Sugiyama et al., 2001) and Oatps (Kis et al., 2013). Probenecid 
is known to inhibit Mrps, Oats and Oatps with a half-maximum inhibition 
constant (IC50) of approximately 50-300 µg/ml (Bakos et al., 2000), 5-20 
µg/ml (Sugiyama et al., 2001) and 1.1 µg/ml (Kis et al., 2013), respectively. 
Previous work by Emanuelsson and Paalzow (1988) has indicated that a 150 
mg/kg dose of probenecid results in plasma concentrations over 10-fold higher 
than the IC50 value up to 3 h after administration. Therefore, it is plausible to 
assume that the dose of probenecid is sufficient to fully inhibit Mrps, Oats and 
Oatps throughout the entire experimental period. 
We investigated the direct relationships between brain ST methotrexate 
concentrations and those in different CSF locations, and unbound plasma 
methotrexate concentrations in the rat. Previous work from our group has 
indicated that the methotrexate brainECF-to-plasmatotal AUC ratio is 
approximately 5% in healthy rats (De Lange et al., 1995). Similar findings have 
been reported for the CSF-to-plasmatotal AUC ratio (Wang et al., 2003). When 
taking into consideration the level of plasma protein binding and the differences 
in sampling methods, our current results are in line with these findings. 
Combined results of De Lange et al. (1995), and Wang et al. (2003), would 
indicate that brainECF exposure and CSF exposure are more-or-less similar. 
However, in the current study, measuring parallelly at both sites within 
individual rats, we have found that brainECF exposure of methotrexate is 
significantly higher than CSF exposure. Inhibition of Mrps, Oats and Oatps by 
probenecid resulted in a significant increase in brainECF concentrations only. 
CSF concentrations seemed to be affected, but not to a significant extent, due to 
variability (as expected for a drug like methotrexate (Spector and Johanson, 
2010)). Interestingly, the brainECF-to-CSF concentration ratio was not 
significantly influenced by co-administration of probenecid. This is in contrast 
Prediction of methotrexate CNS distribution in different species – influence of disease conditions 
169 
 
with the P-gp substrate quinidine, for which the relation between brainECF and 
CSF concentrations was dependent on P-gp functionality (Chapter 4) 
Advanced mathematical modeling was applied, using the same structural 
SBPK model that was previously used for acetaminophen (Chapter 3) and 
quinidine (Chapter 4). For methotrexate the model parameters were estimated 
using the experimental data obtained in this study. The resulting SBPK model 
was further used to predict data obtained in other conditions and species, taking 
into account changes in physiological parameters.  
First, the SBPK model was used to investigate the impact of disease-status 
on the PK of methotrexate in plasmau and brainECF of brain tumor-bearing rats, 
compared to healthy control rats as presented by De Lange et al. (1995). Figure 
4A shows that the model prediction of plasma and brainECF concentrations is 
reasonably good. Then, figure 4B shows the SBPK prediction for healthy rat 
conditions, for rats in which a tumor (rhabdomyosarcoma) had been implanted 
in the brain (De Lange et al., 1995). It shows that tumor-bearing rats have 
specifically increased early methotrexate brainECF concentrations. 
Then, systems-based scaling of our healthy rat data to healthy dogs initially 
resulted in a 10-to-100-fold underestimation of plasmau and CSF 
concentrations. However, by taking into account that hepatic elimination of 
methotrexate in dogs is only a fraction of the renal clearance (Henderson et al., 
1965), the prediction of plasmau and CSF concentrations is much improved. The 
CSFCM-to-plasmau concentration ratio was predicted correctly. This implicates 
that the SBPK model of brain distribution developed for the healthy rat seemed 
to apply correctly for healthy dogs, provided that the hepatic clearance is 
corrected. Our ultimate aim is to predict human brain distribution, in health and 
disease. The human methotrexate data available in literature, however, were all 
obtained under disease conditions, hampering a direct evaluation of the SBPK 
model in predicting human brain distribution of methotrexate. But, with the 
assumption that the SBPK model could appropriately predict methotrexate brain 
distribution in humans, the SBPK model can be used to identify changes 
brought about by disease conditions. To that end, it should be realized that not 
only brain diseases can influence brain distribution, as was demonstrated by 
changes in BBB transport of the permeability marker fluorescein for rats with 
peripheral inflammation upon chronic exposure to rotenone (Ravenstijn et al., 
2008). 
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Extrapolation of our healthy rat data to humans with different disease states 
initially resulted in a 100-fold underestimation of plasmau, brainECF and CSF 
concentrations. However, by taking into account that methotrexate undergoes 
extensive enterohepatic circulation in humans (Hendel and Brodthagen, 1984), 
the prediction of plasmau concentrations is much improved. Yet, under the 
given disease conditions, the brainECF and CSF concentrations are up to 10-fold 
higher than predicted for healthy conditions. Using the SBPK model, 
simulations indicate a possible decreased active efflux from the brainECF as well 
as a lower CSF flow under disease conditions. Actually, Glantz et al. (1998) 
reported that several patients had abnormal (low) CSF flow. It should be 
realized however, that the human data available from literature reflect 
methotrexate disposition in body and brain in a variety of diseases that probably 
do not affect body processes in the same manner. So, more specific data are 
needed to identify specific disease-related processes that influence brain 
distribution of methotrexate, and could lead to more personalized treatment. 
Alternatively, or in addition, differences between SBPK predicted human 
healthy and the observed human disease methotrexate data might originate from 
influences of co-medication, sampling methods and analysis methods (table 4). 
Possible species differences in the abundance levels and activities of the 
different active transport proteins at the BBB and BCSFB, under healthy and 
diseased conditions, probably also play an important role. It has been previously 
shown that the genetic variability in transporters in humans leads to an altered 
sensitivity to methotrexate and thus influences the toxicity and/or efficacy of 
methotrexate treatment (Kotnik et al., 2011). This indicates that additional 
information on the species differences in abundance levels and activities of the 
different active transport proteins and drug-metabolizing enzymes at the BBB 
and BCSFB, as well as at the liver and kidney, under healthy or diseased 
conditions, is essential for extrapolation purposes. 
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Table 4. Different variables in disease states and experimental conditions of the available 
datasets in rats, dogs, children and adults 
Reference Subjects Disease 
state 
Dose (i.v.) BrainECF or CSF 
(sampling 
method) 
Analysis 
This 
manuscript 
Rats (225-
275 g; 
n=32) 
Healthy 40 and 80 
mg/kg (10 
min) 
BrainECF, CSFLV 
and CSFCM 
(microdialysis) 
LC/MS/MS 
De Lange et 
al., 1995 
Rats (160-
200 g; 
n=12) 
Brain tumor 
(implanted 
rhabdomyo-
sarcoma) 
75 mg/kg 
(bolus) 
BrainECF 
(microdialysis) 
HPLC 
Neuwelt et 
al., 1985 
Dogs (20-25 
kg; n=4) 
Healthy 4 mg/kg 
(bolus) + 
Evans blue 
CSFCM 
(Cisterna magna 
sampling) 
Radioimmuno-
assay 
Aumente et 
al., 2006 
Children 
(0.5-17y; 
n=49) 
Acute 
lympho-
blastic 
leukemia 
3 g/m2 (4 h) + 
remission-
induction 
therapy (>24h 
after 
methotrexate) 
N.A. Fluorescence 
polarization 
immunoassay 
Blakeley et 
al., 2009 
Human 
adults 
(>18y; n=2) 
Recurrent 
high grade 
gliomas 
12 g/m2 (4h) + 
sodium 
bicarbonate 
BrainECF 
(intratumoral 
microdialysis) 
LC/MS 
Bore et al., 
1987 
Human 
adults (17-
67y; n=8) 
Sarcoma, 
carcinoma, 
lung 
metastasis 
50 mg/m2 
(bolus) (no 
co-
medication) 
N.A. Radioimmuno-
assay 
Chatelut et 
al., 1991 
Children (2-
17y; n=4) 
Medullo-
blastoma or 
ependymo-
blastoma 
8 g/m2 (4 h) + 
sodium 
bicarbonate 
(i.v. 
hydration) 
CSFLV 
(ventriculo-
peritoneal 
derivation) 
Enzymatic 
assay 
Colom et 
al., 2009 
Children 
(n=14) 
Osteo-
sarcoma 
12 g/m2 (4 h) 
+ leucovorin 
(24h after 
methotrexate) 
N.A. Fluorescence 
polarization 
immunoassay 
Creaven et 
al., 1976 
Human 
adults (n=9) 
Small-cell 
lung 
carcinoma 
15 mg/m2 
(bolus) (no 
co-
medication) 
N.A. [3H]methotrex-
ate 
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Table 4 continued 
Glantz et 
al., 1998 
Human 
adults 
(>18y; 
n=16) 
Histolo-
gically 
diagnosed 
primary 
tumor 
8 g/m2 (4 h) + 
leucovorin 
(24h after 
methotrexate) 
CSFLV 
(ventricular 
reservoirs) 
Fluorescence 
polarization 
immunoassay 
Herman et 
al., 1989 
Human 
adults (16-
80y; n=41) 
Rheumatoid 
arthritis 
10 mg/m2 
(bolus) (no 
co-
medication) 
N.A. Radiochemical-
ligand binding 
assay 
Shapiro et 
al., 1975 
Human 
adults (18-
63y; n=21) 
Leukemia 
and 
carcinoma 
50 mg (bolus) 
(no co-
medication) 
CSFLV 
(Ommaya 
reservoir) 
microbiologic 
disk assay 
Stewart et 
al., 1990 
Human 
adults (30-
78y; n=15) 
Rheutma-
toid arthritis 
15 mg (5 min) 
(received 
naproxen 3 
days before) 
N.A. Radioenzymatic 
assay 
Vassal et 
al., 1990 
Children (3-
15y; n=29) 
Non-
Hodgkin’s 
lymphoma 
3 g/m2 (3 h) + 
sodium 
bicarbonate 
(i.v. 
hydration) 
CSFSAS (lumbar 
puncture) 
Fluorescence 
polarization 
immunoassay 
 
 
CONCLUSION 
 
It is concluded that in parallel obtained data on unbound brainECF, CSF and 
plasma concentrations, under dynamic conditions, combined with advanced 
mathematical modeling is a most valid approach to develop SBPK models that 
allow revealing the mechanisms underlying the relationship between brainECF 
and CSF concentrations. In contrast to the P-gp substrate quinidine and P-gp 
mediated active transport, for methotrexate we have found that inhibition of 
Mrp/Oat/Oatp-mediated active transport processes does not significantly 
influence the relationship between brainECF and CSF concentrations. 
Our results suggest that the extrapolation of our healthy rat data to healthy 
dogs works reasonably well, provided that information on the different 
elimination routes, or the lack thereof, is included in the systems-based scaling 
approach. For the correct prediction of plasmau, brainECF or CSF concentrations 
in diseased humans, additional information is needed on specific disease states 
in order to identify which processes are influenced by the disease condition to 
improve personalized treatment, in which the SBPK model is anticipated to be a 
useful tool. 
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APPENDIX 
 
DIFFERENTIAL EQUATIONS 
 
The mass balance equations describing the final SBPK model were expressed as 
follows: 
 
Plasma: 
 
𝑑𝐴𝑃𝐿,𝑢
𝑑𝑡
= 𝑑𝑜𝑠𝑒 − 𝑘𝑃𝐿−𝑃𝐸𝑅,𝑟𝑎𝑝𝑖𝑑 × 𝐴𝑃𝐿,𝑢 + 𝑘𝑃𝐸𝑅,𝑟𝑎𝑝𝑖𝑑−𝑃𝐿 × 𝐴𝑃𝐸𝑅,𝑟𝑎𝑝𝑖𝑑 
−𝑘𝑃𝐿−𝑃𝐸𝑅,𝑠𝑙𝑜𝑤 × 𝐴𝑃𝐿,𝑢 + 𝑘𝑃𝐸𝑅,𝑠𝑙𝑜𝑤−𝑃𝐿 × 𝐴𝑃𝐸𝑅,𝑠𝑙𝑜𝑤 − 𝑘𝑃𝐿−𝐸𝐶𝐹 × 𝐴𝑃𝐿,𝑢 +𝑘𝐸𝐶𝐹−𝑃𝐿 × 𝐴𝐸𝐶𝐹 − 𝑘𝑃𝐿−𝐿𝑉 × 𝐴𝑃𝐿,𝑢 + 𝑘𝐿𝑉−𝑃𝐿 × 𝐴𝐿𝑉 − 𝑘𝑃𝐿−𝑇𝐹𝑉 × 𝐴𝑃𝐿,𝑢 +𝑘𝑇𝐹𝑉−𝑃𝐿 × 𝐴𝑇𝐹𝑉 − 𝑘𝑃𝐿−𝐶𝑀 × 𝐴𝑃𝐿,𝑢 + 𝑘𝐶𝑀−𝑃𝐿 × 𝐴𝐶𝑀 + �𝑄𝐶𝑆𝐹𝑉𝑆𝐴𝑆 � × 𝐴𝑆𝐴𝑆 − 𝑘𝐸 × 𝐴𝑃𝐿,𝑢 
 
𝐶𝑃𝐿,𝑢 = 𝐴𝑃𝐿,𝑢𝑉𝑃𝐿  
 
Periphery: 
 
𝑑𝐴𝑃𝐸𝑅,𝑟𝑎𝑝𝑖𝑑
𝑑𝑡
= 𝑘𝑃𝐿−𝑃𝐸𝑅,𝑟𝑎𝑝𝑖𝑑 × 𝐴𝑃𝐿,𝑢 − 𝑘𝑃𝐸𝑅,𝑟𝑎𝑝𝑖𝑑−𝑃𝐿 × 𝐴𝑃𝐸𝑅,𝑟𝑎𝑝𝑖𝑑 
 
𝐶𝑃𝐸𝑅,𝑟𝑎𝑝𝑖𝑑 = 𝐴𝑃𝐸𝑅,𝑟𝑎𝑝𝑖𝑑𝑉𝑃𝐸𝑅,𝑟𝑎𝑝𝑖𝑑  
 
𝑑𝐴𝑃𝐸𝑅,𝑠𝑙𝑜𝑤
𝑑𝑡
= 𝑘𝑃𝐿−𝑃𝐸𝑅,𝑠𝑙𝑜𝑤 × 𝐴𝑃𝐿,𝑢 − 𝑘𝑃𝐸𝑅,𝑠𝑙𝑜𝑤−𝑃𝐿 × 𝐴𝑃𝐸𝑅,𝑠𝑙𝑜𝑤 
 
𝐶𝑃𝐸𝑅,𝑠𝑙𝑜𝑤 = 𝐴𝑃𝐸𝑅,𝑠𝑙𝑜𝑤𝑉𝑃𝐸𝑅,𝑠𝑙𝑜𝑤  
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BrainECF: 
 
𝑑𝐴𝐸𝐶𝐹
𝑑𝑡
= 𝑘𝑃𝐿−𝐸𝐶𝐹 × 𝐴𝑃𝐿,𝑢 − 𝑘𝐸𝐶𝐹−𝑃𝐿 × 𝐴𝐸𝐶𝐹 − �𝑄𝐸𝐶𝐹𝑉𝐸𝐶𝐹� × 𝐴𝐸𝐶𝐹 
𝐶𝐸𝐶𝐹 = 𝐴𝐸𝐶𝐹𝑉𝐸𝐶𝐹  
 
CSFLV: 
 
𝑑𝐴𝐿𝑉
𝑑𝑡
= 𝑘𝑃𝐿−𝐿𝑉 × 𝐴𝑃𝐿,𝑢 − 𝑘𝐿𝑉−𝑃𝐿 × 𝐴𝐿𝑉 + �𝑄𝐸𝐶𝐹𝑉𝐸𝐶𝐹� × 𝐴𝐸𝐶𝐹 − �𝑄𝐶𝑆𝐹𝑉𝐿𝑉 � × 𝐴𝐿𝑉 
 
𝐶𝐿𝑉 = 𝐴𝐿𝑉𝑉𝐿𝑉  
 
CSFTFV: 
 
𝑑𝐴𝑇𝐹𝑉
𝑑𝑡
= 𝑘𝑃𝐿−𝑇𝐹𝑉 × 𝐴𝑃𝐿,𝑢 − 𝑘𝑇𝐹𝑉−𝑃𝐿 × 𝐴𝑇𝐹𝑉 + �𝑄𝐶𝑆𝐹𝑉𝐿𝑉 � × 𝐴𝐿𝑉 − �𝑄𝐶𝑆𝐹𝑉𝑇𝐹𝑉� × 𝐴𝑇𝐹𝑉 
 
𝐶𝑇𝐹𝑉 = 𝐴𝑇𝐹𝑉𝑉𝑇𝐹𝑉  
 
CSFCM: 
 
𝑑𝐴𝐶𝑀
𝑑𝑡
= 𝑘𝑃𝐿−𝐶𝑀 × 𝐴𝑃𝐿,𝑢 − 𝑘𝐶𝑀−𝑃𝐿 × 𝐴𝐶𝑀 + �𝑄𝐶𝑆𝐹𝑉𝑇𝐹𝑉� × 𝐴𝑇𝐹𝑉 − �𝑄𝐶𝑆𝐹𝑉𝐶𝑀 � × 𝐴𝐶𝑀 
 
𝐶𝐶𝑀 = 𝐴𝐶𝑀𝑉𝐶𝑀  
 
CSFSAS: 
 
𝑑𝐴𝑆𝐴𝑆
𝑑𝑡
= �𝑄𝐶𝑆𝐹
𝑉𝐶𝑀
� × 𝐴𝐶𝑀 − �𝑄𝐶𝑆𝐹𝑉𝑆𝐴𝑆 � × 𝐴𝑆𝐴𝑆 
 
𝐶𝑆𝐴𝑆 = 𝐴𝑆𝐴𝑆𝑉𝑆𝐴𝑆  
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Where: 
 
𝑘𝐸 = (𝐶𝐿𝐸,𝑝 + 𝐶𝐿𝐸,𝑎)/𝑉𝑃𝐿  
𝑘𝑃𝐿−𝑃𝐸𝑅,𝑟𝑎𝑝𝑖𝑑 = 𝐶𝐿𝑃𝐿−𝑃𝐸𝑅,𝑟𝑎𝑝𝑖𝑑/𝑉𝑃𝐿 
𝑘𝑃𝐸𝑅,𝑟𝑎𝑝𝑖𝑑−𝑃𝐿 = 𝐶𝐿𝑃𝐿−𝑃𝐸𝑅,𝑟𝑎𝑝𝑖𝑑/𝑉𝑃𝐸𝑅,𝑟𝑎𝑝𝑖𝑑  
𝑘𝑃𝐿−𝑃𝐸𝑅,𝑠𝑙𝑜𝑤 = 𝐶𝐿𝑃𝐿−𝑃𝐸𝑅,𝑠𝑙𝑜𝑤/𝑉𝑃𝐿 
𝑘𝑃𝐸𝑅,𝑠𝑙𝑜𝑤−𝑃𝐿 = 𝐶𝐿𝑃𝐿−𝑃𝐸𝑅,𝑠𝑙𝑜𝑤/𝑉𝑃𝐸𝑅,𝑠𝑙𝑜𝑤  
𝑘𝑃𝐿−𝐸𝐶𝐹 = (𝐶𝐿𝑃𝐿−𝐸𝐶𝐹,𝑝 − 𝐶𝐿𝑃𝐿−𝐸𝐶𝐹,𝑎)/𝑉𝑃𝐿 
𝑘𝐸𝐶𝐹−𝑃𝐿 = (𝐶𝐿𝐸𝐶𝐹−𝑃𝐿,𝑝 + 𝐶𝐿𝐸𝐶𝐹−𝑃𝐿,𝑎)/𝑉𝐸𝐶𝐹 
𝑘𝑃𝐿−𝐿𝑉 = (𝐶𝐿𝑃𝐿−𝐿𝑉,𝑝 − 𝐶𝐿𝑃𝐿−𝐿𝑉,𝑎)/𝑉𝑃𝐿 
𝑘𝐿𝑉−𝑃𝐿 = (𝐶𝐿𝐿𝑉−𝑃𝐿,𝑝 + 𝐶𝐿𝐿𝑉−𝑃𝐿,𝑎)/𝑉𝐿𝑉 
𝑘𝑃𝐿−𝑇𝐹𝑉 = (𝐶𝐿𝑃𝐿−𝑇𝐹𝑉,𝑝 − 𝐶𝐿𝑃𝐿−𝑇𝐹𝑉,𝑎)/𝑉𝑃𝐿 
𝑘𝑇𝐹𝑉−𝑃𝐿 = (𝐶𝐿𝑇𝐹𝑉−𝑃𝐿,𝑝 + 𝐶𝐿𝑇𝐹𝑉−𝑃𝐿,𝑎)/𝑉𝑇𝐹𝑉 
𝑘𝑃𝐿−𝐶𝑀 = (𝐶𝐿𝑃𝐿−𝐶𝑀,𝑝 − 𝐶𝐿𝑃𝐿−𝐶𝑀,𝑎)/𝑉𝑃𝐿 
𝑘𝐶𝑀−𝑃𝐿 = (𝐶𝐿𝐶𝑀−𝑃𝐿,𝑝 + 𝐶𝐿𝐶𝑀−𝑃𝐿,𝑎)/𝑉𝐶𝑀 
 
NOMENCLATURE 
 
Ai  Amount of methotrexate in compartment i (ng) 
Ci  Concentration of methotrexate in compartment i (ng/ml) 
k rate constant (min-1) 
Q flow rate (ml/min) 
CL clearance (ml/min) 
V volume (ml) 
 
Subscripts 
 
PL plasma 
PL,u unbound methotrexate in plasma 
PER,rapid rapidly equilibrating peripheral compartment 
PER,slow slowly equilibrating peripheral compartment 
ECF brainECF 
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CSF CSF 
LV lateral ventricle 
TFV third and fourth ventricle 
CM cisterna magna 
SAS subarachnoid space 
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FACTORS THAT GOVERN THE 
PHARMACOKINETICS IN THE BRAIN 
 
In the development of drugs for the treatment of central nervous system (CNS) 
disorders, the prediction of human CNS drug action is a big challenge. In part 
this has been due to the sole focus on the blood-brain barrier (BBB) 
permeability of drugs, which, as classical paradigm, is governed by the 
lipophilicity and molecular weight of drugs (Levin, 1980). However, not all 
processes that determine drug concentrations at the relevant target site within 
the CNS are taken into account. Besides plasma pharmacokinetics (PK), plasma 
protein binding, and passive and active transport across the blood-brain barriers 
(BBB and the blood-cerebrospinal fluid barrier (BCSFB)), processes within the 
brain can also influence brain target site PK, including bulk flow, diffusion, and 
extra-intracellular exchange (Chapter 1). Moreover, it is important to 
distinguish between the rate and the extent of all processes. For example, 
passing of the BBB occurs with a certain rate and to a certain extent 
(Hammarlund-Udenaes et al., 2008). The rate of transport across the BBB is 
reflecting the time needed for a drug molecule to traverse this barrier, while the 
extent of BBB transport expresses the ratio of unbound drug concentrations in 
the brain compared to those in plasma at steady state (Kp,uu). It can also be 
calculated as the ratio of the area under the unbound concentration-time curve 
(AUC0-∞) in brain relative to that in plasma. The rate as well as the extent of 
BBB transport on one hand is dependent on both the (condition-dependent) 
characteristics of this barrier and on the physicochemical properties of the drugs 
(De Lange and Danhof, 2002; Levin, 1980). Likewise, for other processes the 
rate and extent can be defined. Each of the different processes that determine 
drug concentrations at the relevant CNS target has its particular influence on the 
overall rate and extent, and thereby plays a more or less important role in 
having the drug in the right place, at the right time, and at the right 
concentration. 
For many CNS active compounds, brain target site concentrations are best 
reflected by, or may even be equal to unbound drug concentrations in the brain 
extracellular fluid (brainECF) (De Lange et al., 2000; Hammarlund-Udenaes, 
2009; Watson et al., 2009). However, the possibility of direct measurement of 
brainECF concentrations is highly limited in the clinical phase of drug 
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development. Therefore, unbound drug concentrations in human CSF are used 
as a surrogate for human brainECF concentrations. It is often assumed that CSF 
concentrations readily equilibrate with brainECF concentrations due to the lack of 
a physical barrier between the two (Lee et al., 2001). However, the brain is a 
dynamic, multi-compartmental system in which all processes of entry, diffusion, 
metabolism, binding and elimination determine local CNS concentrations. Due 
to qualitative and quantitative differences in processes that govern the PK of 
drugs in the brain, a generally applicable relationship between CSF 
concentrations and brainECF concentrations does not exist (Chapter 1, De 
Lange, 2013a; De Lange and Danhof, 2002; Lin, 2008; Shen et al., 2004). This 
all implies the need for mechanistic investigations on the contribution of the 
different processes that govern the brain target site exposure. 
The rate and extent of drug penetration into the brain can be studied in the 
preclinical setting with several in vitro, ex vivo and in vivo techniques (Chapter 
1), such as the brain perfusion technique or the brain slice technique. So far, 
most of these preclinical techniques determine total brain concentrations, or 
calculate unbound brainECF concentrations using the fraction unbound in brain 
homogenate. When using brain homogenate, cell structures are destroyed and 
binding sites that are normally not accessible to a drug in vivo may be unmasked 
(Liu et al., 2009). This could result in an erroneous estimation of the unbound 
fraction in brain tissue. Moreover, in the drug discovery phase these techniques 
are often used such that information on solely equilibrium distribution is 
obtained. However, this may limit the extrapolative power of the results to the 
human situation. Furthermore, most of these techniques cannot be applied to 
humans, which makes a direct comparison of preclinical and clinical findings 
impossible. In contrast, CSF sampling can be used in both animals and humans, 
and as it provides information on unbound concentrations (with some time-
dependency) it is of special interest. Most useful would be to use the 
intracerebral microdialysis technique for monitoring unbound brain 
concentrations at one (or more) selected site(s) in the brain, but its use in 
humans is highly restricted. However, if applied in animals, intracerebral 
microdialysis may still reveal mechanistic information on the inter-relationships 
of different processes that govern the brainECF-CSF PK in different conditions in 
vivo, and may investigate such in conjunction with pharmacodynamic (PD) 
read-outs. Such information may provide useful links to the human situation. 
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PARALLEL INTRACEREBRAL MICRODIALYSIS 
 
With intracerebral microdialysis it is possible to monitor local unbound 
concentrations of compounds at one or more specific sites in the brain. Thus, 
with the use of multiple intracerebral microdialysis probes in individual animals 
one can directly compare unbound concentrations in brainECF, CSF from lateral 
ventricle (CSFLV) and CSF from cisterna magna (CSFCM), thereby gaining 
insight into the relationship between brainECF and CSF concentrations. 
However, special care should be taken in determining the concentration 
recovery. Because of the continuous flow of the perfusion solution through the 
microdialysis probe, the concentration in the dialysate will be lower than in the 
surrounding brainECF or CSF. (De Lange et al., 2000). This indicates the need 
for determination of the in vivo recovery for proper correction of the dialysate to 
brainECF and CSF concentrations, preferably for each brain location and for each 
experimental condition. 
The aim of the research presented in this thesis was to develop a preclinical 
brain distribution model, allowing the prediction of human brain target site 
concentrations on the basis of preclinical data. In order to be able to build a 
brain distribution model understanding of time-dependent (also non-steady 
state) kinetics of the unbound drug in brainECF and CSF is essential. To that end, 
systematic studies on the inter-relationship of plasma PK, BBB transport, 
BCSFB transport and intra-brain distribution were performed in the rat by using 
probes at multiple brain sites in individual animals.  
As a general approach, three compounds with different physicochemical 
properties were selected as paradigm compounds (table 1). Acetaminophen was 
chosen as paradigm compound for passive transport into, within and out of the 
brain, with a medium logP and no ionization at physiological pH (Chapter 3). 
Quinidine was selected as a paradigm compound with a high logP, indicative of 
high passive BBB transport, and a positive charge at physiological pH. 
Furthermore, quinidine is a known substrate for P-glycoprotein (P-gp)-mediated 
transport out of the brain. To investigate the specific contribution of P-gp-
mediated transport P-gp was inhibited by co-administration of tariquidar, a 
selective P-gp inhibitor (Chapter 4). Methotrexate was selected as a paradigm 
compound with a low logP, indicative of low passive BBB transport, and a 
negative charge at physiological pH. Furthermore, methotrexate is known to be 
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transported by a wide variety of transporters, including the reduced folate 
carrier 1 (RFC1), breast cancer resistance protein (BCRP), the multidrug 
resistance-associated protein (MRP) family, organic anion transporters (OATs) 
and organic anion-transporting polypeptides (OATPs). To investigate the 
specific contribution of the various transporters, probenecid was co-
administered as inhibitor of MRPs, OATs and OATPs (Chapter 5). 
 
Table 1. Physicochemical properties of the selected paradigm compounds 
Compound MW PSA logP Ionization pKa1 pKa2 Ionized at 
physio-
logical pH 
Substrate 
for 
Reference 
Acetamino-
phen 
151.2 49.3 0.46 monoprotic 
acid 
9.38 - 0% 
(neutral) 
- DrugBank 
DB00316 
Quinidine 324.4 45.6 3.44 diprotic base 4.0 9.1 98% 
(positive) 
P-gp DrugBank 
DB00908 
Methotrex-
ate 
454.4 210.5 -1.85 diprotic acid 3.4 4.1 99.9% 
(negative) 
BCRP, 
MRPs, 
OATPs, 
OATs 
DrugBank 
DB00563 
 
Abbreviations: MW, molecular weight; PSA, polar surface area; logP, log octanol:water 
partition coefficient; pKa, acid dissociation constant 
 
Since the rate of equilibration between CSF and brainECF concentrations by 
passive diffusion is dependent on the lipophilicity and size of the compound (De 
Lange et al., 2000; Levin, 1980), we expected the CSF and brainECF 
concentrations to be similar for acetaminophen, because acetaminophen is a 
small and moderately lipophilic compound with anticipated fast transport 
between blood and brain. However, we have observed that brainECF 
concentrations of acetaminophen are ~4-fold higher than its CSF 
concentrations. This can probably be explained by the relatively slow 
distribution from brainECF to CSF compared to the turnover rate of CSF. This 
makes the CSF act as a sink, causing the observed lower concentrations in CSF 
compared to brainECF.  
For the P-gp substrate quinidine we expected significant differences between 
brainECF and CSF concentrations, since it has been well established that P-gp 
functions as an efflux transporter at the BBB (Schinkel, 1999), whereas there 
has been some evidence that P-gp could also function as an influx transporter at 
the BCSFB (Kassem et al., 2007; Rao et al., 1999). Interestingly, we found only 
small differences between brainECF and CSF concentrations of quinidine (0.72 ± 
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0.20 without inhibition of P-gp and 2.22 ± 0.57 with inhibition of P-gp). On the 
basis of the “smaller than threefold brainECF-to-CSF concentration ratio 
paradigm” (Maurer et al., 2005), this result would not be of much importance. 
However, in our perspective, even a small difference in PK could potentially 
lead to quite distinct PD, in case of a steep concentration-effect relationship, and 
therefore still needs to be considered. These results indicate that P-gp 
functionality and variations thereof may have an important effect on the 
brainECF-to-CSF concentration ratio and the extrapolation from rats to humans. 
For quinidine, furthermore, we also expected the unbound brain concentrations 
to be lower than the unbound plasma concentrations. However, to our surprise, 
the unbound brain concentrations in all brain compartments were significantly 
higher than those in plasma. Since quinidine is actively transported out of the 
brain, this suggests that quinidine is also transported by other transporters at the 
BBB and BCSFB, in the direction of the brain, possibly by organic cation 
transporters (Van Montfoort et al., 2001). This illustrates the importance of 
interplay of the different transporters at the BBB and BCSFB. The influence of 
a particular transporter can only be dissected if specific blockers are available. 
Actually, only for P-gp specific blockers are available (e.g. tariquidar). 
Another example of a drug that is transported by multiple active transport 
systems located at the BBB and BCSFB, including BCRP, MRPs, OATs and 
OATPs, is methotrexate. Based on differences in the direction of flux and 
subcellular localization of the different transporter systems at the BBB and 
BCSFB (Chapter 1), for methotrexate we were expecting significant 
differences between brainECF and CSF concentrations. As methotrexate is a very 
hydrophilic compound, the extent of distribution to the brain is much lower than 
for acetaminophen and quinidine. Interestingly, for methotrexate we found that 
brainECF concentrations were significantly higher than CSF concentrations (> 3-
fold), and this difference seemed to be independent of probenecid co-
administration. This indicates that the active transport by Mrps, Oats and Oatps 
does not influence the brainECF-CSF relationship. However, inhibition of Mrps, 
Oats and Oatps did result in a significant increase in both brainECF and CSF 
concentrations. Also, for methotrexate, as transported by multiple active 
transport systems that cannot be inhibited in a specific manner, it becomes 
difficult to identify the specific contribution of each transporter. It is therefore 
more efficient to investigate the transport processes by systematically 
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influencing a subset of variables, either by varying the conditions of the system 
or by varying the drug properties. Using different drugs, with different drug 
properties, such as affinities for the different transporters, one can decipher the 
impact of changes at the level of these variables on the blood-brain transport 
and the distribution beyond. 
 
 
SYSTEMS-BASED PHARMACOKINETIC MODELING 
 
In order to predict human CNS effects, different mathematical modeling 
techniques can be applied (Danhof et al., 2008). The most commonly applied 
has been the compartmental model analysis (Fleishaker and Smith, 1987), in 
which the brain compartment is modeled as an effect compartment 
(Hammarlund-Udenaes et al., 1997; Sheiner et al., 1979). Here the plasma 
concentration is the driving force for brain concentrations, without uptake into 
or elimination from the brain influencing the concentration-time profile in 
blood. Extrapolation of animal PK parameters to the human situation can 
sometimes be performed reasonably well by allometric scaling, using 
bodyweight or body surface area as the main determinant of PK parameters.  
The physiologically-based pharmacokinetic (PBPK) modeling approach has 
provided the basis for interspecies extrapolation. It has focused on quantitative 
modeling of mass transport into and out of physiological compartments and 
made highly significant contributions to knowledge of the body (system) and 
the fates of drugs (Rowland et al., 2011). It has not, however, taken into account 
the distinction between the bound and unbound drug. Inclusion of unbound 
concentrations, however, will provide more accurate information on specifically 
membrane transport processes and can be named systems-based 
pharmacokinetic (SBPK) modeling.  
Information on species- and/or condition-dependent differences in 
abundance levels and activities of the different active transport proteins and 
drug-metabolizing enzymes at the BBB and BCSFB, as well as at the liver and 
kidney, under healthy or diseased conditions, is essential for extrapolation 
purposes. With the use of advanced SBPK modeling the contributions of 
individual mechanisms in animals can be revealed to serve as links to the 
human situation. Thus, SBPK models integrate drug-specific and system-
Chapter 6 
196 
 
specific physiological parameters that vary between species, subjects, or within 
subjects with different age and/or disease state (Colburn, 1988; Espié et al., 
2009; Ings, 1990). However, even though the whole body SBPK approach 
would provide the best information for prediction, it requires an extensive 
amount of information to be able to identify the impact on specific parameters, 
making the whole body SBPK modeling approach highly time-consuming and 
costly. We therefore chose to limit the SBPK approach to the brain only, with 
the plasma kinetics to be defined by a simple compartmental modeling approach 
to determine the input function; the PK exposure of the brain. In the SBPK 
brain model the data that were produced on (unbound) concentrations in plasma, 
brainECF, CSFLV and CSFCM from single animals were used to define the time-
dependent parameters on exchange between plasma, brainECF and CSF 
concentrations between several real brain compartments with their volumes and 
surfaces, by diffusion, fluid flows, and active transport processes. This was all 
performed using non-linear mixed-effects modeling using the NONMEM 
software package. Thereby, also the relationship between brainECF and CSF 
concentrations could be determined.  
Using the same structural model for all three paradigm compounds, the 
impact of drug characteristics on brain kinetics and the brainECF-CSF 
concentration relationship is investigated in a mechanistic manner. This will 
contribute to the predictability of human brain target site concentrations on the 
basis of preclinical data.  
 
 
EXTRAPOLATION TO THE HUMAN SETTING 
 
Given that CSF concentrations are considered to be the best available surrogate 
for brainECF concentrations in humans (Fridén et al., 2009; Kalvass and Maurer, 
2002; Liu et al., 2006; Liu et al., 2009; Maurer et al., 2005), we focused on 
predicting human brainECF concentrations. Thereby human acetaminophen CSF 
concentrations as presented by Bannwarth et al. (1992) were used as a reference 
in Chapter 3. By changing the different values of the physiological parameters 
of the rat to their corresponding human values, and by fitting the human plasma 
data to our model while extrapolating the plasma-brain exchange in a systems-
based manner, we were able to adequately predict human lumbar CSF 
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concentrations as observed by Bannwarth et al. (1992). For acetaminophen in 
humans, it was predicted that brainECF concentrations are on average ~2-fold 
higher than unbound plasma concentrations, whereas the brainECF-to-CSF (from 
the subarachnoid space) concentration relationship is highly dependent on the 
time after dose. Though we do not have data on human acetaminophen brainECF 
data, the data as predicted for human CSF lumbar concentrations that are in line 
with observed lumbar concentrations (Bannwarth et al., 1992) gives confidence 
in the usefulness of our model.  
Next, for quinidine (Chapter 4), the inclusion of the influence of P-gp-
mediated transport at the blood-brain barriers was taken into account. It was 
clear that P-gp functionality is an important factor in the relationship between 
CSF and brainECF exposure, given the fact that the relative distribution of 
quinidine over the brain compartments changes with blocking P-gp-mediated 
transport by co-administration of tariquidar. No data were available on 
quinidine CSF distribution in human, so at this moment in time this observation 
cannot be validated for the human situation. 
For methotrexate there is quite some clinical data available, including 
brainECF concentrations in humans (Blakeley et al., 2009). However, all 
published human data (children and adults) has been obtained from patients 
with different disease states. It is therefore not logical to expect proper 
prediction of diseased human concentrations in different brain compartments on 
the basis of a preclinical model developed on data obtained in healthy rats. This 
is because diseases may influence the rate and extent of several processes that 
govern brain target site concentrations of (also non-) CNS active compounds. 
Actually, it is of high value to identify disease-specific induced changes in 
particular PK processes (and therewith PD impact). Assuming proper 
predictions of human brain concentrations under healthy conditions by the 
preclinical derived model, deviations of particular brain concentrations in 
disease conditions may as well be used to identify parameter “suspects” 
responsible for or contributing to changes in brain compartment concentrations. 
In Chapter 5 we therefore applied the SBPK model on literature data on 
methotrexate brain distribution, first, to predict data obtained in other healthy 
rats (plasma and brainECF data), then, to investigate the impact of disease-status 
on the PK of methotrexate. By using the same PK parameter values that were 
estimated based on our data, we were able to predict the methotrexate plasma 
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and brainECF concentrations in other healthy rats reasonably well. For earlier 
reported brainECF concentrations of methotrexate in brain tumor-bearing rats (De 
Lange et al., 1995) the predictions by the preclinical brain distribution model 
were found to be significantly lower, indicating increased distribution of 
methotrexate at the brain tumor site. The next step was to use our SBPK model 
to predict plasma and CSF concentrations in healthy dogs. When taking into 
account that the hepatic elimination of methotrexate in dogs is only a fraction of 
the renal clearance (Henderson et al., 1965), whereas in rats the hepatic 
elimination of methotrexate is estimated to be over 5-fold higher than the renal 
clearance, the predictions of plasma and CSF concentrations were reasonable. 
In the case where a disease condition is the variable in a cross-compare 
designed study, the SBPK brain distribution model can be used in helping to 
identify which parameters (e.g. the elimination from plasma or the blood-brain 
transport) are possibly influenced. Furthermore, provided that the SBPK brain 
distribution model is able to describe the different processes well in healthy 
conditions, simulations will help in our understanding of the impact of 
parameter changes in disease conditions. With the assumption that our SBPK 
brain distribution model can appropriately predict methotrexate brain 
distribution in healthy humans, this model could be used to identify changes in 
methotrexate distribution brought about by disease conditions (like for the 
tumor-bearing rats).  
In humans, methotrexate undergoes extensive enterohepatic circulation, 
effectively reducing the hepatic elimination rate to the same level as the renal 
elimination rate (Hendel and Brodthagen, 1984). With this information 
incorporated into the model, the prediction of human unbound methotrexate 
plasma concentrations is reasonable. However, under the given disease 
conditions, the brainECF and CSF concentrations are significantly higher than 
predicted for healthy conditions. Simulations indicate a possible decreased 
active efflux from the brainECF as well as a lower CSF flow could be the cause 
of these higher brainECF and CSF concentrations under the given disease 
conditions. The reduced CSF flow as “suspect” contributor to changed 
methotrexate brain PK is in line with the observation that several adult patients 
had an obstruction to normal CSF flow (Glantz et al., 1998).  
So, interestingly, apart from blood-brain transport, the CSF flow seems to 
play an important role in the brainECF-CSF relationship. For acetaminophen and 
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methotrexate, the CSF acts as a sink, causing the observed lower concentrations 
in CSF compared to brainECF. As the relative rate of CSF turnover in rats is 
much higher than in humans, the sink effect in humans could be smaller as 
compared to that in rats. Then, certain drugs and certain diseases may influence 
CSF formation. This indicates that CSF turnover should also be considered in 
the brainECF-CSF relationship.  
 
 
FUTURE PERSPECTIVES 
 
To be able to predict CNS drug effects in humans on the basis of preclinical 
data, it is essential to study the underlying processes and mechanisms that 
govern the ultimate concentration-effect relationship. Therefore, it is of 
importance to investigate the inter-relationship between plasma PK, BBB and 
BCSFB transport, intra-brain distribution, target binding, target activation, 
transduction, homeostatic feedback, and disease processes (Danhof et al., 2007; 
De Lange, 2013b; De Lange et al., 2005). The current preclinical SBPK brain 
distribution model is a first step into that direction. It allows the investigation of 
the relationship between plasma PK, BBB and BCSFB transport and intra-brain 
distribution, in a systems-specific manner.  
By systematically varying one (or a subset) of conditions (such as P-gp 
functionality), one can decipher the impact of changes on brain distribution in 
integrative cross-compare designed studies. To that end we also need advanced 
mathematical modeling procedures to dissect contributions of individual 
mechanisms, being key to translation from one condition to the other (De 
Lange, 2013b). The current preclinical SBPK brain distribution model follows 
that approach, and needs to be further developed/refined by using more data on 
other drugs with distinct physicochemical properties. By doing so we will be 
able to pin-point the influence of particular drug properties on the 
pharmacokinetic brain distribution behavior of drugs. Furthermore, the PK of a 
drug at different sites in the brain should be connected to (biomarkers of) the 
effect in order to unravel those concentrations that can be considered as target 
site concentrations. 
Other aspects that need to be included for improving the SBPK brain 
distribution model are target-mediated drug disposition and target association 
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and dissociation kinetics. This may cause non-linearity in PK and/or PD, which 
may complicate the characterization of the PK-PD relationship. When drugs are 
bound with high affinity and to a significant extent (relative to the dose) to their 
target sites, the drug can be retained much longer in target rich tissue spaces 
than expected on the basis of the plasma elimination rate (Levy, 1996; Mager, 
2006; Mager and Jusko, 2001). As an example, this may hold for the 
antipsychotic drugs risperidone and paliperidone with their targets being the 
dopamine D2 and serotonin 5-HT2A receptor. For these compounds, information 
on the regional brain distribution, together with information on the target 
density as well as the target association and dissociation kinetics provides a 
better understanding of processes that govern the PK-PD relationship (Johnson 
et al., 2011; Kozielska et al., 2012).  
Thus, apart from blood-brain and intra-brain transport processes, target-
mediated disposition adds on to the limited value of plasma PK to predict target 
site PK and stresses the importance of having additional information on target 
site PK that actually drives the PK-PD relationship. Since CNS target site 
concentrations cannot be obtained directly from humans, the aim should be to 
predict target site concentrations and effects in humans on the best indirect way, 
such as based on preclinical data. 
The value of intracerebral microdialysis in this prediction is clearly 
exemplified by recent work by Stevens et al. (2012). They have shown that the 
effect of remoxipride, a dopamine D2/D3-receptor antagonist, on prolactin 
concentrations in plasma could be directly linked to remoxipride brainECF 
concentrations as measured by microdialysis in the rat. To that end, human 
brainECF remoxipride concentrations were predicted by allometric and 
physiological scaling of the rat data, which were then used to predict human 
plasma prolactin concentrations by applying the same structural PK-PD model 
as was developed on the basis of the rat data. The predicted human plasma 
prolactin concentrations show a great similarity to clinically observed plasma 
prolactin concentrations, indicating that advanced PK-PD modeling of 
preclinical data allows the prediction of drug effects in humans. 
Further development of the preclinical SBPK brain distribution-effect model 
lies in improvement of the quality of the CNS effect data. Often, the focus has 
been on a single biomarker to reflect the CNS drug effect. However, given the 
complexity of brain diseases, it can be seen that the search for a single 
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biomarker to explain the disease relative to the healthy condition, and/or 
changes in the disease condition by (drug) treatment will never lead to a 
success. Actually we do not deal with “the” effect, but a composite of effects. 
The search should therefore be on “fingerprints” of multiple biomarkers, in a 
time-dependent manner, for investigations on the “effect spectrum”. With 
metabolomics as an emerging scientific tool, many more compounds in brain 
fluids and in plasma can be measured in parallel, in a quantitative and time-
dependent manner. Furthermore, the emphasis should lie on measures that can 
be obtained both preclinically and clinically, to enhance translational insights 
and therewith predictive power of preclinically obtained information (De Lange, 
2014). 
In conclusion, the future perspective is that by combining drug-specific and 
system-specific information on brain target site distribution with mechanistic 
information on the concentration-effect spectrum relationship (as they vary in 
between species, between subjects, or within subjects with age and/or disease 
state) will ultimately result in a systems-based PK-PD model that is anticipated 
to be able to predict human CNS drug effect on the basis of preclinical PK data 
(figure 1). 
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Figure 1. Schematic representation of a systems-based PK-PD model. On the right several 
underlying processes or mechanisms that are important for the pharmacokinetics and 
pharmacodynamics of a (unbound) drug are highlighted 
 
 
REFERENCES 
 
Bannwarth B, Netter P, Lapicque F, Gillet P, Péré P, Boccard E, Royer RJ, Gaucher A. Plasma 
and cerebrospinal fluid concentrations of paracetamol after a single intravenous dose of 
propacetamol. Br J Clin Pharmacol 1992; 34: 79-81. 
 
Blakeley JO, Olson J, Grossman SA, He X, Weingart J, Supko JG. Effect of blood brain barrier 
permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of 
methotrexate: a microdialysis study. J Neurooncol 2009; 91: 51-58. 
Prediction of brain target site concentrations on the basis of CSF PK: General discussion and perspectives 
203 
 
Colburn WA. Physiologic pharmacokinetic modeling. J Clin Pharmacol 1988; 28: 673-677. 
 
Danhof M, de Jongh J, de Lange ECM, Della Pasqua OE, Ploeger BA, Voskuyl RA. Mechanism-
based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and 
dynamical systems analysis. Annu Rev Pharmacol Toxicol 2007; 47: 357-400. 
 
Danhof M, de Lange ECM, Della Pasqua OE, Ploeger BA, Voskuyl RA. Mechanism-based 
pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends 
Pharmacol Sci 2008; 29: 186-191. 
 
De Lange ECM, Danhof M. Considerations in the use of cerebrospinal fluid pharmacokinetics to 
predict brain target concentrations in the clinical setting. Implications of the barriers between 
blood and brain. Clin Pharmacokin 2002; 41: 691-703. 
 
De Lange ECM. Utility of CSF in translational neuroscience. J Pharmacokinet Pharmacodyn. 
2013a; 40: 315-26. 
 
De Lange ECM. The mastermind approach to CNS drug therapy: translational prediction of 
human brain distribution, target site kinetics, and therapeutic effects. Fluids Barriers CNS 2013b; 
10: 12. 
 
De Lange ECM. Pharmacometrics in psychiatric diseases. In “Applied Pharmacometrics”. Eds S. 
Schmidt and H. Derendorf. Springer. 2014. 
 
De Lange ECM, de Vries JD, Zurcher C, Danhof M, De Boer AG, Breimer DD. The use of 
intracerebral microdialysis to study blood-brain barrier transport of anticancer drugs in tumor-
bearing tat brain. Pharm Res 1995; 12: 1924-1931. 
 
De Lange ECM, de Boer AG, Breimer DD. Methodological issues in microdialysis sampling for 
pharmacokinetic studies. Adv Drug Del Rev 2000; 45: 125-148. 
 
De Lange ECM, Ravenstijn PGM, Groenendaal D, van Steeg TS. Toward the prediction of CNS 
drug effect profiles in physiological and pathological conditions using microdialysis and 
mechanism-based pharmacokinetic-pharmacodynamic modeling. AAPS J 2005; 7: article 54. 
 
Espié P, Tytgat D, Sargentini-Maier M-L, Poggesi I, Watelet J-P. 2009. Physiologically based 
pharmacokinetics (PBPK). Drug Metab Rev 41: 391-407. 
 
Fleishaker JC, Smith RB. Compartmental model analysis in pharmacokinetics. J Clin Pharmacol 
1987; 27: 922-926. 
 
Fridén M, Winiwarter S, Jerndal G, Bengtsson O, Wan H, Bredberg U, Hammarlund-Udenaes M, 
Antonsson M. Structure-brain exposure relationships in rat and human using a novel data set of 
Chapter 6 
204 
 
unbound drug concentrations in brain interstitial and cerebrospinal fluids. J Med Chem 2009; 52: 
6233-6243. 
 
Glantz MJ, Cole BF, Recht L, Akerley W, Milles P, Saris S, Hochberg F, Calabresi P, Egorin MJ. 
High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is 
intrathecal chemotherapy necessary? J Clin Oncol 1998; 16: 1561-1567. 
 
Hammarlund-Udenaes M. Active-site concentrations of chemicals – are they a better predictor of 
effect than plasma/organ/tissue concentrations? Basic Clin Pharmacol Toxicol 2009; 106: 215-
220. 
 
Hammarlund-Udenaes M, Paalzow LK, de Lange ECM. Drug equilibration across the blood-brain 
barrier – pharmacokinetic considerations based on the microdialysis method. Pharm Res 1997; 
14: 128-134. 
 
Hammarlund-Udenaes M, Fridén M, Syvänen S, Gupta A. On the rate and extent of drug delivery 
to the brain. Pharm Res 2008; 25: 1737-1750. 
 
Hendel J, Brodthagen H. Entero-hepatic cycling of methotrexate estimated by use of the D-isomer 
as a reference marker. Eur J Clin Pharmacol 1984; 26: 103-107. 
 
Henderson ES, Adamson RH, Denham C, Oliverio VT. The metabolic fate of tritiated 
methotrexate I. absorption, excretion, and distribution in mice, rats, dogs and monkeys. Cancer 
Res 1965; 25: 1008-1017. 
 
Ings RMJ. Interspecies scaling and comparisons in drug development and toxicogenetics. 
Xenobiotica 1990; 20: 1201-1231. 
 
Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Li C, Grimwood S, de Greef R, 
Groothuis GMM, Danhof M, Proost JH. Mechanism-based pharmacokinetic-pharmacodynamic 
modeling of the dopamine D2 receptor occupancy of olanzapine in rats. Pharm Res 2011; 28: 
2490-2504. 
 
Kalvass JC, Maurer TS. Influence of nonspecific brain and plasma binding of CNS exposure: 
implications for rational drug discovery. Biopharm Drug Dispos 2002; 23: 327-338. 
 
Kassem NA, Deane R, Segal MB, Chen RL, Preston JE. Thyroxine (T4) transfer from CSF to 
choroid plexus and ventricular brain regions in rabbit: contributory role of P-glycoprotein and 
organic anion transporting polypeptides. Brain Res 2007; 1181: 44-50. 
 
Kozielska M, Johnson M, Pilla Reddy V, Vermeulen A, Li C, Grimwood S, de Greef R, 
Groothuis GMM, Danhof M, Proost JH. Pharmacokinetic-pharmacodynamic modeling of the D2 
Prediction of brain target site concentrations on the basis of CSF PK: General discussion and perspectives 
205 
 
and 5-HT2A receptor occupancy of risperidone and paliperidone in rats. Pharm Res 2012; 29: 
1932-1948. 
 
Lee G, Dallas S, Hong M, Bendayan R. Drug transporters in the central nervous system: brain 
barriers and brain parenchyma considerations. Pharmacol Rev 2001; 53: 569-596. 
 
Levin VA. Relationship of octanol/water partition coefficient and molecular weight to rat brain 
capillary permeability. J Med Chem 1980; 23: 682-684.  
 
Levy G. Pharmacological target-mediated drug disposition. Clin Pharmacol Ther 1994; 56: 248-
52. 
 
Lin JH. CSF as a surrogate for assessing CNS exposure: an industrial perspective. Curr Drug 
Metab 2008; 9: 46-59. 
 
Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, 
Gibbs JP, Hosea N, Liu J, Nelson FR, Szewc MA, Van Deusen J.. Evaluation of cerebrospinal 
fluid concentration and plasma free concentration as surrogate measurement for brain free 
concentration. Drug Metab Dispos 2006; 34: 1443-1447. 
 
Liu X, Van Natta K, Yeo H, Vilenski O, Weller PE, Worboys PD, Monshouwer M. Unbound 
drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for 
unbound concentration in brain interstitial fluid. Drug Metab Dispos 2009; 37: 787-793. 
 
Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug 
disposition. J Pharmacokin Pharmacodyn 2001; 28: 507-532. 
 
Mager DE. Target-mediated drug disposition and dynamics. Biochem Pharmacol 2006; 72: 1-10. 
 
Maurer TS, DeBartolo DB, Tess DA, Scott D. Relationship between exposure and nonspecific 
binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 2005; 33: 175-
181. 
 
Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC, Piwnica-Worms D. 
Choroid plexus epithelial expression of MDR1 P-glycoprotein and multidrug resistance-associated 
protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci 
USA 1999; 96: 3900-3905. 
 
Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and 
regulatory science. Annu Rev Pharmacol Toxicol 2011; 51: 45-73. 
 
Schinkel AH. P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Del Rev 1999; 
36: 179-194. 
Chapter 6 
206 
 
Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of 
pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 
1979; 25: 358-371. 
 
Shen DD, Artru AA, Adkison KK. Principles and applicability of CSF sampling for the 
assessment of CNS drug delivery and pharmacodynamics. Adv Drug Del Rev 2004; 56: 1825-
1857. 
 
Stevens J, Ploeger BA, Hammarlund-Udenaes M, Osswald G, van der Graaf PH, Danhof M, de 
Lange ECM. Mechanism-based PK-PD model for the prolactin biological system response 
following an acute dopamine inhibition challenge: quantitative extrapolation to humans. J 
Pharmacokinet Pharmacodyn 2012; 39: 463-477. 
 
Van Montfoort JE, Müller M, Groothuis GMM, Meijer DKF, Koepsell H, Meier PJ. Comparison 
of “type I” and “type II” organic cation transport by organic cation transporters and organic 
anion-transporting polypeptides. J Pharmacol Exp Ther 2001; 298: 110-115. 
 
Watson J, Wright S, Lucas A, Clarke KL, Viggers J, Cheetham S, Jeffrey P, Porter R, Read KD. 
Receptor occupancy and brain free fraction. Drug Metab Dispos 2009; 37: 753-60. 
Prediction of brain target site concentrations on the basis of CSF PK: General discussion and perspectives 
207 
 
 
208 
 
  
209 
 
Appendix 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
210 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nederlandse samenvatting 
211 
 
Nederlandse samenvatting 
 
Factoren die de farmacokinetiek in de hersenen bepalen 
 
De ontwikkeling van geneesmiddelen voor aandoeningen aan het centrale 
zenuwstelsel (CZS), waaronder de ziekte van Alzheimer, de ziekte van 
Parkinson, multiple sclerose, schizofrenie, migraine, slapeloosheid, depressie en 
“attention deficit hyperactivity disorder” (ADHD) verloopt veelal moeizaam, 
omdat het moeilijk is om de concentratie van het geneesmiddel op de plaats van 
werking in de hersenen te meten of voorspellen. Veel potentiële CZS 
geneesmiddelen in ontwikkeling falen doordat deze onvoldoende de bloed-
hersen barrière (BHB) weten te passeren. De BHB beschermt de hersenen tegen 
blootstelling aan lichaamsvreemde stoffen (waaronder geneesmiddelen) die zich 
in de bloedbaan bevinden door de aanwezigheid van “tight junction” eiwitten, 
welke de endotheelcellen van bloedvaten in de hersenen met elkaar verbinden. 
Daarnaast zijn er ook nog verschillende actieve transportsystemen en enzymen 
aanwezig op de BHB die de concentratie van geneesmiddelen in de hersenen 
laag houden. Echter is de BHB niet de enige oorzaak van het lage 
slagingspercentage van geneesmiddelonderzoek voor CZS aandoeningen. 
Naast de plasma farmacokinetiek (PK), plasma eiwitbinding, passieve en 
actieve transportsystemen op de bloed-hersen barrières (de BHB en de bloed-
cerebrospinale vloeistof barrière (BCSFB)) zijn er ook processen binnen de 
hersenen die een rol kunnen spelen. Binnen de hersenen heb je te maken met 
verschillende vloeistofstromen, diffusie en extracellulaire-intracellulaire 
uitwisseling. Dit geeft aan dat er ook nog andere processen zijn die een 
belangrijke rol spelen om het geneesmiddel op de juiste plek, de juiste tijd en 
met de juiste concentratie te krijgen.  
Veel (potentiële) CZS geneesmiddelen hebben hun plaats van werking aan 
de buitenzijde van de hersencellen. Doelconcentraties zijn daarmee in veel 
gevallen gelijk aan de ongebonden concentraties in de extracellulaire vloeistof 
van de hersenen (hersenECF). Echter is het meten van concentraties in hersenECF 
zeer beperkt mogelijk in de mens, dus als alternatief worden vaak ongebonden 
concentraties in CSF gebruikt. Vaak wordt aangenomen dat CSF concentraties 
goed vergelijkbaar zijn met hersenECF concentraties vanwege het gebrek aan een 
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fysieke barrière tussen de twee vloeistoffen. De hersenen zijn echter een 
dynamisch, complex orgaan, waarbij alle processen van opname, diffusie, 
metabolisme, binding en eliminatie de lokale hersenconcentraties bepalen. Door 
kwalitatieve en kwantitatieve verschillen in de processen die de PK van de 
geneesmiddelen in de hersenen bepalen bestaat er geen algemeen toepasbare 
relatie tussen CSF concentraties en hersenECF concentraties (Hoofdstuk 1). Dit 
geeft aan dat er de behoefte is aan mechanistisch onderzoek naar de bijdrage 
van de verschillende processen die de uiteindelijke doelconcentraties bepalen. 
In de preklinische fase van geneesmiddelonderzoek kunnen de snelheid en 
mate van distributie naar de hersenen met verschillende in vitro, ex vivo en in 
vivo technieken bestudeerd worden, zoals beschreven staat in Hoofdstuk 1. 
Vaak worden totale hersenconcentraties in proefdieren bepaald met behulp van 
technieken zoals de hersenperfusie techniek. Ongebonden hersenECF 
concentraties worden dan vervolgens berekend door de mate van binding te 
bepalen met hersen homogenaat monsters. Het nadeel van het homogeniseren 
van de hersenen is echter dat de cellulaire structuur van de hersenen verloren 
gaat, waardoor mogelijk andere bindingsplaatsen beschikbaar komen die bij 
intacte hersenen niet toegankelijk zijn. Hierdoor kan er een vertekend beeld 
ontstaan van de mate van binding, waardoor de berekening van de ongebonden 
concentraties onjuist zal zijn. Bovendien is deze techniek niet toepasbaar in de 
mens, dus dat maakt het lastig om de resultaten te extrapoleren. Het nemen van 
CSF monsters wordt veelal gezien als zeer waardevolle techniek omdat het 
toepasbaar is in zowel proefdieren als de mens. De intracerebrale microdialyse 
techniek is echter het meest bruikbaar, omdat met deze techniek de ongebonden 
concentraties op meerdere plaatsen in de hersenen (bijvoorbeeld CSF en 
hersenECF) gemeten kunnen worden. Aangezien de microdialyse techniek een 
invasieve techniek is wordt deze slechts zeer beperkt in de mens toegepast. Het 
toepassen van deze techniek in proefdieren stelt ons echter in staat om 
mechanistische informatie te verzamelen over de verschillende processen die de 
relatie bepalen tussen hersenECF en CSF PK. In combinatie met 
farmacodynamische (PD) parameters kan de informatie zeer bruikbaar zijn om 
de processen in de mens beter te begrijpen en voorspellen.  
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Parallelle intracerebrale microdialyse 
 
In Hoofdstuk 3 hebben we een experimentele methode ontwikkeld waarbij 
simultaan de ongebonden concentraties van paracetamol in bloed (plasma), 
hersenECF en CSF kon worden bepaald. De implantatie van meerdere 
microdialyse probes in hersenECF, CSF in de laterale ventrikel (CSFLV) of CSF 
in de cisterna magna (CSFCM) van een enkel dier stelde ons in staat om de 
relatie tussen hersenECF en CSF concentraties te bepalen. Het toepassen van de 
intracerebrale microdialyse techniek vereist echter wel dat de relatieve 
opbrengst wordt bepaald. Aangezien de microdialyse probe constant 
geperfuseerd wordt zal de concentratie in het dialysaat lager zijn dan de 
concentratie in de omliggende hersenECF of CSF. Dit geeft aan dat de relatieve 
opbrengst bij voorkeur in vivo voor elke probe locatie dient te worden bepaald 
om de dialysaat concentraties om te kunnen rekenen naar hersenECF en CSF 
concentraties. 
Het doel van het onderzoek waar dit proefschrift over gaat was het opstellen 
van een preklinisch hersendistributiemodel waarmee de vrije concentraties op 
de plaats van werking in de hersenen van de mens kan worden voorspeld op 
basis van preklinische data. Om dit model te kunnen opstellen is het essentieel 
om te begrijpen hoe de kinetiek van het ongebonden geneesmiddel afhankelijk 
is van de tijd en waarbij de concentraties niet met elkaar in evenwicht zijn. 
Hiervoor hebben we een aantal studies uitgevoerd in de rat, waarbij we op een 
systematische manier hebben gekeken naar de onderlinge verhouding tussen 
plasma PK, BHB transport, BCSFB transport en distributie binnen de hersenen. 
Om dit te kunnen doen hebben we in elke rat op meerdere plaatsen in de 
hersenen een microdialyse probe geïmplanteerd. Voor de studies hebben we 
drie stoffen geselecteerd met verschillende fysisch-chemische eigenschappen. 
Paracetamol (Hoofdstuk 3) was geselecteerd als modelstof voor passief 
transport van, naar en in de hersenen, met een logP van 0.46 en geen lading bij 
fysiologische pH. Aangezien in het geval van passieve diffusie de snelheid 
waarmee het evenwicht tussen CSF en hersenECF concentraties zich instelt wordt 
bepaald door de lipofiliciteit en het molecuulgewicht gingen wij er van uit dat 
de concentraties in het CSF en hersenECF vergelijkbaar zouden zijn. Wij hebben 
echter gevonden dat de concentraties in CSF ongeveer een factor 4 lager zijn 
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dan hersenECF concentraties. Mogelijk wordt dit veroorzaakt door de relatief 
hoge verversingssnelheid van CSF, waarbij het CSF als afvoer kan dienen. 
Quinidine (Hoofdstuk 4) was geselecteerd als modelstof met een hoge logP 
van 3.44, indicatief van een hoge mate van passief transport over de BHB, en 
een positieve lading bij fysiologische pH. Daarnaast is quinidine een bekend 
substraat voor actief transport uit de hersenen door P-glycoproteïne (P-gp). Om 
de bijdrage van P-gp-gemedieerd transport te kunnen bepalen is een selectieve 
inhibitor van P-gp, tariquidar, toegediend. Voor quinidine hadden we verwacht 
dat er significante verschillen zouden zijn tussen hersenECF concentraties en CSF 
concentraties, aangezien van P-gp bekend is dat deze functioneert als afvoer 
transporter op de BHB, terwijl deze mogelijk als opname transporter zou 
functioneren op de BCSFB. Gek genoeg vonden wij slechts kleine verschillen 
tussen hersenECF concentraties en CSF concentraties. De hersenECF-CSF 
concentratieratio was 0.72 ± 0.20 zonder inhibitie van P-gp en 2.22 ± 0.57 met 
de inhibitie van P-gp.  
Op basis van de algemeen geaccepteerde foutmarge van factor 3 zou dit 
betekenen dat deze resultaten als niet significant kunnen worden beschouwd. 
Wij zijn er echter van overtuigd dat zelfs een klein verschil in de PK van een 
stof drastische gevolgen kan hebben voor de PD van de stof als er een sterke 
relatie is tussen de concentratie en het effect van de stof. Zodoende vinden wij 
dat zelfs de kleinste verschillen als potentieel relevant moeten worden 
beschouwd. Deze resultaten geven aan dat de variatie in P-gp functionaliteit een 
grote invloed hebben op de hersenECF-CSF concentratieratio en mogelijk ook op 
de extrapolatie van de rat naar de mens.  
Voor quinidine hadden we verwacht dat de ongebonden concentraties in de 
hersenen lager zouden zijn dan de ongebonden concentraties in plasma. Tot 
onze verbazing waren de ongebonden concentraties in de hersenen echter 
significant hoger dan die in plasma. Aangezien quinidine actief uit de hersenen 
wordt getransporteerd door P-gp geven deze resultaten aan dat quinidine 
mogelijk ook door andere transportsystemen, zoals organische cation 
transporters, op de BHB en BCSFB in de richting van de hersenen wordt 
getransporteerd. Dit geeft aan dat er een belangrijke samenwerking kan zijn 
tussen de verschillende transportsystemen op de BHB en BCSFB. Om de 
bijdrage van een enkele transporter te kunnen bestuderen is het essentieel om 
inhibitoren te hebben met een hoge specificiteit voor die transporter. 
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Vooralsnog zijn er alleen specifieke inhibitoren voor P-gp beschikbaar, zoals 
tariquidar. 
Tot slot was methotrexaat (Hoofdstuk 5) geselecteerd als modelstof met een 
lage logP van –1.85, indicatief van weinig passief transport over de BHB, en 
een negatieve lading bij fysiologische pH. Verder is methotrexaat substraat voor 
een breed scala aan actieve transportsystemen op de BHB en BCSFB, 
waaronder de “reduced folate carrier 1”, “breast cancer resistance protein” 
(BCRP), de “multidrug resistance-associated protein” (MRP) familie, 
organische anion transporters (OATs) en organische anion-transporterende 
polypeptides (OATPs). Om de invloed van verschillende transportsystemen te 
kunnen bepalen werd probenecid toegediend als inhibitor van MRPs, OATs en 
OATPs. Op basis van de verschillen in de richting van transport en de 
lokalisatie van de verschillende transportsystemen op de BHB en BCSFB 
hadden we significant verschillende concentraties in hersenECF en CSF 
verwacht. Deze verwachtingen bleken te kloppen, want hersenECF concentraties 
waren meer dan 3-voud hoger dan CSF concentraties, ook na de toediening van 
probenecid. Dit geeft aan dat actief transport van methotrexaat door Mrps, Oats 
en Oatps geen invloed heeft op de relatie tussen hersenECF en CSF concentraties. 
De inhibitie van Mrps, Oats en Oatps heeft echter wel geleid tot significant 
hogere concentraties in zowel hersenECF als CSF. 
Aangezien methotrexaat wordt getransporteerd door meerdere transporters 
die niet individueel geblokkeerd kunnen worden is het lastig om de bijdrage van 
elke transporter afzonderlijk te bepalen. Om dit toch te kunnen bestuderen is het 
efficiënter om op een systematische manier te werk te gaan, waarbij telkens een 
aantal variabelen kunnen worden gevarieerd, bijvoorbeeld door een andere 
inhibitor te gebruiken waarbij alleen de Oats en Oatps geblokkeerd worden. 
Ook zouden andere stoffen gekozen kunnen worden die in meer of mindere 
mate affiniteit hebben voor één of meerdere transporters. Op deze manier 
kunnen we de betekenis van de veranderingen van het transport naar en 
distributie in de hersenen ontrafelen. 
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Systeem-gebaseerd farmacokinetisch modeleren 
 
Om de effecten van geneesmiddelen in de hersenen van de mens te kunnen 
voorpellen zijn verschillende farmacokinetische modellen toepasbaar. Vaak 
wordt een compartimenteel model gebruikt waarbij de hersenen als 
effectcompartiment worden beschreven. Bij deze aanpak is de ongebonden 
plasmaconcentratie de belangrijkste drijfkracht voor de concentraties in de 
hersenen, waarbij de opname in de hersenen of eliminatie uit de hersenen geen 
invloed hebben op de concentraties in bloed. Extrapolatie van PK parameters 
die zijn bepaald in dieren gaat in sommige gevallen best goed door 
allometrische schaling op basis van lichaamsgewicht of lichaamsoppervlak.  
In fysiologisch-gebaseerde farmacokinetische (PBPK) modellen staat de 
fysiologie van het organisme centraal. In ieder PBPK model wordt het 
onderscheid gemaakt tussen systeem-specifieke parameters en stof-specifieke 
parameters. De systeem-specifieke fysiologische parameters van het PBPK 
model kunnen aangepast worden aan het organisme waar naar gekeken wordt, 
dus op deze manier is het schalen tussen diersoorten beter onderbouwd dan bij 
de allometrische schaling. Het gebruik van een andere stof, met zijn eigen stof-
specifieke eigenschappen, stelt ons in staat om de bijdrage van de verschillende 
eigenschappen op het transport naar en distributie in de hersenen te ontrafelen. 
Het toevoegen van mechanistische informatie over bijvoorbeeld het transport 
over de BHB en BCSFB resulteert in een meer systeem-gebaseerd 
farmacokinetisch (SBPK) model. 
Informatie over de verschillen in de dichtheid en activiteit van verschillende 
actieve transportsystemen en enzymen op de BHB en BCSFB, maar ook in de 
lever en nier, onder gezonde en zieke omstandigheden, is essentieel voor de 
extrapolatie van dier naar mens. Door gebruik te maken van specifieke SBPK 
modellen kunnen individuele mechanismen in dieren geïdentificeerd worden die 
ons veel kunnen leren over de processen in de mens. In principe zouden de 
beste voorspellingen gedaan kunnen worden met een SBPK model waarbij het 
hele organisme in alle detail is beschreven. Dit vergt echter een enorme 
hoeveelheid informatie, tijd en geld om de bijdrage van specifieke parameters te 
kunnen identificeren. Daarom hebben wij ervoor gekozen om alleen de 
hersenen te beschrijven met een SBPK model, waarbij de plasmakinetiek 
beschreven kon worden met een compartimenteel model. Met de gemeten 
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ongebonden concentraties in plasma, hersenECF, CSFLV en CSFCM zijn de 
tijdsafhankelijke parameters voor de uitwisseling tussen de verschillende 
hersencompartimenten bepaald. De hersencompartimenten zijn hierbij 
beschreven op basis van hun anatomie, met een bepaald volume en oppervlakte, 
onderling verbonden door middel van diffusie, vloeistofstromen en actieve 
transportsystemen. Voor deze aanpak hebben we gebruik gemaakt van non-
lineaire gemengde effecten modellen, waarbij NONMEM als software is 
gebruikt. Hierbij hebben we de onderlinge relatie tussen hersenECF concentraties 
en CSF concentraties bepaald. 
Door gebruik te maken van hetzelfde structurele SBPK model voor de drie 
modelstoffen kan de bijdrage van de verschillende stof-specifieke 
eigenschappen op de PK in de hersenen en de hersenECF-CSF concentratierelatie 
bestudeerd worden op een mechanistische manier. Deze aanpak zal bijdragen 
aan de voorspelbaarheid van doelconcentraties in de mens op basis van 
preklinische data. 
 
Extrapolatie naar de mens 
 
Aangezien CSF concentraties beschouwd worden als best beschikbare 
alternatief voor hersenECF concentraties hebben we in Hoofdstuk 3 geprobeerd 
om hersenECF concentraties van paracetamol in de mens te voorspellen om deze 
te kunnen vergelijken met gemeten CSF concentraties. Hiervoor hebben we 
eerst de verschillende fysiologische parameters van de rat veranderd in de 
waarden van de mens en is de uitwisseling tussen plasma en de hersenen 
geëxtrapoleerd op basis van de fysiologie. Door vervolgens de humane plasma 
data te fitten met ons SBPK model, konden lumbale CSF concentraties, zoals 
gepresenteerd in de literatuur, goed worden voorspeld. Op basis van ons model 
is voorspeld dat hersenECF concentraties ongeveer een factor 2 hoger zijn dan 
ongebonden plasmaconcentraties. De hersenECF-CSF (in de subarachnoïdale 
ruimte) concentratieratio was erg afhankelijk van de tijd na doseren. Ondanks 
dat we deze voorspelling niet kunnen valideren geeft de juiste voorspelling van 
de lumbale CSF concentraties wel aan dat we vertrouwen kunnen hebben in het 
nut van ons model. 
Voor quinidine (Hoofdstuk 4) hebben we de invloed van het actieve 
transport door P-gp op beide hersenbarrières toegevoegd aan het model. We 
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hebben gezien dat de functionaliteit van P-gp een belangrijke rol speelt in de 
relatie tussen hersenECF en CSF concentraties. Helaas is er geen data 
beschikbaar van quinidine concentraties in CSF van de mens, dus het is nog niet 
mogelijk om deze observatie te valideren. 
Voor methotrexaat (Hoofdstuk 5) was er aardig wat literatuur beschikbaar 
waarin CSF concentraties in zowel kinderen als volwassenen zijn gemeten. In 
een enkel geval zijn zelfs hersenECF concentraties gemeten met behulp van de 
intracerebrale microdialyse techniek. We moeten er echter wel rekening mee 
houden dat deze data is verkregen uit patiënten met verschillende ziektebeelden. 
Het was dan ook niet te verwachten dat de voorspelling van hersenconcentraties 
in de zieke mens goed zou gaan met het model dat is gebaseerd op data 
verkregen uit de gezonde rat. Het is namelijk bekend dat ziekte in het algemeen 
een invloed kan hebben op de relatieve bijdrage van de verschillende processen 
die de doelconcentraties van (niet-)CZS actieve stoffen bepalen. Het is daarom 
van belang om te bepalen op welke PK parameters een ziekte effect heeft, 
aangezien hiermee ook het potentiële effect op de PD bepaald kan worden. Op 
basis van de aanname dat het preklinische SBPK model de situatie voor de 
gezonde mens goed voorspelt is het mogelijk om “verdachte” parameters te 
identificeren die afwijkende hersenconcentraties bepalen.  
In Hoofdstuk 5 hebben we het SBPK model toegepast op literatuurdata 
(plasma en hersenECF concentraties) van gezonde ratten en van ratten die een 
tumor geïmplanteerd hadden gekregen in de hersenen. Door dezelfde PK 
parameters te gebruiken die wij op basis van onze data hadden bepaald konden 
de plasma en hersenECF concentraties in de gezonde rat goed worden voorspeld. 
Voor de ratten met een hersentumor bleek de voorspelling van de 
plasmaconcentraties nog goed te kloppen, maar er was een onderschatting van 
de hersenECF concentraties nabij de hersentumor. Dit geeft aan dat er een 
toename is in de distributie van methotrexaat naar de hersentumor. Daarna werd 
het SBPK model toegepast op plasma en CSF concentraties gemeten in gezonde 
honden. Met de voorkennis dat de klaring van methotrexaat in honden door de 
lever slechts een fractie is van de klaring door de nieren, terwijl de hepatische 
klaring in de rat juist meer dan 5 keer hoger is dan de renale klaring, konden 
plasma en CSF concentraties redelijk goed voorspeld worden. 
Als de status van de ziekte gebruikt wordt als variabele in een kruislings-
vergelijkende studie dan is het mogelijk om de parameters te identificeren die 
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worden beïnvloed in het SBPK hersendistributiemodel. Deze parameters zouden 
bijvoorbeeld de eliminatie vanuit plasma of het transport tussen bloed en de 
hersenen kunnen zijn. In de veronderstelling dat het SBPK model de processen 
onder gezonde omstandigheden goed beschrijft kan de relatieve bijdrage van de 
veranderingen van de verschillende parameters inzichtelijk gemaakt worden aan 
de hand van simulaties. 
In de mens is er een substantiële enterohepatische circulatie van 
methotrexaat, waardoor de hepatische eliminatiesnelheid effectief gereduceerd 
wordt tot ongeveer de renale eliminatiesnelheid. Met deze voorkennis is de 
voorspelling van ongebonden plasmaconcentraties in de mens redelijk. De 
gemeten concentraties in hersenECF en CSF waren echter significant hoger dan 
wat was voorspeld op basis van gezonde omstandigheden. Simulaties hebben 
aangegeven dat zowel een gereduceerde afvoer vanuit hersenECF als een 
gereduceerde CSF vloeistofstroom hier mogelijk de oorzaken van kunnen zijn. 
De mogelijke invloed van een gereduceerde CSF vloeistofstroom komt overeen 
met bevindingen in de literatuur. 
Interessant genoeg is het niet alleen het transport van en naar de hersenen die 
een belangrijke rol speelt in de relatie tussen hersenECF concentraties en CSF 
concentraties. De vloeistofstroom van CSF mag hierin niet onderschat worden. 
Voor paracetamol en methotrexaat ziet het er naar uit dat CSF als afvoer kan 
dienen, wat resulteert in lagere concentraties in CSF in vergelijking tot 
hersenECF concentraties. Aangezien de relatieve CSF vloeistofstroom in ratten 
veel hoger is dan die in de mens zou het kunnen betekenen dat de afvoer in de 
mens veel minder is. Daarnaast kan het zo zijn dat een geneesmiddel of ziekte 
een effect kan hebben op de productie van CSF. Dit geeft aan dat er rekening 
moet worden gehouden met de verversingssnelheid van CSF bij het bepalen van 
de relatie tussen hersenECF concentraties en CSF concentraties. 
 
Toekomstperspectieven 
 
Om het effect van CZS geneesmiddelen in de mens te kunnen voorspellen op 
basis van preklinische data is het essentieel om de onderliggende processen en 
mechanismen te bestuderen die uiteindelijk de concentratie-effect relatie 
bepalen. Het is daarom belangrijk om de onderlinge relatie tussen plasma PK, 
BHB en BCSFB transport, distributie in de hersenen, binding aan het doeleiwit, 
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activatie van het doeleiwit, transductie, homeostatische terugkoppeling en 
ziekteprocessen te bestuderen. Het preklinische hersendistributiemodel dat wij 
hebben opgesteld is een stap in de goede richting en stelt ons in staat om de 
onderlinge relatie tussen plasma PK, BHB en BCSFB transport en distributie in 
de hersenen te kunnen bepalen. 
Door op een systematische manier één of meerdere parameters (bijvoorbeeld 
de functionaliteit van P-gp) te variëren kan de relatieve bijdrage van die variatie 
op de hersendistributie in kaart worden gebracht. Om deze informatie te kunnen 
bevatten is het essentieel om vooruitstrevende wiskundige modellen te 
gebruiken die de bijdragen van individuele mechanismen van elkaar kunnen 
onderscheiden. Dit is namelijk essentieel voor de extrapolatie van de ene 
situatie naar de andere. Ons huidige preklinische SBPK hersendistributiemodel 
volgt deze aanpak en dient nog verder ontwikkeld en verfijnd te worden door 
data toe te voegen van andere stoffen met hun eigen fysisch-chemische 
eigenschappen. Hiermee kunnen we de invloed van specifieke eigenschappen 
op de kinetiek en distributie in de hersenen inzichtelijk maken. Daarnaast is het 
van belang om de PK van het geneesmiddel op meerdere plaatsen in de 
hersenen te koppelen aan (biomarkers van) het effect om te kunnen ontrafelen 
welke concentraties als doelconcentraties kunnen worden beschouwd. 
Het SBPK hersendistributiemodel kan nog verder aangevuld worden met 
informatie over de doeleiwit-gemedieerde dispositie en de kinetiek van 
doeleiwit associatie en dissociatie. Als een geneesmiddel in hoge mate (ten 
opzichte van de dosis) sterk bindt aan een doeleiwit kan het zijn dat het 
geneesmiddel langer het doeleiwit kan activeren dan wat je op basis van de 
plasma eliminatiesnelheid zou verwachten. Dit maakt het lastig om de PK-PD 
relatie vast te stellen. De doeleiwit-gemedieerde dispositie speelt een 
belangrijke rol in de PD van bijvoorbeeld risperidon en paliperidon, met de 
dopamine D2 en seretonine 5-HT2A receptor als doeleiwit. Naast informatie over 
de regionale distributie van de geneesmiddelen in de hersenen geeft de 
toevoeging van informatie over de receptordichtheid en de kinetiek van 
associatie en dissociatie een beter beeld van de processen die de PK-PD relatie 
bepalen. 
Naast informatie over de transportprocessen tussen bloed en de hersenen en 
binnen de hersenen biedt informatie over doeleiwit-gemedieerde dispositie een 
toegevoegde waarde ten opzichte van alleen plasma PK om doelconcentraties te 
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kunnen voorspellen. Dit geeft aan dat er meer informatie nodig is over de PK in 
de nabijheid van het doeleiwit, aangezien dit de PK-PD relatie bepaalt. Omdat 
deze informatie niet verkregen kan worden in de mens is het het doel om de 
doelconcentraties en het effect in de mens op de best mogelijke manier te 
kunnen voorspellen, bijvoorbeeld op basis van preklinische data. 
De toegevoegde waarde van de intracerebrale microdialyse techniek is 
eerder al bewezen. In een studie met remoxipride, een dopamine D2/D3-receptor 
antagonist, is aangetoond dat plasmaconcentraties van de biomarker prolactine 
direct gekoppeld konden worden aan remoxipride concentraties in hersenECF, 
gemeten met de intracerebrale microdialyse techniek in de rat. Op basis van 
allometrische schaling en schaling op basis van de fysiologie was het mogelijk 
om remoxipride hersenECF concentraties in de mens te voorspellen, waarop ook 
de prolactine concentraties in plasma konden worden voorspeld. Deze 
voorspellingen kwamen goed overeen met gemeten prolactine concentraties in 
plasma, wat aangeeft dat de voorspelling van het effect van geneesmiddelen in 
de mens op basis van preklinische PK-PD data goed kan werken. 
De verdere ontwikkeling van het preklinische SBPK hersendistributiemodel 
is vooral afhankelijk van de meetbaarheid van het effect van het geneesmiddel 
in de hersenen. Veelal wordt gezocht naar een enkele biomarker die het effect 
van het geneesmiddel in het CZS moet kunnen vertegenwoordigen. Echter, 
vanwege de complexiteit van de verschillende aandoeningen aan het CZS, is het 
zeer onwaarschijnlijk dat er een enkele biomarker kan worden geïdentificeerd 
die het onderscheid kan maken tussen gezondheid en ziekte. Dit maakt het lastig 
om het effect van geneesmiddelen op de status van de ziekte te kunnen volgen. 
Eigenlijk kunnen we niet echt spreken van “het” effect, maar gaat het meer om 
een samenstelling van meerdere effecten. Daarom zouden we beter kunnen 
zoeken op de tijdsafhankelijke “vingerafdruk” van meerdere biomarkers, om zo 
het brede scala aan effecten te kunnen bestuderen. Met de opkomende techniek 
van de metabolomics zijn we in staat om veel meer stoffen in de 
hersenvloeistoffen en plasma in parallel te meten in de tijd. Daarnaast moet de 
aandacht uit gaan naar de metingen die zowel preklinisch als klinisch verricht 
kunnen worden, om zo onze inzichten in de vertaling tussen dier en mens te 
vergroten en de voorspellende waarde van preklinische data te verhogen. 
Samenvattend kunnen we zeggen dat de toekomst ligt in het combineren van 
stof-specifieke informatie, systeem-specifieke informatie over de distributie 
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naar het doeleiwit en mechanistische informatie over het concentratie-effect 
spectrum (en de variatie daarin, afhankelijk van de diersoort, de leeftijd en de 
status van de ziekte, maar ook de variatie tussen individuen en binnen 
individuen). De combinatie van deze informatie zal uiteindelijk leiden naar een 
systeem-gebaseerd PK-PD model, waarvan wij verwachten dat deze het effect 
van geneesmiddelen in de hersenen van de mens op basis van preklinische data 
goed kan voorspellen. 
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Ook wil ik Meindert bedanken voor de kans die ik heb gekregen om dit mooie 
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